0001437749-22-013417.txt : 20220524 0001437749-22-013417.hdr.sgml : 20220524 20220524172352 ACCESSION NUMBER: 0001437749-22-013417 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220524 DATE AS OF CHANGE: 20220524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PETMED EXPRESS INC CENTRAL INDEX KEY: 0001040130 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 650680967 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28827 FILM NUMBER: 22958165 BUSINESS ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 BUSINESS PHONE: (561) 426-4444 MAIL ADDRESS: STREET 1: 420 SOUTH CONGRESS AVENUE CITY: DELRAY BEACH STATE: FL ZIP: 33445 10-K 1 pets20220331_10k.htm FORM 10-K pets20220331_10k.htm
0001040130 PETMED EXPRESS INC false --03-31 FY 2022 39 39 0.001 0.001 5,000 5,000 3 3 3 3 4 4 0.001 0.001 40,000 40,000 20,979 20,979 20,269 20,269 8.2 37.1 11.6 11.2 13.4 11.6 39,000 30 3 10 0 0 5 80 2,500 0 0.30 6,081 May 21, 2021 0.30 6,102 August 13, 2021 0.30 6,283 November 19, 2021 0.30 6,294 February 18, 2022 10 2 2 1 3 00010401302021-04-012022-03-31 iso4217:USD 00010401302021-09-30 xbrli:shares 00010401302022-05-24 thunderdome:item 00010401302022-03-31 00010401302021-03-31 iso4217:USDxbrli:shares 00010401302020-04-012021-03-31 00010401302019-04-012020-03-31 0001040130us-gaap:PreferredStockMember2019-03-31 0001040130us-gaap:CommonStockMember2019-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2019-03-31 0001040130us-gaap:RetainedEarningsMember2019-03-31 00010401302019-03-31 0001040130us-gaap:PreferredStockMember2019-04-012020-03-31 0001040130us-gaap:CommonStockMember2019-04-012020-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2019-04-012020-03-31 0001040130us-gaap:RetainedEarningsMember2019-04-012020-03-31 0001040130us-gaap:PreferredStockMember2020-03-31 0001040130us-gaap:CommonStockMember2020-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2020-03-31 0001040130us-gaap:RetainedEarningsMember2020-03-31 00010401302020-03-31 0001040130us-gaap:PreferredStockMember2020-04-012021-03-31 0001040130us-gaap:CommonStockMember2020-04-012021-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2020-04-012021-03-31 0001040130us-gaap:RetainedEarningsMember2020-04-012021-03-31 0001040130us-gaap:PreferredStockMember2021-03-31 0001040130us-gaap:CommonStockMember2021-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2021-03-31 0001040130us-gaap:RetainedEarningsMember2021-03-31 0001040130us-gaap:PreferredStockMember2021-04-012022-03-31 0001040130us-gaap:CommonStockMember2021-04-012022-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2021-04-012022-03-31 0001040130us-gaap:RetainedEarningsMember2021-04-012022-03-31 0001040130us-gaap:PreferredStockMember2022-03-31 0001040130us-gaap:CommonStockMember2022-03-31 0001040130us-gaap:AdditionalPaidInCapitalMember2022-03-31 0001040130us-gaap:RetainedEarningsMember2022-03-31 0001040130pets:ReorderMember2021-04-012022-03-31 xbrli:pure 0001040130pets:ReorderMember2020-04-012021-03-31 0001040130pets:NewOrderMember2021-04-012022-03-31 0001040130pets:NewOrderMember2020-04-012021-03-31 0001040130pets:InternetMember2021-04-012022-03-31 0001040130pets:InternetMember2020-04-012021-03-31 0001040130pets:ContactCenterMember2021-04-012022-03-31 0001040130pets:ContactCenterMember2020-04-012021-03-31 0001040130pets:ReorderMember2019-04-012020-03-31 0001040130pets:NewOrderMember2019-04-012020-03-31 0001040130pets:InternetMember2019-04-012020-03-31 0001040130pets:ContactCenterMember2019-04-012020-03-31 utr:Y 0001040130us-gaap:BuildingMember2020-04-012021-03-31 0001040130pets:FurnitureFixturesEquipmentAndComputerSoftwareMembersrt:MinimumMember2020-04-012021-03-31 0001040130pets:FurnitureFixturesEquipmentAndComputerSoftwareMembersrt:MaximumMember2020-04-012021-03-31 0001040130us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMember2022-03-31 0001040130us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMember2021-03-31 0001040130us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberpets:FiveSuppliersMember2021-04-012022-03-31 0001040130us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberpets:FiveSuppliersMember2020-04-012021-03-31 0001040130us-gaap:BuildingMember2022-03-31 0001040130us-gaap:BuildingMember2021-03-31 0001040130us-gaap:LandMember2022-03-31 0001040130us-gaap:LandMember2021-03-31 0001040130us-gaap:BuildingImprovementsMember2022-03-31 0001040130us-gaap:BuildingImprovementsMember2021-03-31 0001040130us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-03-31 0001040130us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-03-31 0001040130us-gaap:FurnitureAndFixturesMember2022-03-31 0001040130us-gaap:FurnitureAndFixturesMember2021-03-31 0001040130us-gaap:DomesticCountryMember2021-03-31 00010401301998-04-30 00010401301998-04-011998-04-30 0001040130us-gaap:ConvertiblePreferredStockMember2022-03-31 0001040130us-gaap:ConvertiblePreferredStockMember2021-03-31 00010401302006-11-08 00010401302008-10-312008-10-31 00010401302019-01-252019-01-25 00010401302021-05-03 0001040130pets:DividendDeclaredMay42020Member2022-03-31 0001040130pets:DividendDeclaredMay42020Member2022-01-012022-03-31 0001040130pets:DividendDeclaredJuly202020Member2022-03-31 0001040130pets:DividendDeclaredJuly202020Member2022-01-012022-03-31 0001040130pets:DividendDeclaredOctober262020Member2022-03-31 0001040130pets:DividendDeclaredOctober262020Member2022-01-012022-03-31 0001040130pets:DividendDeclaredJanuary192021Member2022-03-31 0001040130pets:DividendDeclaredJanuary192021Member2022-01-012022-03-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember2015-07-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember2015-07-012015-07-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember2016-07-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMembersrt:MinimumMember2016-07-012016-07-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMembersrt:MaximumMember2016-07-012016-07-31 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember2022-03-31 0001040130us-gaap:RestrictedStockMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2022-03-31 0001040130pets:EmployeePlanMember2021-03-31 0001040130pets:DirectorPlanMember2021-03-31 0001040130pets:EmployeePlanMember2021-04-012022-03-31 0001040130pets:DirectorPlanMember2021-04-012022-03-31 0001040130pets:EmployeePlanMember2022-03-31 0001040130pets:DirectorPlanMember2022-03-31 0001040130pets:NonvestedRestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2022-03-31 0001040130pets:NonvestedRestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2021-03-31 0001040130pets:NonvestedRestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2021-04-012022-03-31 0001040130pets:NonvestedRestrictedStockMemberpets:EmployeeAndDirectorEquityCompensationPlanMember2020-04-012021-03-31 0001040130pets:DelrayBeachPropertyMember2016-01-012016-01-31 utr:sqft 0001040130pets:DelrayBeachPropertyMember2016-01-31 0001040130pets:DelrayBeachPropertyMember2021-04-012022-03-31 0001040130pets:DelrayBeachPropertyMember2020-04-012021-03-31 0001040130pets:DelrayBeachPropertyMember2022-03-31 0001040130srt:ChiefExecutiveOfficerMember2020-07-312020-07-31 0001040130srt:ChiefExecutiveOfficerMember2021-07-312021-08-30 0001040130srt:ChiefExecutiveOfficerMember2021-08-102021-08-10 0001040130srt:ChiefExecutiveOfficerMember2021-08-252021-08-25 0001040130us-gaap:RestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockMemberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle1Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle1Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle2Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle2Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle3Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle3Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle4Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle4Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle5Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-302021-08-30 0001040130pets:PerformanceRestrictedStockPriceHurdle5Memberpets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMember2021-08-30 0001040130us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:SubsequentEventMember2022-04-012022-05-24 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:SubsequentEventMembersrt:DirectorMember2022-04-012022-05-24 0001040130us-gaap:RestrictedStockMemberpets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:SubsequentEventMembersrt:DirectorMember2022-04-222022-04-22 0001040130us-gaap:SubsequentEventMemberpets:PartnershipAgreementWithVetsterMember2022-04-192022-04-19 0001040130us-gaap:SubsequentEventMemberpets:PartnershipAgreementWithVetsterMember2022-04-19 0001040130us-gaap:SubsequentEventMember2022-05-09 0001040130us-gaap:SubsequentEventMember2022-05-27 0001040130pets:ProphetMember2021-03-012021-03-31 0001040130pets:ProphetMember2020-04-012021-03-31 0001040130pets:ProphetMember2022-03-31 00010401302021-04-012021-06-30 00010401302021-07-012021-09-30 00010401302021-10-012021-12-31 00010401302022-01-012022-03-31 00010401302020-04-012020-06-30 00010401302020-07-012020-09-30 00010401302020-10-012020-12-31 00010401302021-01-012021-03-31
 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

   ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

       For the fiscal year ended March 31, 2022

 

OR

 

   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number 000-28827

 

 

PETMED EXPRESS, INC.

(Exact name of registrant as specified in its charter)

 

Florida

 

65-0680967

(State or other jurisdiction of

 

(IRS Employer

incorporation or organization)

 

Identification No.)

   

420 South Congress Avenue, Delray Beach, Florida 33445

(Address of principal executive offices) (Zip Code)

 

       Registrant’s telephone number, including area code: (561) 526-4444

 

     Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

    Name of each exchange on which registered

   

Common Stock, PETS

$.001 Par value per share

PETS

The NASDAQ Stock Market LLC

(NASDAQ Global Select Market)

 

Securities registered under Section 12(g) of the Act:

 
NONE

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 Large accelerated filer☐Accelerated filer☒
 Non-accelerated filer☐Smaller reporting company ☐
   Emerging growth company☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s Common Stock held by non-affiliates of the registrant as of September 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was $540.1 million based on the closing sales price of the registrant’s Common Stock on that date, as reported on the NASDAQ Global Select Market.

 

The number of shares of the registrant’s Common Stock outstanding as of May 24, 2022, was 20,988,237.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Information to be set forth in our Proxy Statement relating to our 2022 Annual Meeting of Stockholders to be held on July 28, 2022, is incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this report.

 

 

 
 
 

 

 

PETMED EXPRESS, INC.

 

2022 Annual Report on Form 10-K

 

TABLE OF CONTENTS

 

Page

 

PART I   1
Item 1. Business 1
Item 1A. Risk Factors 7
Item 1B. Unresolved Staff Comments 14
Item 2 Properties 14
Item 3. Legal Proceedings 14
Item 4. Mine Safety Disclosures 14
     
PART II   15
Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 15
Item 6. [Reserved] 17
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 27
Item 8. Financial Statements and Supplementary Data 28
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 48
Item 9A. Controls and Procedures 48
Item 9B. Other Information 48
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 48
     
PART III   49
Item 10. Directors, Executive Officers, and Corporate Governance 49
Item 11. Executive Compensation 49
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 49
Item 13. Certain Relationships and Related Transactions, and Director Independence 49
Item 14. Principal Accountant Fees and Services 49
     
PART IV   50
Item 15. Exhibit and Financial Statement Schedules 50
Item 16. Form 10-K Summary 51
     
SIGNATURES 52

 

 
 

 

 

PART I

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

 

Certain information in this Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plan," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of this Annual Report on Form 10-K under the heading “Risk Factors.” A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Annual Report on Form 10-K. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

 

When used in this Annual Report on Form 10-K, "PetMed Express," "1-800-PetMeds," “PetMeds,” "PetMed," “PetMeds.com,” "PetMed Express.com," "the Company," "we," "our," and "us" refers collectively to PetMed Express, Inc. and its wholly owned subsidiaries.

 

ITEM 1. BUSINESS

 

General

 

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products and supplies for dogs, cats, and horses direct to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, speed of delivery, and valued customer service.

 

The Company markets its products through national advertising campaigns, which aim to increase the recognition of the “PetMeds” brand name, increase traffic on its website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Virtually all of the Company’s sales are to residents in the United States. Our fiscal year end is March 31, our executive offices are currently located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444.

 

Our Products

 

We offer a broad selection of products for dogs, cats, and horses. Our current product line contains approximately 3,000 SKUs of the most popular pet medications, health products, and supplies. These products include a majority of the well-known brands of pet medications. Generally, our prices are competitive with the prices for medications charged by veterinarians, online retailers and other retailers. We also offer additional pet supplies on our website for sale, which are drop shipped to our customers by third parties. These pet supplies include: food, beds, crates, stairs, and other popular pet supplies. We research new products, and regularly select new products or the latest generation of existing products to become part of our product selection. In addition, we also refine our current products to respond to changing consumer-purchasing habits. Our website is designed to give us the flexibility to change featured products or promotions. Our product line provides customers with a wide variety of selections across the most popular health categories for dogs, cats, and horses. Our current products include:

 

Non-Prescription Medications (OTC) and supplies: Flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies.

 

Prescription Medications (Rx): Heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

 

 

1
 

 

Sales

 

We offer our products through two main sales channels: (1) the Internet through our website and mobile app, and (2) the telephone contact center through our toll-free number. We have designed our website and mobile application to provide a convenient, cost-effective, and informative shopping experience that encourages consumers to purchase products important for a pet’s health and quality of life. We believe that these channels allow us to increase the visibility of our brand name and provide our customers with increased shopping flexibility and excellent service.

 

Internet

 

We seek to combine our product selection and pet health information with the shopping ease of the Internet to deliver a convenient and personalized shopping experience. Our website offers health and nutritional product selections for dogs, cats, and horses, and relevant editorial and easily obtainable or retrievable resource information. Customers can search our website for products and access resources on a variety of information on dogs, cats, and horses. Customers can shop at our website by category, product line, individual product, or symptom. We attracted approximately 28 million visits to our website (including our mobile app) during fiscal 2022, approximately 8.5% of those visits resulted in an order, and our website generated approximately 84% of our total sales for the same time period. On our website pet owners have access to health information covering pets’ behavior and illnesses, and natural and pharmaceutical remedies specifically for a pet’s problem. The pet education content on our main website is periodically updated with the latest research for pet owners. As part of our multichannel strategy, we also offer mobile versions of our website (www.petmeds.com) and an application for mobile phones, tablets, and other devices. Our website and mobile application features include: AutoShip & Save subscription (“AutoShip”); “ask-the-vet”; live web chat; easy refill medication reminders; local veterinarian finder; and express checkout to provide our customers with fast, easy, and helpful service from their mobile devices.

 

In July 2021 we launched the new AutoShip program on our website. AutoShip is a new convenient way for our loyal customer base to have future pet medication orders delivered directly to them without the need to place an order each time. Currently, approximately 37% of our sales were generated via our AutoShip program in the month of March. The Company has set a goal of generating approximately 50% of its sales via the AutoShip program in FY 2023.

 

Telephone Contact Center

 

Our customer care representatives receive and process inbound and outbound customer calls, facilitate our live web chat, and process customer e-mails. Our telephone system is equipped with certain features including pop-up screens and call blending capabilities that give us the ability to efficiently utilize our customer care representatives’ time, providing excellent customer care, service, and support. Our customer care representatives receive a base salary and are rewarded with commissions for sales, and bonuses and other awards for achieving certain quality goals.

 

Our Customers

 

Approximately 2.0 million customers have purchased from us within the last two years. We attracted approximately 263,000 and 443,000 new customers in fiscal 2022 and 2021, respectively. Our customers are located throughout the United States, with approximately 50% of customers residing in California, Florida, Texas, New York, Pennsylvania, North Carolina, Georgia, and Virginia. Our primary focus has been on retail customers and the average purchase was approximately $93 and $89 for fiscal 2022 and fiscal 2021, respectively.

 

Marketing

 

The goal of our marketing strategy is to build brand recognition, increase customer traffic, add new customers, build strong customer loyalty, maximize reorders, and develop incremental revenue opportunities. We have an integrated marketing campaign that includes digital marketing, television advertising, and direct mail/print and e-mail.

 

2
 

 

Digital Marketing

 

We advertise and market our products primarily online. We make our brand available to Internet consumers by purchasing targeted keywords and achieving prominent placement on the top search engines and search engine networks. We utilize Internet display and video advertisements, social media, and comparison shopping, and we are also members of an affiliate program with merchant clients and affiliate websites.

 

Television Advertising

 

Our television advertising is designed to build brand equity, create brand awareness, and generate initial purchases of products via the telephone and the Internet. Our television commercials typically focus on our ability to rapidly deliver to customers the same medications offered by veterinarians. We believe that television advertising is particularly effective and instrumental in building brand awareness. Our most current television commercial, airing nationally, speaks to pet owners about the savings and convenience of purchasing the same exact pet medications from PetMeds.

 

Direct Mail/Print and E-mail

 

We use direct mail/print and e-mail to acquire new customers and to remind our existing customers to reorder.

 

Operations

 

Order Processing

 

Our website allows customers to easily browse and purchase all of our products online. Our website is designed to be fast, secure, and easy to use with order and shipping confirmations, and with online order tracking capabilities. We provide our customers with toll-free telephone access to our customer care representatives. Our call center generally operates from 7:00 AM to 11:00 PM, Monday through Thursday, 7:00 AM to 9:00 PM on Friday, 9:00 AM to 6:00 PM on Saturday, and 9:00 AM to 5:00 PM on Sunday, Eastern Time. The process of customers purchasing products from PetMeds consists of a few simple steps. A customer first places an order online or by calling our toll-free telephone number. The following information is needed to process prescription orders: pet information, prescription information, and the veterinarian’s name and phone number. This information is entered into our order process system. Then our pharmacists and pharmacy technicians verify all prescriptions. The order process system checks for the verification for prescription medication orders and a valid payment method for all orders. Verified orders are then sent to our fulfillment center, where items are picked, and then shipped via the United States Postal Service and United Parcel Service. Our customers enjoy the convenience of rapid home delivery, with the majority of all orders being shipped within 24 hours of ordering.

 

Customer Care and Support

 

We believe that a high level of customer care and support is critical in retaining and expanding our customer base. Customer care representatives participate in ongoing training programs under the supervision of our training managers. These training sessions include a variety of topics such as product knowledge, computer usage, customer service tips, and the relationship between our Company and veterinarians. Our customer care representatives respond to customers’ e-mails, calls, and live web chats that are related to products, order status, prices, and shipping. We believe our customer care representatives are a valuable source of feedback regarding customer satisfaction.

 

Warehousing and Shipping

 

We inventory our products and fill most customer orders from our corporate headquarters in Delray Beach, Florida. We have an in-house fulfillment and distribution operation, which is used to manage the entire supply chain, beginning with the placement of the order, continuing through order processing, and then fulfilling and shipping of the product to the customer. We offer a variety of shipping options, including next day delivery. We ship to anywhere in the United States served by the United States Postal Service or United Parcel Service. Priority orders are expedited in our fulfillment process. Our goal is to ship the products the same day that the order is received. For prescription medications, our goal is to ship the product immediately after the prescription has been authorized by the customer’s veterinarian. We currently offer free shipping to all customers whose order value is $49 or more.

 

3
 

 

Purchasing and Supply of Products

 

We purchase our products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. There were five suppliers from whom we purchased approximately 80% of all products in fiscal 2022. We believe having strong relationships with product manufacturers and distributors will ensure the availability of an adequate volume of products ordered by our customers. Part of our growth strategy included developing direct relationships with all of the leading pharmaceutical manufacturers of the more popular prescription and non-prescription medications. We now have direct relationships with all these major manufacturers.

 

Technology

 

We utilize integrated technologies in our call centers, e-commerce, order entry, and inventory control/fulfillment operations. Our systems are custom configured by us to optimize our computer telephone integration and mail-order processing. The systems are designed to maintain a large database of specialized information and process a large volume of orders efficiently and effectively. Our systems provide our customer care representatives, and our customers on our website, including on our mobile application, with real time product availability information and updated customer information to enhance our customer care.

 

We also have an integrated direct connection for processing credit cards to ensure that a valid credit card number and authorization have been received at the same time our customer care representatives are on the telephone with the customer or when a customer submits an order on our website. Our information systems provide our customer care representatives with records of all prior contact with a customer, including the customer’s address, telephone number, e-mail address, prescription information, order history, payment history, and notes.

 

Competition

 

The pet medications market is competitive and highly fragmented. Our competitors consist of veterinarians, and online and traditional retailers. We believe that the following are the principal competitive factors in our market:

 

 

●

Product selection and availability, including the availability of prescription and non-prescription medications;
 

●

Brand recognition;
 

●

Reliability and speed of delivery;
 

●

Personalized service and convenience;
 

●

Price; and
 

●

Website and mobile application usability and content.

 

We compete with veterinarians, and online and traditional retailers for the sale of prescription and non-prescription pet medications and other health products. Many pet owners may prefer the convenience of purchasing their pet medications or other health products at the time of a veterinarian visit. In order to effectively compete with veterinarians, we must continue to educate pet owners about the service, convenience, and savings offered by our Company.

 

According to the American Pet Products Association, pet spending in the United States increased 19.3% to $123.6 billion in 2021. Veterinary care and Rx medications represented $34.3 billion, or 28% of the total spending on pets in the United States. The pet medication market, which included prescription and nonprescription medication, is estimated to be approximately $10.0 billion, with veterinarians having the majority of the prescription market share. The dog and cat population is approximately 184 million, with approximately 70% of all households having a pet.

 

We believe that the following are the main competitive strengths that differentiate PetMeds from the competition:

 

 

●

Pure Play Channel leader, in an estimated $10.0 billion industry;
 

●

“1-800-PetMeds” brand name with 25 years of experience, consumers know us as the trusted pet medication experts;
 

●

Licensed pharmacy to conduct business in 50 states, and a Pharmacy Verified website (a website verification program by the National Association of Boards of Pharmacy®, which identifies online pharmacies and pharmacy-related websites as safe and legitimate); and
 

●

Exceptional customer care and support.

 

4
 

 

Intellectual Property

 

We conduct our business under the trade name “PetMeds” and use a family of trade names all containing the term “PetMeds” or “PetMed” in some form. We believe the “1-800-PetMeds” trade name, which is also our toll-free telephone number, and the “PetMeds” family of trademarks, have added significant value and are important factors in the marketing of our products. We have also obtained the right to use and control the Internet addresses www.1800petmeds.com, www.1888petmeds.com, www.petmedexpress.com, www.petmed.com, and www.petmeds.com.

 

We also obtained the right to use and control the Internet addresses www.petmeds.pharmacy, www.petmed.pharmacy, and www.1800petmeds.pharmacy, through a National Association of Boards of Pharmacy® initiative to ensure high standards for online pharmacies. We do not expect to lose the ability to use the Internet addresses; however, there can be no assurance in this regard and the loss of these addresses may have a material adverse effect on our financial position and results of operations. We are the exclusive owners of United States Trademark Registrations for “America’s Largest Pet Pharmacy®,” “America’s Most Trusted Pet Pharmacy®,” “Trusted Pet Medication Experts®,” “PetMed Express and Design®,”1-800-PetMeds and Design®,” 1-800-PetMeds®,” and “PetMeds®,” among numerous others.

 

Government Regulation

 

Dispensing prescription medications is governed at the state level by Boards of Pharmacy, or similar regulatory agencies, of each state where prescription medications are dispensed. We are subject to regulation by the State of Florida and are licensed as a community pharmacy by the Florida Board of Pharmacy. Our current license is valid until February 28, 2023, and prior to that date a renewal application will be submitted to the Board of Pharmacy. During fiscal 2015 we obtained a federal registration, and state registrations/permits as required, to dispense Schedule IV controlled substances, and we also updated our federal registration and state registrations/permits as required to include the ability to dispense Schedule V controlled substances.

 

Our pharmacy practice is also licensed and/or regulated by 49 other state pharmacy boards, the District of Columbia Board of Pharmacy, and the United States Drug Enforcement Administration, and with respect to our products, by other regulatory authorities including, but not necessarily limited to, the United States Food and Drug Administration (“FDA”) and the United States Environmental Protection Agency. As a licensed pharmacy in the State of Florida, we are subject to the Florida Pharmacy Act and regulations promulgated thereunder. To the extent that we are unable to maintain our license as a community pharmacy with the Florida Board of Pharmacy, or if we do not maintain the licenses granted by other state pharmacy boards, or if we become subject to actions by the FDA, or other enforcement regulators, our distribution of prescription medications to pet owners could cease, which could have a material adverse effect on our financial condition and results of operations.

 

We rely on legal and operational compliance programs, as well as outside counsel, to guide our business in complying with applicable laws and regulations in the areas in which we do business. In addition, regulatory regime changes may add cost and complexity to our compliance efforts. Based on information currently available, we believe that our compliance in general with federal and state regulations will not have a material effect on our earnings or financial condition. However, it is difficult to predict with certainty the potential impact of future compliance efforts and thus, future costs associated with such matters may exceed current reserves. As of March 31, 2022 we have no reserves related to federal and state regulations.

 

Human Capital Resources

 

We strive to create a high-performance culture that embraces diversity, inclusion, diverse perspectives and experiences, to ensure that employees have opportunities to develop the skills they need to grow and excel in their fields. Human capital management is a priority for our executives and Board of Directors, and we are committed to identifying and developing the talent necessary for our long-term success. We have a talent and succession planning process and have established programs to support the development of our talent pipeline for critical roles in our organization. We conduct an annual review with human resources and the departmental leadership teams, focusing on high performing and high potential talent, diverse talent and succession for our critical roles.

 

We also recognize that it is important to develop our future leaders. We provide a variety of resources to help our employees build and develop their skills, including online development resources as well as individual development opportunities and projects for key talent. Additionally, we have leadership development resources for our future leaders as they continue to develop their skills.

 

5
 

 

We also foster a strong corporate culture that promotes high standards of ethics and compliance for our business, including policies that set forth principles to guide employee, officer, director, and vendor conduct, such as our Code of Business Conduct and Ethics. We also maintain a whistleblower policy and anonymous hotline for the confidential reporting of any suspected policy violations or unethical business conduct on the part of our employees, officers, directors, or vendors.

 

We currently have 212 full time employees, including: 126 in customer care and marketing; 23 in fulfillment and purchasing; 46 in our pharmacy; 4 in information technology; 7 in accounting/human resources; and 6 in management. None of our employees are represented by a labor union or governed by any collective bargaining agreements. We consider relations with our employees to be in good standing. The majority of our employees work at our headquarters and distribution center located in Delray Beach, Florida. As a result of the COVID-19 pandemic many of our personnel are currently working remotely, and in the long term, we expect some personnel to transition into working remotely on a regular basis.

 

In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees as well as the communities in which we operate. These measures include allowing most employees to work from home and implementing additional safety measures for employees continuing critical on-site work. We believe in supporting our employees’ health and well-being. Our goal is to help employees make informed decisions about their health by providing the tools and resources necessary to achieve a healthier lifestyle. We offer our employees a wide array of benefits such as life and health (medical, dental, and vision) insurance, paid time off and retirement benefits, as well as emotional well-being services through our health insurance program.

 

We offer competitive compensation to attract and retain the best people, and we help care for our people so they can focus on our mission. Our employees' total compensation package includes market-competitive salary, bonuses or sales commissions, and equity. We generally offer annual equity grants to certain full-time employees, primarily management. Having compensation tied to annual equity grants helps ensure that our employees will be committed to the Company’s long-term success. We have conducted an annual pay equity analysis and continue to be committed to pay equity.

 

Available Information

 

Our website address is www.petmeds.com. The information on our website is not, and shall not be deemed to be, a part of or incorporated into this Annual Report on Form 10-K or any other filings we make with the Securities and Exchange Commission ("SEC"). We file annual, quarterly, and current reports, proxy statements, and other information with the SEC. Our SEC filings, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to the Exchange Act are available free of charge over the Internet on our website or at the SEC's web site at www.sec.gov. Our SEC filings will be available through our website as soon as reasonably practicable after we have electronically filed or furnished them to the SEC.

 

6
 

 

ITEM 1A. RISK FACTORS

 

Our operations and financial results are subject to various risks and uncertainties, including those described below, that could materially and adversely affect our business, financial condition, operating results and the trading price of our common stock. Because of the following factors, as well as other factors affecting the Company’s results of operations and financial condition, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods. This discussion of risk factors contains forward-looking statements. This section should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.

 

Regulatory Risks

 

We may inadvertently fail to comply with various state or federal regulations covering the dispensing of prescription pet medications which may subject us to reprimands, sanctions, probations, fines, suspensions, or the loss of one or more of our pharmacy licenses.

 

The sale and delivery of prescription pet medications is generally governed by state laws and state regulations, and with respect to controlled substances, also by federal law. Since our pharmacy is located in the State of Florida, the Company is governed by the laws and regulations of the State of Florida. Each prescription pet medication sale we make is likely also to be covered by the laws of the state where the customer is located. The laws and regulations relating to the sale and delivery of prescription pet medications vary from state to state, but generally require that prescription pet medications be dispensed with the authorization from a prescribing veterinarian. Our current license is valid until February 28, 2023, and there is no guarantee that we will be able to renew it. To the extent that we are unable to maintain our license as a community pharmacy with the Florida Board of Pharmacy, or if we do not maintain the licenses granted by other state boards, or if we become subject to actions by the FDA, or other enforcement regulators, our dispensing of prescription medications to pet owners could cease, which could have a material adverse effect on our operations.

 

The Company is a party to routine litigation and administrative complaints incidental to its business. Management does not believe that the resolution of any or all of such routine litigation and administrative complaints is likely to have a material adverse effect on the Company’s financial condition or results of operations. While we make every effort to fully comply with all applicable state rules, laws, and regulations, from time to time we have been the subject of administrative complaints regarding the authorization of prescriptions prior to shipment. We cannot assure you that we will not be the subject of administrative complaints in the future. We cannot guarantee you that we will not be subject to reprimands, sanctions, probations, or fines, or that one or more of our pharmacy licenses will not be suspended or revoked. If we were unable to maintain our license as a community pharmacy in the State of Florida, or if we are not granted licensure in a state that begins to require licensure, or if one or more of the licenses granted by other state boards should be suspended or revoked, our ability to continue to sell prescription medications and to continue our business as it is presently conducted could be in jeopardy.

 

Business Risks

 

Our failure to properly manage our inventory may result in excessive inventory carrying costs, or inadequate supply of products, which could materially adversely affect our financial condition and results of operations.

 

Our current product line contains approximately 3,000 SKUs. A significant portion of our sales is attributable to products representing approximately 100 SKUs, including the most popular flea and tick, and heartworm preventative brands. We need to properly manage our inventory to provide an adequate supply of these products and avoid excessive inventory of the products representing the balance of the SKUs. We generally place orders for products with our suppliers based upon our internal estimates of the amounts of inventory we will need to fill future orders. These estimates may be significantly different from the actual orders we receive.

 

In the event that subsequent orders fall short of original estimates, we may be left with excess inventory. Significant excess inventory could result in price discounts, increased inventory carrying costs, and obsolescence. Similarly, if we fail to have an adequate supply of some SKUs, we may lose sales opportunities. We cannot guarantee that we will maintain appropriate inventory levels. Any failure on our part to maintain appropriate inventory levels may have a material adverse effect on our financial condition and results of operations.

 

7
 

 

Resistance from veterinarians to authorize prescriptions, or attempts/efforts on their part to discourage pet owners from purchasing from us could cause our sales to decrease and could materially adversely affect our financial condition and results of operations.

 

Since we began our operations, some veterinarians have resisted providing our customers with a copy of their pet’s prescription or authorizing the prescription to our pharmacy staff, thereby effectively preventing us from filling such prescriptions under state law. We have also been informed by customers and consumers that veterinarians have tried to discourage pet owners from purchasing from internet mail-order pharmacies.

 

Although veterinarians in some states are required by law to provide a pet owner with a prescription if medically appropriate, if the number of veterinarians who refuse to authorize prescriptions should increase, or if veterinarians are successful in discouraging pet owners from purchasing from internet mail-order pharmacies, our sales could decrease, and our financial condition and results of operations may be materially adversely affected.

 

Significant portions of our sales are made to residents of eight states. If we should lose our pharmacy license in one or more of these states, our financial condition and results of operations would be materially adversely affected.

 

While we ship pet medications to customers in all 50 states, approximately 50% of our sales for the fiscal year ended March 31, 2022, were made to customers located in the states of California, Florida, Texas, New York, Pennsylvania, North Carolina, Georgia, and Virginia. If for any reason our license to operate a pharmacy in one or more of those states should be suspended or revoked, or if it is not renewed, our ability to sell prescription medications to residents of those states would cease and our financial condition and results of operations in future periods would be materially adversely affected.

 

We now have direct buying relationships with all the major pet medication manufacturers; the contractual relationship depends on our compliance with their minimum advertised pricing policies (MAPP).

 

During fiscal 2020, the Company established direct purchasing relationships with all the major pet medication manufacturers. These relationships entitle the Company to buy directly from the manufacturer under the terms and conditions of a purchasing agreement which dictates purchase pricing of inventory and criteria to obtain additional discounts and rebates. The terms of these agreements also require the Company to comply with the manufacturers’ MAPP. Each advertisement and/or promotion of a product below the MAPP price, should they occur, would be a violation of the policy. This policy applies to all advertisements of products in all media including, without limitation, flyers, posters, coupons, mailers, inserts, newspapers, magazines, on-line catalogs, mail order catalogs, public signage and all Internet or similar electronic media, television, radio and public signage, including websites, email newsletters, forums, and auction sites.

 

At the discretion of the manufacturers, non-compliance with the MAPP can result in one or more of the following actions: (1) forfeiture of future rebates or discounts from the manufacturer, (2) suspension of future purchases from the manufacturer, (3) or termination of current or future business relationship. The Company has and will continue to make every attempt to abide by the manufacturers MAPP. However, no assurances can be made that the Company will not violate MAPP inadvertently. A reduction or discontinuance of these rebates or discounts would increase our costs and could reduce our profitability. If any of these major pet medication manufacturers were to terminate our purchasing relationship it could materially adversely affect our business. If the manufacturers are not able to enforce their MAPP industry-wide, then our profit margins and results of operations may also be impacted negatively.

 

The loss of any of our key suppliers would negatively impact our business.

 

We have direct purchasing relationships with all of the major pet medication manufacturers, the majority of which we purchase significant quantities of pet medication products, with the majority from these major manufacturers. We do maintain annual purchasing contracts with these major manufacturers. While we believe that our supplier relationships are good, a supplier could discontinue selling to us at any time. The loss of any of our key suppliers of pet medications offered by us would have a negative impact on our business, financial condition, and results of operations.

 

8
 

 

Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements could adversely affect our business, financial condition, and results of operations.

 

We currently rely on third-party national, regional, and local logistics providers to deliver the products we offer on our website. If we are not able to negotiate acceptable pricing and other terms with these providers, or if these providers experience performance problems or other difficulties in processing our orders or delivering our products to customers, it could negatively impact our results of operations and our customers’ experience. In addition, our ability to receive inbound inventory efficiently and ship merchandise to customers may be negatively affected by factors beyond our and these providers’ control, including inclement weather, fire, flood, power loss, earthquakes, acts of war or terrorism or other events, such as labor shortages and disputes, financial difficulties, volatility in the prices of fuel, gasoline and commodities such as paper and packing supplies, system failures and other disruptions to the operations of the shipping companies on which we rely. We are also subject to risks of damage or loss during delivery by our shipping vendors. Further, due to the continuing spread of COVID-19 and its variant strains and related work and travel restrictions, there may be disruptions and delays in national, regional and local shipping, which may negatively impact our customers’ experience and our operations and financial results. The spread of COVID-19, and any future similar outbreak, may disrupt our suppliers and logistics providers and other third- party delivery agents, as their workers may be prohibited or otherwise unable to report to work and transporting products within regions may be limited due to factory closures, port closures and increased border controls and closures, among other things. If the products ordered by our customers are not delivered in a timely fashion or are damaged or lost during the delivery process, our customers could become dissatisfied and cease buying products through our website and mobile applications, which would adversely affect our business, financial condition, and results of operations.

 

The content of our website could expose us to various kinds of liability, which, if prosecuted successfully, could negatively impact our business.

 

Because we post product and pet health information and other content on our website, we face potential liability for negligence, copyright infringement, patent infringement, trademark infringement, defamation, and/or other claims based on the nature and content of the materials we post. Various claims have been brought, and sometimes successfully prosecuted, against Internet content distributors. We could be exposed to liability with respect to the unauthorized duplication of content or unauthorized use of other parties’ proprietary technology. Although we maintain general liability insurance, our insurance may not cover potential claims of this type or may not be adequate to indemnify us for all liability that may be imposed. Any imposition of liability that is not covered by insurance, or is in excess of insurance coverage, could materially adversely affect our financial condition and results of operations.

 

We may not be able to protect our intellectual property rights, and/or we may be found to infringe on the proprietary rights of others.

 

We rely on a combination of trademarks, trade secrets, copyright laws, and contractual restrictions to protect our intellectual property rights. These afford only limited protection. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy our non-prescription private label or generic equivalents, when and if developed, as well as aspects of our sales formats, or to obtain and use information that we regard as proprietary, including the technology used to operate our website and our content, and our trademarks. Litigation or proceedings before the United States Patent and Trademark Office or other bodies may be necessary in the future to enforce our intellectual property rights, to protect our trade secrets and domain names, or to determine the validity and scope of the proprietary rights of others. Any litigation or adverse proceeding could result in substantial costs and diversion of resources and could seriously harm our business and operating results. Third parties may also claim infringement by us with respect to past, current, or future technologies. We expect that participants in our market will be increasingly involved in infringement claims as the number of services and competitors in our industry segment grows. Any claim, whether meritorious or not, could be time-consuming, result in costly litigation, cause service upgrade delays, or require us to enter into royalty or licensing agreements. These royalty or licensing agreements might not be available on terms acceptable to us or at all.

 

If we are unable to protect our Internet addresses or to prevent others from using Internet addresses that are confusingly similar, our business may be adversely impacted.

 

Our Internet addresses, www.1800petmeds.com, www.1888petmeds.com, www.petmedexpress.com, www.petmed.com, www.petmeds.com, www.petmeds.pharmacy, www.petmed.pharmacy, and www.1800petmeds.pharmacy, are critical to our brand recognition and our overall success. If we are unable to protect these Internet addresses, our competitors could capitalize on our brand recognition. There may be similar Internet addresses used by competitors. Governmental agencies and their designees generally regulate the acquisition and maintenance of Internet addresses. The regulation of Internet addresses in the United States and in foreign countries has changed and may undergo further change in the near future. Furthermore, the relationship between regulations governing Internet addresses and laws protecting trademarks and similar proprietary rights is unclear. Therefore, we may not be able to protect our own Internet addresses or prevent third parties from acquiring Internet addresses that are confusingly similar to, infringe upon, or otherwise decrease the value of our Internet addresses.

 

9
 

 

Since all of our operations are housed in a single location, we are more susceptible to a business interruption in the event of damage to, or disruptions in, our facility.

 

Our headquarters and distribution center are currently located in one location in South Florida, and most of our shipments of products to our customers are made from this sole distribution center. Because we consolidate our operations in one location, we are more susceptible to power and equipment failures, and business interruptions in the event of fires, floods, and other natural disasters than if we had additional locations. Furthermore, because we are located in South Florida, which is a hurricane-sensitive area, we are particularly susceptible to the risk of damage to, or total destruction of, our headquarters and distribution center and surrounding transportation infrastructure caused by a hurricane. We cannot assure you that we are adequately insured to cover the amount of any losses relating to any of these potential events, including business interruptions resulting from damage to or destruction of our headquarters and distribution center, or power and equipment failures relating to our call center or websites, or interruptions or disruptions to major transportation infrastructure, or other events that do not occur on our premises. The occurrence of one or more of these events could adversely impact our ability to generate revenues in future periods.

 

A failure of our information systems and customer-facing technology systems or any security breach or unauthorized disclosure of confidential information, or other cyber-attacks on our systems, could result in litigation and regulatory risk, harm our reputation and have a material adverse effect on our business.

 

Our business is dependent upon the efficient operation of our information systems. In particular, we rely on our information systems to effectively manage our business model strategy, with tools to track and manage sales, inventory, marketing, customer service efforts, the preparation of our consolidated financial and operating data, credit card information, and customer information. The failure of our information systems to perform as designed or the failure to maintain and enhance or protect the integrity of these systems could disrupt our business operations, adversely impact sales and the results of operations, expose us to customer or third-party claims, or result in adverse publicity.

 

Through our information technology, we are able to provide an improved overall shopping and interconnected retail experience that empowers our customers to shop and interact with us from computers, tablets, smartphones and other mobile devices. We use our website and our mobile application both as sales channels for our products and also as methods of providing product and other relevant information to our customers to drive online sales. Our online programs, communities and knowledge center allow us to inform, assist and interact with our customers. We also continually seek to enhance all of our online properties to provide an attractive user-friendly interface for our customers. Disruptions, failures or other performance issues with these customer-facing technology systems could impair the benefits that they provide to our online business and negatively affect our relationship with our customers.

 

Additionally, we collect, process, and retain sensitive and confidential customer information in the normal course of our business. Despite the security measures we have in place and any additional measures we may implement in the future, our facilities and systems, and those of our third-party service providers, could be vulnerable to security breaches, computer viruses, lost or misplaced data, programming errors, human errors, acts of vandalism, or other events. Any security breach or event resulting in the misappropriation, loss, or other unauthorized disclosure of confidential information, whether by us directly or our third-party service providers, could damage our reputation, expose us to the risks of litigation and liability, disrupt our business, or otherwise affect our results of operations.

 

Our operating results are difficult to predict and may fluctuate, and a portion of our sales are seasonal.

 

Factors that may cause our operating results to fluctuate include:

 

 

●

Our ability to obtain new customers at a reasonable cost, retain existing customers, or encourage reorders;
 

●

Our ability to increase the number of visitors to our website, or our ability to convert visitors to our website into customers;
 

●

The mix of medications and other pet products sold by us;
 

●

Our ability to manage inventory levels or obtain an adequate supply of products;
 

●

Our ability to adequately maintain, upgrade, and develop our website, the systems that we use to process customers’ orders and payments, or our computer network;
 

●

Increased competition within our market niche;

 

10
 

 

 

●

Price competition;
 

●

New products introduced to the market, including generics;
 

●

Increases in the cost of advertising;
 

●

The amount and timing of operating costs and capital expenditures relating to expansion of our product line or operations;
 

●

Disruption of our toll-free telephone service, technical difficulties, or systems and Internet outages or slowdowns;
 

●

The impact of COVID-19 on our business operations and generally on the economy, including the measures taken by governmental authorities to address it; and
 

●

Unfavorable general economic trends.

 

Because our operating results are difficult to predict, we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance. The majority of our product sales are affected by the seasons, due to the seasonality of mainly flea, tick, and heartworm medications. For the quarters ended June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, Company sales were 29%, 25%, 22%, and 24%, respectively. In addition to the seasonality of our sales, our annual and quarterly operating results have fluctuated in the past and may fluctuate significantly in the future due to a variety of factors, including weather, many of which are out of our control. Any change in one or more of these factors could materially adversely affect our financial condition and results of operations in future periods.

 

Uncertainties in economic conditions and their impact on consumer spending patterns could adversely impact our business, financial condition, and results of operations.

 

Our results of operations are sensitive to changes in certain macro-economic conditions that impact consumer spending on pet products and services. Some of the factors that may affect consumer spending on pet products and services include consumer confidence, levels of unemployment, inflation, interest rates, tax rates and general uncertainty regarding the overall future economic environment. We may experience declines in sales or changes in the types of products sold during economic downturns. Any material decline in the amount of consumer spending or other adverse economic changes could reduce our sales, and a decrease in the sales of higher-margin products could reduce profitability and, in each case, harm our business, financial condition, and results of operations.

 

We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses, facilities, technologies, offerings, or products, or through strategic alliances, and the failure to manage these acquisitions, investments, or other strategic alliances, or to integrate them with our existing business, could have a material adverse effect on us.

 

We recently entered into, and made an investment in, a strategic alliance, and we may in the future consider opportunities to acquire or make investments in new or complementary businesses, facilities, technologies, offerings, or products, or enter into other strategic alliances, which may enhance our capabilities, complement our current products and services or expand the breadth of our markets. Acquisitions, investments and other strategic alliances involve numerous risks, including:

 

 

●

problems integrating the acquired business, facilities, technologies or products, including issues maintaining uniform standards, procedures, controls and policies;
 

●

unanticipated costs associated with acquisitions, investments or strategic alliances;
 

●

losses we may incur as a result of declines in the value of an investment or as a result of incorporating an investee’s financial performance into our financial results;
 

●

diversion of management’s attention from our existing business;
 

●

risks associated with entering new markets in which we may have limited or no experience;
 

●

the risks associated with businesses we acquire or invest in, which may differ from or be more significant than the risks our other businesses face;
 

●

potential unknown liabilities associated with a business we acquire or in which we invest; and
 

●

increased legal and accounting compliance costs.

 

Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, facilities, technologies, products and services. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations. As a result of future strategic transactions, we might need to issue additional equity securities, spend our cash, or incur debt (which may only be available on unfavorable terms, if at all) or contingent liabilities, any of which could reduce our profitability and harm our business. If we are unable to identify suitable acquisitions, investments or strategic relationships, or if we are unable to integrate any acquired businesses, facilities, technologies, offerings and products effectively, our business, financial condition, and results of operations could be materially and adversely affected. Also, while we employ several different methodologies to assess potential business opportunities, the new businesses or investments may not meet or exceed our expectations or desired objectives.

 

11
 

 

Financial Risks

 

We are subject to payment-related risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business.

 

We accept payments using a variety of methods, including credit and debit cards, PayPal, and checks, and we may offer new payment options over time. Acceptance of these payment options subjects us to rules, regulations, contractual obligations and compliance requirements, including payment network rules and operating guidelines, data security standards and certification requirements, and rules governing electronic funds transfers. These requirements may change over time or be reinterpreted, making compliance more difficult or costly. For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise our operating costs.

 

We rely on third parties to provide payment processing services, including the processing of credit cards, debit cards, and other forms of electronic payment. If these companies become unable to provide these services to us, or if their systems are compromised, it could potentially disrupt our business. The payment methods that we offer also subject us to potential fraud and theft by criminals, who are becoming increasingly more sophisticated, seeking to obtain unauthorized access to or exploit weaknesses that may exist in the payment systems. If we fail to comply with applicable rules or requirements for the payment methods we accept, or if payment-related data is compromised due to a breach or misuse of data, we may be liable for costs incurred by payment card issuing banks and other third parties or subject to fines and higher transaction fees, or our ability to accept or facilitate certain types of payments may be impaired. As a result, our business and operating results could be adversely affected.

 

Industry Risks

 

We face significant competition from veterinarians and online and traditional retailers and may not be able to compete profitably with them.

 

We compete directly and indirectly with veterinarians for the sale of pet medications and other health products. Veterinarians hold a competitive advantage over us because many pet owners may find it more convenient or preferable to purchase these products directly from their veterinarians at the time of an office visit. We also compete directly and indirectly with both online and traditional retailers. Both online and traditional retailers may hold a competitive advantage over us because of longer operating histories, established brand names, greater resources, and/or an established customer base. Online retailers may have a competitive advantage over us because of established affiliate relationships to drive traffic to their website. Traditional retailers may hold a competitive advantage over us because pet owners may prefer to purchase these products from a store instead of online. In addition, we face growing competition from online and multichannel retailers, some of whom may have a lower cost structure than ours, as customers now routinely use computers, tablets, smartphones, and other mobile devices and mobile applications to shop online and compare prices and products in real time. In order to effectively compete in the future, we may be required to offer promotions and other incentives, which may result in lower operating margins and adversely affect the results of operations. We also face a significant challenge from our competitors forming alliances with each other, such as those between online and traditional retailers. These relationships may enable both their online and retail stores to negotiate better pricing and better terms from suppliers by aggregating the demand for products and negotiating volume discounts, which could be a competitive disadvantage to us.

 

Risks Related to COVID-19

 

The COVID-19 global pandemic and related government, private sector and individual consumer responsive actions may adversely affect our business operations, employee availability, financial performance, liquidity and cash flow for an unknown period of time.

 

12
 

 

The outbreak of COVID-19 was declared a pandemic by the World Health Organization and continues to spread in the United States, Canada, and in many other countries globally. COVID-19 has had, and continues to have, a significant impact in the United States and around the world, prompting governments and businesses to take unprecedented measures in response. Such measures have included restrictions on travel and business operations, temporary closures of businesses, and quarantine and shelter-in-place orders. The COVID-19 pandemic has at times significantly curtailed economic activity in the United States and globally, and caused significant volatility and disruption in global financial markets. The continued adverse public health developments, the related government and private sector responsive actions, and the economic effects of the COVID-19 pandemic may adversely affect our business operations. It is impossible to predict the effect and ultimate impact of the COVID-19 pandemic, as the situation is continually evolving. The COVID-19 pandemic may disrupt the global supply chain and may cause disruptions to our operations if a significant number of employees are quarantined or if they are otherwise limited in their ability to work at our fulfillment center. Additional federal or state mandates could also impact our ability to take or fulfill our customers’ orders and operate our business. As an essential business, we have been open during our normal business hours without any material disruptions to our operations. We are dedicated to making every effort to ensure the health and safety of our employees. We have implemented working from home where possible and enhanced disinfection and social distancing within our workplace. Many of our personnel are working remotely and it is possible that this could have a negative impact on the execution of our business plans and operations. If a natural disaster, power outage, connectivity issue, or other event occurs that impacts our employees’ ability to work remotely, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The increase in remote working may also result in consumer privacy, IT security and fraud concerns as well as operational inefficiencies.

 

The operations of our fulfillment center may be substantially disrupted by additional federal or state mandates ordering shutdowns or by the inability of our employees to travel to work due to COVID-19. The inability to ship from our fulfillment center due to a COVID-19 outbreak, disruptions to the operations of our fulfillment center, or increased costs in fulfillment center capacity may negatively impact our financial performance or slow our future growth.

 

The uncertainty around the duration of business disruptions and the extent of the spread of the virus and the emergence of new variants of the virus in the United States and to other areas of the world will likely continue to adversely impact the national and global economy and negatively impact consumer spending. Any of these outcomes could have a material adverse impact on our business, financial condition, operating results and ability to execute and capitalize on our strategies. The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity and new variants of the virus, its spread to other regions as well as the actions taken to contain it, among others.

 

Securities Risks

 

Our stock price fluctuates from time to time and may fall below expectations of securities analysts and investors, and could subject us to litigation, which may result in you suffering a loss on your investment.

 

The market price of our common stock may fluctuate significantly in response to a number of factors, many of which are out of our control. These factors include: quarterly variations in operating results; changes in accounting treatments or principles; announcements by us or our competitors of new products and services offerings; significant contracts, acquisitions, or strategic relationships; additions or departures of key personnel; any future sales of our common stock or other securities; stock market price and volume fluctuations of publicly traded companies; and general political, economic, and market conditions. In some future quarter our operating results may fall below the expectations of securities analysts and investors, which could result in a decrease in the trading price of our common stock. In addition, if the Company fails to meet expectations related to future growth, profitability, dividends, or other market expectations, the price of the Company’s common stock may decline significantly, which could have a material adverse impact on investor confidence and employee retention. In the past, securities class action litigation has often been brought against a company following periods of volatility in the market price of its securities. We may be the target of similar litigation in the future. Securities litigation could result in substantial costs and divert management's attention and resources, which could seriously harm our business and operating results.

 

We may issue additional shares of preferred stock that could defer a change of control or dilute the interests of our common shareholders. Our charter documents could defer a takeover effort which could inhibit your ability to receive an acquisition premium for your shares.

 

Our charter permits our Board of Directors to issue up to 5.0 million shares of preferred stock without shareholder approval. Currently there are 2,500 shares of our Convertible Preferred Stock issued and outstanding. This leaves slightly less than 5.0 million shares of preferred stock available for issuance at the discretion of our Board of Directors. These shares, if issued, could contain dividend, liquidation, conversion, voting, or other rights which could adversely affect the rights of our common shareholders and which could also be utilized, under some circumstances, as a method of discouraging, delaying, or preventing a change in control. Provisions of our articles of incorporation, bylaws and Florida law could make it more difficult for a third party to acquire us, even if many of our shareholders believe it is in their best interest.

 

13
 

 

Our ability to pay regular dividends to our shareholders and the amounts of any such dividends are subject to the discretion of the Board and may be limited by our financial condition, or limitations under Florida law.

 

We have paid dividends to our shareholders since 2009 and it is currently anticipated that we will continue to pay regular quarterly dividends, any such determination to pay dividends and the amounts thereof will be at the discretion of the Board and will be dependent on then-existing conditions, including our financial condition, income, legal requirements, including limitations under Florida law, and other factors the Board deems relevant. The Board has previously decided, and may in the future decide, in its sole discretion, to change the amount or frequency of dividends or discontinue the payment of dividends entirely. For these reasons, shareholders will not be able to rely on dividends to receive a return on investment. Accordingly, realization of any gain on shares of our common stock may depend on the appreciation of the price of our common stock, which may not occur.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None

 

ITEM 2. PROPERTIES

 

We own our facilities, including our principal executive offices and distribution center, which are located at 420 South Congress Avenue, Delray Beach, Florida 33445 (the “Property”). The Property consists of approximately 634,000 square feet of land or 14.6 acres with two building complexes totaling approximately 185,000 square feet, with additional land for future use. The first building complex consists of approximately 125,000 square feet and the second building complex consists of approximately 60,000 square feet each consisting of both office and warehouse space. The Company occupies approximately 97,000 square feet of the first building for its principal offices and distribution center. As of March 31, 2022, 48% of the Property was leased to two tenants with a remaining weighted average lease term of 3.0 years. We believe that our facilities are sufficient for our current needs and are in good condition in all material respects.

 

ITEM 3. LEGAL PROCEEDINGS         

 

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made other states will not attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.          

 

14
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES          ’

 

Price Range of Common Stock

 

Our common stock is traded on the NASDAQ Global Select Market (“NASDAQ”) under the symbol “PETS.” The prices set forth below reflect the high and low sale prices per share in each of the quarters of fiscal 2022 and 2021 as reported by the NASDAQ.

 

Fiscal 2022:

  

High

    

Low

  

First Quarter

     $46.06       $27.73  

Second Quarter

     $34.00       $26.50  

Third Quarter

     $32.00       $25.26  

Fourth Quarter

     $29.18       $23.62  
                 

Fiscal 2021:

  

High

    

Low

  

First Quarter

     $40.96       $27.94  

Second Quarter

     $41.83       $29.00  

Third Quarter

     $33.77       $28.96  

Fourth Quarter

     $51.80       $29.77  

 

Holders

 

There were 105 holders of record of our common stock on May 24, 2022, and approximately 48,300 of our holders are “street name” or beneficial holders, whose shares are held by banks, brokers, or other financial institutions.

 

Dividends

 

During fiscal 2021 and 2022, our Board of Directors declared the following dividends:

 

Declaration Date

  

Per Share

Dividend

  

Record Date

  

Total Amount

(In thousands)

  

Payment Date
                     

May 4, 2020

     $0.28  

May 15, 2020

     $5,647  

May 22, 2020

July 20, 2020

     $0.28  

July 31, 2020

     $5,647  

August 7, 2020

October 26, 2020

     $0.28  

November 9, 2020

     $5,676  

November 20, 2020

January 19, 2021

     $0.28  

February 1, 2021

     $5,676  

February 12, 2021

May 3, 2021

     $0.30  

May 14, 2021

     $6,081  

May 21, 2021

July 26, 2021

     $0.30  

August 6, 2021

     $6,102  

August 13, 2021

October 25, 2021

     $0.30  

November 8, 2021

     $6,283  

November 19, 2021

January 24, 2022

     $0.30  

February 7, 2022

     $6,294  

February 18, 2022

 

On May 3, 2021, the Company’s Board of Directors declared an increased quarterly dividend from $0.28 to $0.30 per share, on its common stock. The Company’s Board of Directors declared a quarterly dividend of $0.30 per share on May 9, 2022. The Board established a May 20, 2022 record date and a May 27, 2022 payment date. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.

 

Issuer Purchases of Equity Securities

 

On November 8, 2006, the Company's Board of Directors approved a share repurchase plan of up to $20.0 million. On October 31, 2008, November 1, 2010, and August 1, 2011, the Company’s Board of Directors approved an increase under the share repurchase plan, each for an additional $20.0 million. The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company's discretion, subject to market conditions and other factors, in accordance with SEC requirements.

 

15
 

 

There can be no assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company may discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements. Shares purchased pursuant to the share repurchase plan will either be cancelled or held in the Company's treasury. On January 25, 2019, the Company’s Board of Directors authorized an additional $30.0 million under the repurchase plan. During fiscal 2020 the Company purchased and retired approximately 613,000 shares of its common stock for approximately $11.5 million, averaging approximately $18.73 per share. As of March 31, 2022, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan. Since the inception of the share repurchase plan up to March 31, 2022, approximately 6.2 million shares have been repurchased under the plan for approximately $81.3 million, averaging approximately $13.11 per share.

 

Performance Graph

 

Set forth below is a line graph comparing the five-year cumulative performance of our Common Stock with the Nasdaq Composite, the Russell 2000, and our SIC Code 5912 (pharmacy peer group) from March 31, 2017, to March 31, 2022. The graph assumes that $100 was invested on March 31, 2017, in each of our Common Stock, the Nasdaq Composite, the Russell 2000, and the SIC Code 5912 (pharmacy peer group). Because we have historically paid dividends on a quarterly basis, the graph assumes that dividends were reinvested. The performance graph and related information below shall not be deemed “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act or Exchange Act, each as amended, except to the extent that we specifically incorporate it by reference into such filing.

 

graph01.jpg

 

Performance graph data:

 

   

Fiscal Year Ended March 31,

  
   

2017

    

2018

    

2019

    

2020

    

2021

    

2022

  

PetMed Express, Inc.

     100.00       211.75       119.69       159.37       201.60       155.76  

Nasdaq Composite

     100.00       120.76       133.60       134.52       233.26       252.05  

SIC Code 5912

     100.00       80.17       75.01       70.52       92.62       108.31  

Russell 2000

     100.00       111.79       114.09       86.72       168.96       159.19  

 

16
 

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table sets forth securities authorized for issuance under equity compensation plans, including individual compensation arrangements, by us under our 2015 Outside Director Equity Compensation Restricted Stock Plan and 2016 Employee Equity Compensation Restricted Stock Plan as of March 31, 2022:

 

EQUITY COMPENSATION PLAN INFORMATION

(In thousands)
   

Number of securities

           

Number of securities

 
   

to be issued upon

   

Weighted average

   

remaining available

 
   

exercise of outstanding

   

exercise price of

   

for future issuance

 
   

options, warrants

   

outstanding options,

   

under equity

 

Plan category

  

and rights

   

warrants and rights

   

compensation plans

 
                         

2015 Outside Director Equity Compensation Restricted Stock Plan

     65       -       488 (1)
                         

2016 Employee Equity Compensation Restricted Stock Plan

     706       -       107  
                         

Total

     771               595  

 

 

(1)

The number of shares of common stock available for issuance under the 2015 Outside Director Equity Compensation Restricted Stock Plan automatically increase on the first trading day of January each calendar year during the term of the 2015 Outside Director Equity Compensation Restricted Stock Plan, by an amount equal to ten percent (10%) of the total number of shares of common stock authorized under the 2015 Outside Director Equity Compensation Restricted Stock Plan.

 

ITEM 6. [RESERVED]

 

17
 

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Executive Summary

 

PetMed Express (the “Company”) was incorporated in the state of Florida in January 1996, and since 2004 its common stock has traded on the NASDAQ Global Select Market under the symbol “PETS.” The Company began selling pet medications and other pet health products in September 1996, and in March 2010, the Company started offering additional pet supplies on its website for sale, and these items are drop shipped to customers by third party vendors. Presently, the Company’s product line includes approximately 3,000 of the most popular pet medications, health products, and supplies for dogs, cats, and horses.

 

The Company markets its products through national advertising campaigns which aim to increase the recognition of the “PetMeds” brand name, increase traffic on its website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Approximately 84% of all sales were generated via the Internet in both fiscal 2022 and fiscal 2021. The twelve-month average purchase was approximately $93 per order for the fiscal year ended March 31, 2022, compared to $89 for the fiscal year ended March 31, 2021.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our Consolidated Financial Statements and the data used to prepare them. The Company’s Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

 

Revenue recognition

 

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

 

The Company disaggregates revenue in the following two categories: (1) reorder sales vs new order sales, and (2) internet sales vs contact center sales. The following table illustrates sales by various classifications:

 

Year Ended March 31,

  

Sales (In thousands)

  

2022

    

%

    

2021

    

%

    

$ Variance

    

% Variance

  
                                                 

Reorder Sales

   $ 250,401       91.6 %   $ 272,648       88.2 %   $ (22,247 )     -8.2 %

New Order Sales

   $ 23,016       8.4 %   $ 36,567       11.8 %   $ (13,551 )     -37.1 %
                                                 

Total Net Sales

   $ 273,417       100.0 %   $ 309,215       100.0 %   $ (35,798 )     -11.6 %
                                                 

Internet Sales

   $ 230,263       84.2 %   $ 259,404       83.9 %   $ (29,141 )     -11.2 %

Contact Center Sales

   $ 43,154       15.8 %   $ 49,811       16.1 %   $ (6,657 )     -13.4 %
                                                 

Total Net Sales

   $ 273,417       100.0 %   $ 309,215       100.0 %   $ (35,798 )     -11.6 %

 

18
 

 

Year Ended March 31,

  

Sales (In thousands)

  

2021

    

%

    

2020

    

%

    

$ Variance

    

% Variance

  
                                                 

Reorder Sales

   $ 272,648       88.2 %   $ 248,560       87.5 %   $ 24,088       9.7 %

New Order Sales

   $ 36,567       11.8 %   $ 35,565       12.5 %   $ 1,002       2.8 %
                                                 

Total Net Sales

   $ 309,215       100.0 %   $ 284,125       100.0 %   $ 25,090       8.8 %
                                                 

Internet Sales

   $ 259,404       83.9 %   $ 238,054       83.8 %   $ 21,350       9.0 %

Contact Center Sales

   $ 49,811       16.1 %   $ 46,071       16.2 %   $ 3,740       8.1 %
                                                 

Total Net Sales

   $ 309,215       100.0 %   $ 284,125       100.0 %   $ 25,090       8.8 %

 

Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had no material contract asset or contract liability balances as of March 31, 2022, or March 31, 2021.

 

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at both March 31, 2021, and March 31, 2022.

 

Valuation of inventory

 

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at March 31, 2022 and 2021, respectively.

 

Advertising

 

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related brochures and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.

 

Accounting for income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740, (“Accounting for Income Taxes”), which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the Consolidated Financial Statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

 

19
 

 

Results of Operations

 

The following should be read in conjunction with the Company’s Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in the Company’s Consolidated Statements of Income:

 

   

Fiscal Year Ended March 31,

 
                         
   

2022

   

2021

   

2020

 
                         

Sales

     100.0

%

     100.0

%

     100.0

%

Cost of sales

     71.4       70.9       71.4  
                         

Gross profit

     28.6       29.1       28.6  
                         

Operating expenses:

                        

General and administrative

     11.3       9.1       8.9  

Advertising

     6.9       7.0       8.0  

Depreciation

     1.0       0.8       0.8  
Total operating expenses        19.2        16.9        17.7  
                         

Income from operations

     9.4       12.2       10.9  
                         

Total other income

     0.5       0.5       1.0  
                         

Income before provision for income taxes

     9.9       12.7       11.9  
                         

Provision for income taxes

     2.2       2.8       2.8  
                         

Net income

     7.7

%

     9.9

%

     9.1

%

 

Non-GAAP Financial Measures

 

Adjusted EBITDA and Adjusted EBITDA per share

 

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA and adjusted EBITDA per share, non-GAAP financial measures that we calculate as net income excluding; share-based compensation expense; depreciation and amortization; income tax provision; and interest income (expense). We have provided reconciliations below of adjusted EBITDA to net income and adjusted EBITDA per share to diluted earnings per share, the most directly comparable GAAP financial measures.

 

We have included adjusted EBITDA and adjusted EBITDA per share, herein, because they are key measures used by our management and Board of Directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses. Accordingly, we believe that adjusted EBITDA and adjusted EBITDA per share provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

 

20
 

 

We believe it is useful to exclude non-cash charges, such as, share-based compensation expense, depreciation and amortization from our adjusted EBITDA and adjusted EBITDA per share because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. In addition, we believe it is useful to exclude in our adjusted EBITDA and adjusted EBITDA per share income tax provision and interest income (expense), as neither are components of our core business operations. Adjusted EBITDA and adjusted EBITDA per share have limitations as financial measures, these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

 

 

●

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA and adjusted EBITDA per share do not reflect capital expenditure requirements for such replacements or for new capital expenditures;

 

 

●

Adjusted EBITDA and adjusted EBITDA per share do not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;

 

 

●

Adjusted EBITDA and adjusted EBITDA per share do not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital; and

 

 

●

Other companies, including companies in our industry, may calculate adjusted EBITDA and adjusted EBITDA per share differently, which reduces these measures’ usefulness as comparative measures.

 

Because of these and other limitations, you should consider adjusted EBITDA and adjusted EBITDA per share only as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

 

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA and adjusted EBITDA per share for each of the periods indicated:

 

Reconciliation of Non-GAAP Measures

  

PetMed Express, Inc.

  

 

   

Three Months Ended

                    

Year Ended

                  
   

March 31,

   

March 31,

     $    

%

    

March 31,

   

March 31,

     $    

%

  

($ in thousands, except percentages)

  

2022

    

2021

    

Change

    

Change

    

2022

    

2021

    

Change

    

Change

  
                                                                 

Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:

  
                                                                 

Net income

   $ 6,066     $ 6,812     $ (746 )     -11 %   $ 21,100     $ 30,603     $ (9,503 )     -31 %
                                                                 

Add (subtract):

                                                                

Share-based compensation

   $ 1,509     $ 1,013     $ 496       49 %   $ 4,549     $ 3,307     $ 1,242       38 %

Income Taxes

   $ 1,368     $ 2,037     $ (669 )     -33 %   $ 5,971     $ 8,613     $ (2,642 )     -31 %

Depreciation

   $ 687     $ 636     $ 51       8 %   $ 2,738     $ 2,427     $ 311       13 %

Interest Income/Expense

   $ (92 )   $ (85 )   $ (7 )     8 %   $ (335 )   $ (314 )   $ (21 )     7 %
                                                                 

Adjusted EBITDA

   $ 9,538     $ 10,413     $ (875 )     -8 %   $ 34,023     $ 44,636     $ (10,613 )     -24 %

 

 

   

Three Months Ended

                    

Year Ended

                  

($ in thousands, except percentages

  

March 31,

   

March 31,

     $    

%

    

March 31,

   

March 31,

     $    

%

  

and per share amounts)

  

2022

    

2021

    

Change

    

Change

    

2022

    

2021

    

Change

    

Change

  
                                                                 

Consolidated Reconciliation of GAAP Net Income Per Share to Adjusted EBITDA per share:

  
                                                                 

Net income per share, diluted

   $ 0.30     $ 0.34     $ (0.04 )     -12 %   $ 1.04     $ 1.52     $ (0.48 )     -32 %
                                                                 

Add (subtract):

                                                                

Share-based compensation

   $ 0.07     $ 0.05     $ 0.02       40 %   $ 0.22     $ 0.16     $ 0.06       38 %

Income Taxes

   $ 0.07     $ 0.10     $ (0.03 )     -30 %   $ 0.29     $ 0.43     $ (0.14 )     -33 %

Depreciation

   $ 0.03     $ 0.03     $ -       0 %   $ 0.13     $ 0.12     $ 0.01       8 %

Interest Income/Expense

   $ -     $ -     $ -       0 %   $ (0.01 )   $ (0.01 )   $ -       0 %
                                                                 

Adjusted EBITDA Per Share

   $ 0.47     $ 0.52     $ (0.05 )     -9 %   $ 1.67     $ 2.22     $ (0.55 )     -25 %

 

21
 

 

Fiscal 2022 Compared to Fiscal 2021

 

COVID-19

 

We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our workplace. The Company has been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain; however, we have experienced some delays in the delivery of some inventory items. See risk factor “The outbreak of the COVID-19 global pandemic and related government, private sector and individual consumer responsive actions may adversely affect our business operations, employee availability, financial performance, liquidity and cash flow for an unknown period of time” in Part I, Item 1A of this Form 10-K.

 

Sales

 

Sales decreased by approximately $35.8 million, or 11.6%, to $273.4 million for the fiscal year ended March 31, 2022, from approximately $309.2 million for the fiscal year ended March 31, 2021. The decrease in sales for the fiscal year ended March 31, 2022, was primarily due to decreases in reorder and new order sales. Sales for fiscal year 2022 were impacted by a much more competitive environment, and a crowded advertising market which had substantially higher advertising costs compared to the same period in the prior year. Veterinary visits increased during fiscal year 2022, compared to being down during the prior year. We believe the increase in veterinary visits was primarily due to pet owners needing to visit their veterinarian for their pets’ annual exam in order to renew their prescriptions, as many veterinarians were closed in the prior year due to the pandemic. The Company acquired approximately 263,000 new customers for the fiscal year ended March 31, 2022, compared to approximately 443,000 new customers for the same period the prior year. The following chart illustrates sales by various sales classifications:

 

Year Ended March 31,

  

Sales (In thousands)

  

2022

    

%

    

2021

    

%

    

$ Variance

    

% Variance

  
                                                 

Reorder Sales

   $ 250,401       91.6 %   $ 272,648       88.2 %   $ (22,247 )     -8.2 %

New Order Sales

   $ 23,016       8.4 %   $ 36,567       11.8 %   $ (13,551 )     -37.1 %
                                                 

Total Net Sales

   $ 273,417       100.0 %   $ 309,215       100.0 %   $ (35,798 )     -11.6 %
                                                 

Internet Sales

   $ 230,263       84.2 %   $ 259,404       83.9 %   $ (29,141 )     -11.2 %

Contact Center Sales

   $ 43,154       15.8 %   $ 49,811       16.1 %   $ (6,657 )     -13.4 %
                                                 

Total Net Sales

   $ 273,417       100.0 %   $ 309,215       100.0 %   $ (35,798 )     -11.6 %

 

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior post pandemic makes future sales somewhat challenging to predict. No guarantees can be made that sales will continue to grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications. For the quarters ended June 30, September 30, December 31, and March 31 of fiscal year 2022, the Company’s sales were approximately 29%, 25%, 22%, and 24%, respectively. For the quarters ended June 30, September 30, December 31, and March 31 of fiscal year 2021, the Company’s sales were approximately 31%, 25%, 21%, and 23%, respectively.

 

Cost of sales

 

Cost of sales decreased by approximately $24.0 million, or 10.9% to $195.3 million for the fiscal year ended March 31, 2022, from $219.3 million for the fiscal year ended March 31, 2021. The cost of sales decrease can be directly related to the decrease in sales during fiscal year 2022. As a percentage of sales, cost of sales was 71.4% in fiscal year 2022, as compared to 70.9% in fiscal 2021. The cost of sales percentage increase was adversely impacted due to the major manufacturers, with whom we have a purchasing relationship, shifting their rebate funding from discounting product costs to more cooperative marketing rebates.

 

22
 

 

Gross profit

 

Gross profit decreased by approximately $11.8 million, or 13.2%, to $78.1 million for the fiscal year ended March 31, 2022, from $89.9 million for the fiscal year ended March 31, 2021. The decrease in gross profit can be directly related to the decrease in sales during fiscal 2022. Gross profit as a percentage of sales for fiscal 2022 was 28.6% compared to 29.1% for fiscal 2021. The decrease in the gross profit percentage was adversely impacted due to the major manufacturers, with whom we have a purchasing relationship, shifting their rebate funding from discounting product costs to more cooperative marketing rebates.

 

General and administrative expenses

 

General and administrative expenses increased by approximately $2.5 million, or 9.0%, to $30.8 million for the fiscal year ended March 31, 2022, from $28.3 million for the fiscal year ended March 31, 2021. The increase in general and administrative expenses for the fiscal year ended March 31, 2022 was primarily due to the following: a $1.4 million increase in payroll expenses, the majority of which related to increased stock compensation expense; a $989,000 increase in professional fees related to brand and marketing consultation, legal, and investment banking; and a $514,000 increase in other expenses which include property expenses, travel related expense, insurance expense, and other expenses. Offsetting the increase was a decrease of $397,000 primarily related to decreased bank service fees due to the decrease in sales. General and administrative expenses as a percentage of sales was 11.3% for the fiscal year ended March 31, 2022, compared to 9.1% for the fiscal year ended March 31, 2021. The Company expects general and administrative expense as a percentage of sales to approximate 12.5% and expects stock compensation expense to approximate $6.4 million in fiscal 2023.

 

Advertising expenses

 

Advertising expenses decreased by approximately $2.8 million to $18.8 million for the fiscal year ended March 31, 2022, from $21.6 million for the fiscal year ended March 31, 2021. The decrease in advertising expenses for fiscal 2022 was due to the Company receiving increased cooperative marketing funds from product manufacturers to offset our advertising expenses, within the terms of our contractual relationships. Overall advertising spending was flat compared to fiscal 2021, yet total net advertising expenses decreased due to increased cooperative advertising rebates. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $72 for the fiscal year ended March 31, 2022, compared to $49 for the fiscal year ended March 31, 2021. The increase to customer acquisition costs for the fiscal year ended March 31, 2022, was due to an increase in overall advertising prices and a less efficient variable marketing spend. Advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, advertising spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future sales, whereas a less favorable advertising environment may negatively impact future sales. As a percentage of sales, advertising expense was 6.9% and 7.0% for the fiscal years ended March 31, 2022, and 2021, respectively. The Company currently anticipates advertising as a percentage of sales to be approximately 7.0% for fiscal year 2023. However, the advertising percentage may fluctuate quarter to quarter due to seasonality and advertising availability.

 

Depreciation

 

Depreciation expense for the fiscal year ended March 31, 2022, increased to approximately $2.7 million from $2.4 million for the fiscal year ended March 31, 2021. This increase to depreciation expense for the fiscal year ended March 31, 2022, can be attributed to increased new property and equipment additions in fiscal 2022.

 

Other income

 

Other income decreased by approximately $268,000, to $1.4 million for the fiscal year ended March 31, 2022, from $1.6 million for the fiscal year ended March 31, 2021. The decrease was related to a reduction in advertising income in fiscal 2022. Interest income was flat compared to the prior year. Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $28.7 million remaining as of March 31, 2022, on any quarterly dividend payment, on future investment/partnerships, or on its operating activities.

 

23
 

 

Provision for income taxes

 

For the fiscal years ended March 31, 2022 and 2021, the Company recorded an income tax provision of approximately $6.0 million and $8.6 million, respectively. The decrease to the income tax provision for fiscal 2022 is related to a decrease in operating income compared to fiscal 2021. The effective tax rate for the fiscal years ended March 31, 2022, and 2021 were 22.1% and 22.0%, respectively. The slight increase to the effective rate for the fiscal year ended March 31, 2022, can be attributed to the Company receiving more one-time tax benefits in fiscal 2021 than in fiscal 2022. The one-time tax benefits received in fiscal 2021 included a one-time state income tax refund of $285,000 in the June 2020 quarter and a $135,000 income tax benefit related to restricted stock compensation in the September 2020 and March 2021 quarters. This compared to a $196,000 one-time state income tax refund and a $131,000 benefit due to a state rate reduction in the March 2022 quarter. The Company estimates its effective tax rate will be approximately 23.0% for fiscal 2023.

 

Net income

 

Net income decreased by approximately $9.5 million, or 31%, to approximately $21.1 million for the fiscal year ended March 31, 2022, from approximately $30.6 million for the fiscal year ended March 31, 2021. The decrease to net income was primarily related to a decrease in sales and resulting gross profit, and an increase in general and administrative expenses, all partially offset by a decrease in advertising expenses, during the fiscal year.

 

Fiscal 2021 Compared to Fiscal 2020

 

Sales

 

Sales increased by approximately $25.1 million, or 8.8%, to $309.2 million for the fiscal year ended March 31, 2021, from approximately $284.1 million for the fiscal year ended March 31, 2020. The increase in sales for the fiscal year ended March 31, 2021 was primarily due to increased reorder sales and new order sales. Fiscal 2021 started out with greater than expected e-commerce demand due to COVID-19, with consumers shifting their purchases to online, which positively impacted our reorder and new order sales during the year. In the latter half of fiscal 2021, veterinarian clinics and retail stores re-opened. The Company acquired approximately 443,000 new customers for the fiscal year ended March 31, 2021, compared to approximately 421,000 new customers for the same period the prior year. The following chart illustrates sales by various sales classifications:

 

Year Ended March 31,

  

Sales (In thousands)

  

2021

    

%

    

2020

    

%

    

$ Variance

    

% Variance

  
                                                 

Reorder Sales

   $ 272,648       88.2 %   $ 248,560       87.5 %   $ 24,088       9.7 %

New Order Sales

   $ 36,567       11.8 %   $ 35,565       12.5 %   $ 1,002       2.8 %
                                                 

Total Net Sales

   $ 309,215       100.0 %   $ 284,125       100.0 %   $ 25,090       8.8 %
                                                 

Internet Sales

   $ 259,404       83.9 %   $ 238,054       83.8 %   $ 21,350       9.0 %

Contact Center Sales

   $ 49,811       16.1 %   $ 46,071       16.2 %   $ 3,740       8.1 %
                                                 

Total Net Sales

   $ 309,215       100.0 %   $ 284,125       100.0 %   $ 25,090       8.8 %

 

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior post pandemic makes future sales somewhat challenging to predict. No guarantees can be made that sales will continue to grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick medications. For the quarters ended June 30, September 30, December 31, and March 31 of fiscal 2021, the Company’s sales were approximately 31%, 25%, 21%, and 23%, respectively. For the quarters ended June 30, September 30, December 31, and March 31 of fiscal 2020, the Company’s sales were approximately 28%, 25%, 21%, and 26%, respectively.

 

Cost of sales

 

Cost of sales increased by approximately $16.4 million, or 8.1% to $219.3 million for the fiscal year ended March 31, 2021, from $202.9 million for the fiscal year ended March 31, 2020. The cost of sales increase can be directly related to the increase in sales during fiscal 2021. As a percentage of sales, cost of sales was 70.9% in fiscal 2021, as compared to 71.4% in fiscal 2020. The cost of sales percentage decrease can be attributed to the benefit of having direct relationships with all major manufacturers, which helped reduce product costs, and these manufacturers having minimum advertised price policies. In the future, cost of sales may be adversely impacted due to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates.

 

24
 

 

Gross profit

 

Gross profit increased by approximately $8.7 million, or 10.7%, to $89.9 million for the fiscal year ended March 31, 2021, from $81.2 million for the fiscal year ended March 31, 2020. The increase in gross profit can be directly related to the increase in sales during fiscal 2021. Gross profit as a percentage of sales for fiscal 2021 was 29.1% compared to 28.6% for fiscal 2020. The increase in gross profit percentage can be attributed to the benefit of having direct relationships with all major manufacturers, which helped reduce product costs, and these manufacturers having minimum advertised price policies. Going forward gross profit may be adversely affected due to increased competition and consumers giving more consideration to price. In the future, gross profit may also be adversely impacted due to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates.

 

General and administrative expenses

 

General and administrative expenses increased by approximately $3.0 million, or 12.0%, to $28.3 million for the fiscal year ended March 31, 2021 from $25.3 million for the fiscal year ended March 31, 2020. The increase in general and administrative expenses for the fiscal year ended March 31, 2021 was primarily due to the following: a $1.9 million increase in payroll expenses, due to increased sales and increased COVID-19 related work from home expenses, with $485,000 related to increased stock compensation expense due to the accelerated release of restrictions of the Company’s former Chairman Robert Schweitzer’s restricted stock upon his passing on February 23, 2021; a $619,000 increase in bank service fees due to increased sales; a $388,000 increase in property expenses related to the Company’s e-commerce platform; and a $207,000 increase in telephone expenses due to employees working from home in response to COVID-19. Offsetting the increase was a net decrease of $48,000 to other expenses which include insurance, professional fees, and bad debt expense. General and administrative expenses as a percentage of sales was 9.1% for the fiscal year ended March 31, 2021, compared to 8.9% for the fiscal year ended March 31, 2020.

 

Advertising expenses

 

Advertising expenses decreased by approximately $1.1 million to $21.6 million for the fiscal year ended March 31, 2021, from $22.7 million for the fiscal year ended March 31, 2020. The decrease in advertising expenses for fiscal 2021 was due to the Company receiving increased cooperative marketing funds from product manufacturers to offset our advertising expenses, within the terms of our contractual relationships. Overall advertising spending increased over the prior year, yet total net advertising expenses decreased due to increased cooperative advertising rebates. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $49 for the fiscal year ended March 31, 2021, compared to $54 for the fiscal year ended March 31, 2020. The decrease to customer acquisition costs for the fiscal year ended March 31, 2021 can also be attributed to receiving increased cooperative marketing funds from product manufacturers. Advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, advertising spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future sales, whereas a less favorable advertising environment may negatively impact future sales.

 

As a percentage of sales, advertising expense was 7.0% and 8.0% for the fiscal years ended March 31, 2021 and 2020, respectively. The decrease in advertising expense as a percentage of total sales for the fiscal year ended March 31, 2021 can be attributed to a decrease in advertising expenses and an increase in sales as compared to the same period in the prior year. The Company currently anticipates advertising as a percentage of sales to be approximately 7% for fiscal 2022. However, the advertising percentage may fluctuate quarter to quarter due to seasonality and advertising availability.

 

Depreciation

 

Depreciation expense for the fiscal year ended March 31, 2021 increased slightly to approximately $2.4 million from $2.3 million for the fiscal year ended March 31, 2020. This increase to depreciation expense for the fiscal year ended March 31, 2021 can be attributed to increased new property and equipment additions in fiscal 2021.

 

25
 

 

Other income

 

Other income decreased by approximately $1.3 million to $1.6 million for the fiscal year ended March 31, 2021, from $2.9 million for the fiscal year ended March 31, 2020. The decrease to other income was primarily related to decreased interest income due to decreased interest rates compared to the prior year. Interest income may decrease in the future as the Company utilizes its cash balances on its share repurchase plan, with approximately $28.7 million remaining at March 31, 2021, on any quarterly dividend payment, on its operating activities, or with further decreases in interest rates.

 

Provision for income taxes

 

For the fiscal years ended March 31, 2021 and 2020, the Company recorded an income tax provision of approximately $8.6 million and $8.0 million, respectively. The increase to the income tax provision for fiscal 2021 is related to an increase in operating income compared to fiscal 2020. The effective tax rate for the fiscal years ended March 31, 2021 and 2020 were 22.0% and 23.7%, respectively. The decrease to the effective rate for the fiscal year ended March 31, 2021 can be attributed to the Company receiving a one-time state income tax refund of $285,000 in the June 2020 quarter and a $135,000 income tax benefit related to restricted stock compensation in the September 2020 and March 2021 quarters, compared to a $322,000 income tax charge related to restricted stock compensation, which was recognized in the September 2019 quarter. The Company estimates its effective tax rate will be approximately 23.5% for fiscal 2022.

 

Net income

 

Net income increased by approximately $4.7 million, or 18.4%, to approximately $30.6 million for the fiscal year ended March 31, 2021 from approximately $25.9 million for the fiscal year ended March 31, 2020. The increase to net income was primarily related to an increase in gross profit, offset by an increase in operating expenses and a decrease to interest income during the fiscal year.

 

Liquidity and Capital Resources

 

The Company’s working capital at March 31, 2022 and 2021 was approximately $117.8 million and approximately $116.3 million, respectively. The $1.5 million increase in working capital was primarily attributable to income generated by operations and a reduction to accounts payable, offset by dividends paid in the period. Net cash provided by operating activities was $18.5 million and $40.1 million for the fiscal years ended March 31, 2022 and 2021, respectively. This change can be mainly attributed to a decrease in the Company’s net income for the fiscal year ended March 31, 2022 and a decrease to accounts payable compared to the prior year. Net cash used in investing activities was $1.8 million and $2.4 million for the fiscal years ended March 31, 2022 and 2021, respectively. This change in investing activities is related to decreased property and equipment additions acquired in fiscal 2022. Net cash used in financing activities was $24.4 million and $22.7 million for the fiscal years ended March 31, 2022 and 2021, respectively. The increase to financing activities relates to an increase in the dividend paid in fiscal 2022, compared to the dividend paid in fiscal 2021. At March 31, 2022, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

 

Subsequent to March 31, 2022, the Company’s Board of Directors declared a quarterly dividend of $0.30 per share on May 9, 2022. The Board established a May 20, 2022 record date and a May 27, 2022 payment date. Depending on future market conditions the Company may utilize its cash and cash equivalents on the remaining balance of its current share repurchase plan, on quarterly dividends, or on its operating activities.

 

At March 31, 2022 the Company had no material outstanding lease commitments. We are not currently bound by any long- or short-term agreements for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any future increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Presently, we have approximately $5.0 million forecasted for capital expenditures in fiscal 2023, which will be funded through cash from operations. The Company’s primary source of working capital is cash from operations. The Company presently has no need for alternative sources of working capital and has no commitments or plans to obtain additional capital.

 

Recent Accounting Pronouncements

 

Other than disclosures included in Note 1 of the Consolidated Financial Statements, which are incorporated by reference as if fully set forth herein, the Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

 

26
 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At March 31, 2022, we had $111.1 million in cash and cash equivalents, primarily money market accounts. A majority of our cash and cash equivalents generates interest income based on prevailing interest rates.

 

A significant change in interest rates could impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our investments are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our investments to high-quality debt instruments with both short- and long-term maturities. We do not hold any derivative financial instruments that could expose us to significant market risk. At March 31, 2022, we had no debt obligations.

 

27
 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Page

 

Report of Independent Registered Public Accounting Firm (PCAOB ID:49) 29
   
Consolidated Balance Sheets as of March 31, 2022 and 2021 30
   
Consolidated Statements of Income for each of the three years in the period ended March 31, 2022 31
   
Consolidated Statements of Changes in Shareholders’ Equity for each of the three years in the period ended March 31, 2022 32
   
Consolidated Statements of Cash Flows for each of the three years in the period ended March 31, 2022 33
   
Notes to Consolidated Financial Statements 34
   
Report of Management on Internal Control Over Financial Reporting 46
   
Report of Independent Registered Public Accounting Firm 47

                                                                                                                                                                                                                                  

28
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and the Board of Directors of PetMed Express, Inc. and subsidiaries

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of PetMed Express, Inc. and its subsidiaries (the Company) as of March 31, 2022 and 2021, the related consolidated statements of income, changes in shareholders’ equity and cash flows for each of the three years in the period ended March 31, 2022, and the related notes to the consolidated financial statements (collectively, the financial statements).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2022 and 2021, and the results of their operations and their cash flows for each of the three years in the period ended March 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of March 31, 2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013, and our report dated May 24, 2022 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (i) relate to accounts or disclosures that are material to the financial statements and (ii) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

 

/s/ RSM US LLP

 

We have served as the Company’s auditor since 2007.

 

Fort Lauderdale, Florida

May 24, 2022

 

29
 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share amounts)

 

  

March 31,

  

March 31,

 
  

2022

  

2021

 

ASSETS

        
         

Current assets:

        

Cash and cash equivalents

 $111,080  $118,718 

Accounts receivable, less allowance for doubtful accounts of $39 and $39, respectively

  1,913   2,587 

Inventories - finished goods

  32,455   34,420 

Prepaid expenses and other current assets

  4,866   4,503 

Prepaid income taxes

  681   959 
         

Total current assets

  150,995   161,187 
         

Noncurrent assets:

        

Property and equipment, net

  24,464   25,450 

Intangible assets

  860   860 
         

Total noncurrent assets

  25,324   26,310 
         

Total assets

 $176,319  $187,497 
         

LIABILITIES AND SHAREHOLDERS' EQUITY

        
         

Current liabilities:

        

Accounts payable

 $27,500  $39,548 

Accrued expenses and other current liabilities

  5,697   5,387 
         

Total current liabilities

  33,197   44,935 
         

Deferred tax liabilities

  936   1,281 
         

Total liabilities

  34,133   46,216 
         

Commitments and contingencies

          
         

Shareholders' equity:

        

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

  9   9 

Common stock, $.001 par value, 40,000 shares authorized; 20,979 and 20,269 shares issued and outstanding, respectively

  21   20 

Additional paid-in capital

  11,660   7,111 

Retained earnings

  130,496   134,141 
         

Total shareholders' equity

  142,186   141,281 
         

Total liabilities and shareholders' equity

 $176,319  $187,497 

 

See accompanying notes to consolidated financial statements.

 

30
 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES 

CONSOLIDATED STATEMENTS OF INCOME 

(In thousands, except for per share amounts) 

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Sales

 $273,417  $309,215  $284,125 

Cost of sales

  195,341   219,267   202,879 
             

Gross profit

  78,076   89,948   81,246 
             

Operating expenses:

            

General and administrative

  30,829   28,293   25,264 

Advertising

  18,799   21,641   22,748 

Depreciation

  2,738   2,427   2,257 

Total operating expenses

  52,366   52,361   50,269 
             

Income from operations

  25,710   37,587   30,977 
             

Other income (expense):

            

Interest income, net

  335   314   1,747 

Other, net

  1,026   1,315   1,169 

Total other income

  1,361   1,629   2,916 
             

Income before provision for income taxes

  27,071   39,216   33,893 
             

Provision for income taxes

  5,971   8,613   8,042 
             

Net income

 $21,100  $30,603  $25,851 
             

Net income per common share:

            

Basic

 $1.05  $1.53  $1.29 

Diluted

 $1.04  $1.52  $1.29 
             

Weighted average number of common shares outstanding:

            

Basic

  20,176   20,060   20,041 

Diluted

  20,358   20,119   20,055 
             

Cash dividends declared per common share

 $1.20  $1.12  $1.08 

 

See accompanying notes to consolidated financial statements.

 

31
 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY 

Years ended March 31, 2020, March 31, 2021, and March 31, 2022 

(In thousands) 

 

  

Convertible

  

Common

  

Additional

         
  

Preferred Stock

  

Stock

  

Paid-In

  

Retained

     
  

Shares

  

Amounts

  

Shares

  

Amounts

  

Capital

  

Earnings

  

Total

 
                             

Balance, March 31, 2019

  3   9   20,674   21   12,478   122,172   134,680 
                             

Issuance of restricted stock, net

  -   -   105   -   -   -   - 
                             

Share based compensation

  -   -   -   -   2,822   -   2,822 
                             

Repurchased and retired shares

  -   -   (613)  (1)  (11,496)  -   (11,497)
                             

Dividends declared

  -   -   -   -   -   (21,846)  (21,846)
                             

Net income

  -   -   -   -   -   25,851   25,851 
                             

Balance, March 31, 2020

  3   9   20,166   20   3,804   126,177   130,010 
                             

Issuance of restricted stock, net

  -   -   103   -   -   -   - 
                             

Share based compensation

  -   -   -   -   3,307   -   3,307 
                             

Dividends declared

  -   -   -   -   -   (22,639)  (22,639)
                             

Net income

  -   -   -   -   -   30,603   30,603 
                             

Balance, March 31, 2021

  3   9   20,269   20   7,111   134,141   141,281 
                             

Issuance of restricted stock, net

  -   -   710   1   -   -   1 
                             

Share based compensation

  -   -   -   -   4,549   -   4,549 
                             

Dividends declared

  -   -   -   -   -   (24,745)  (24,745)
                             

Net income

  -   -   -   -   -   21,100   21,100 
                             

Balance, March 31, 2022

  3  $9   20,979  $21  $11,660  $130,496  $142,186 

 

See accompanying notes to consolidated financial statements.

 

32
 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

  

Year Ended

 
  

March 31,

 
  

2022

  

2021

  

2020

 

Cash flows from operating activities:

            

Net income

 $21,100  $30,603  $25,851 

Adjustments to reconcile net income to net cash provided by operating activities:

            

Depreciation

  2,738   2,427   2,257 

Share based compensation

  4,549   3,307   2,822 

Deferred income taxes

  (345)  311   (151)

Bad debt expense

  165   130   191 

(Increase) decrease in operating assets and increase (decrease) in liabilities:

            

Accounts receivable

  509   1,126   (1,492)

Inventories - finished goods

  1,965   (16,536)  3,486 

Prepaid income taxes

  278   (959)  582 

Prepaid expenses and other current assets

  (363)  (974)  (376)

Accounts payable

  (12,048)  19,890   3,383 

Accrued expenses and other current liabilities

  (50)  1,221   1,820 

Income taxes payable

  -   (471)  471 

Net cash provided by operating activities

  18,498   40,075   38,844 
             

Cash flows from investing activities:

            

Purchases of property and equipment

  (1,752)  (2,432)  (2,311)

Net cash used in investing activities

  (1,752)  (2,432)  (2,311)
             

Cash flows from financing activities:

            

Dividends paid

  (24,384)  (22,687)  (21,803)

Repurchase and retirement of common stock

  -   -   (11,497)

Net cash used in financing activities

  (24,384)  (22,687)  (33,300)
             

Net (decrease) increase in cash and cash equivalents

  (7,638)  14,956   3,233 
             

Cash and cash equivalents, at beginning of year

  118,718   103,762   100,529 
             

Cash and cash equivalents, at end of year

 $111,080  $118,718  $103,762 
             

Supplemental disclosure of cash flow information:

            
             

Cash paid for income taxes

 $6,085  $10,018  $7,140 
             

Property and equipment in current assets

 $-  $-  $1,745 
             

Dividends payable in accrued expenses

 $558  $198  $246 

 

See accompanying notes to consolidated financial statements.

 

33
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(1)         Summary of Significant Accounting Policies

 

Organization

 

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds® (the “Company”), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs, cats, and horses, direct to the consumer. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the “1-800-PetMeds” brand name and “PetMeds” family of trademarks, increase traffic on its website atwww.petmeds.com, acquire new customers, and maximize repeat purchases. Virtually all of the Company's sales are to residents in the United States. The Company’s corporate headquarters and distribution facility are located in Delray Beach, Florida. The Company's fiscal year end is March 31, and references herein to fiscal 2022, 2021, or 2020 refer to the Company's fiscal years ended March 31, 2022, 2021, and 2020, respectively.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.

 

Revenue Recognition

 

The Company generates revenue by selling pet medication products and pet supplies. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

 

The Company disaggregates revenue in the following two categories: (1) reorder sales vs new order sales, and (2) internet sales vs contact center sales. The following table illustrates s by various classifications:

 

Year Ended March 31,

 

Sales (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $250,401   91.6% $272,648   88.2% $(22,247)  -8.2%

New Order Sales

 $23,016   8.4% $36,567   11.8% $(13,551)  -37.1%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%
                         

Internet Sales

 $230,263   84.2% $259,404   83.9% $(29,141)  -11.2%

Contact Center Sales

 $43,154   15.8% $49,811   16.1% $(6,657)  -13.4%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%

 

34
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(1)         Summary of Significant Accounting Policies (Continued)

 

Year Ended March 31,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $272,648   88.2% $248,560   87.5% $24,088   9.7%

New Order Sales

 $36,567   11.8% $35,565   12.5% $1,002   2.8%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%
                         

Internet Sales

 $259,404   83.9% $238,054   83.8% $21,350   9.0%

Contact Center Sales

 $49,811   16.1% $46,071   16.2% $3,740   8.1%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%

 

Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had no material contract asset or liability balances as of March 31, 2022 and 2021.

 

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at March 31, 2022 and March 31, 2021.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2022 and 2021 consisted of the Company’s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Inventories

 

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at March 31, 2022 and 2021, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from three to ten years.

 
35
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(1)         Summary of Significant Accounting Policies (Continued)

 

Long-lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.

 

Intangible Assets

 

The intangible assets consist of a toll-free telephone number and an internet domain name. In accordance with the Accounting Standards Codification (“ASC”) Topic 350 (“Goodwill and Other Intangible Assets”) the intangible assets are not being amortized and are subject to an annual review for impairment.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

 

Advertising

 

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.

 

Comprehensive Income

 

The Company applies ASC Topic 220 (“Reporting Comprehensive Income”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended March 31, 2022, 2021 and 2020 the Company had no unrealized gains or losses.

 

Income Taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

The Company applies “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remains open. The Company files tax returns in the U.S. federal jurisdiction and Florida and Arizona.  With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March 31, 2019, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).

 

36
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(1)         Summary of Significant Accounting Policies (Continued)

 

Business Concentrations

 

The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our products to obtain the lowest cost. There were five suppliers from which we purchased approximately 80% of all products in fiscal 2022 and 2021.

 

Accounting for Share Based Compensation

 

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.

 

Recent Accounting Pronouncements         

 

In March 2020, the Financial Accounting Standards Board issued ASU 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU 2020-03 on April 1, 2022. The Company does not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

 

The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.

 

 

(2)         Property and Equipment

 

Major classifications of property and equipment consist of the following (in thousands):

 

  

March 31,

 
  

2022

  

2021

 
         

Building

 $14,997  $14,997 

Land

  3,700   3,700 

Building Improvements

  2,834   2,834 

Computer Software

  5,512   5,621 

Furniture, fixtures and equipment

  9,106   8,626 
   36,149   35,778 

Less: accumulated depreciation

  (11,685)  (10,328)
         

Property and equipment, net

 $24,464  $25,450 

 
 

(3)         Valuation and Qualifying Accounts

 

Activity in the Company's valuation and qualifying accounts consists of the following (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Allowance for doubtful accounts:

            

Balance at beginning of period

 $39  $59  $39 

Provision for doubtful accounts

  165   130   191 

Write-off of uncollectible accounts receivable

  (165)  (150)  (171)
             

Balance at end of year

 $39  $39  $59 

 

37
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(4)         Accrued Expenses and Other Current Liabilities

 

Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):

 

  

March 31,

 
  

2022

  

2021

 
         

Accrued sales tax

 $1,106  $1,063 

Accrued credit card fees

  428   456 

Accrued salaries and benefits

  1,134   1,525 

Accrued merchandise credits / reward program

  1,623   1,413 

Accrued professional expenses

  459   290 

Accrued sales return allowance

  190   220 

Accrued dividends payable

  558   198 

Accrued real estate taxes

  111   114 

Other accrued liabilities

  88   108 
         

Accrued expenses and other current liabilities

 $5,697  $5,387 

 
 

(5)         Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

  

March 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Accrued expenses

 $364  $406 

Deferred stock compensation

  662   321 

Bad debt and inventory reserves

  27   29 
         

Total deferred tax assets

  1,053   756 
         

Deferred tax liabilities:

        

Property and equipment

  (1,989)  (2,037)
         

Total net deferred tax liabilities

 $(936) $(1,281)

 

At March 31, 2022, the Company had no federal net operating loss carryforwards.

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Current taxes

            

Federal

 $5,801  $7,446  $7,352 

State

  515   856   841 

Total current taxes

  6,316   8,302   8,193 
             

Deferred taxes

            

Federal

  (317)  279   (135)

State

  (28)  32   (16)

Total deferred taxes

  (345)  311   (151)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 

 
38
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(5)         Income Taxes (Continued)

 

The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Income taxes at U.S. statutory rates

 $5,685  $8,235  $7,118 

State income taxes, net of federal tax benefit

  379   708   649 

Restricted stock (windfall) shortfall adjustment

  33   (135)  322 

Other

  (126)  (195)  (47)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 

 

In fiscal 2022 the Company recognized a stock compensation shortfall charge of approximately $33,000 and recognized a one-time charge of approximately $29,000 related to a return to provision true up of the fiscal 2021 income tax provision. In fiscal 2021 the Company recognized a stock compensation windfall benefit of approximately $135,000, and recognized a one-time benefit of approximately $194,000, related to a return to provision true up of the fiscal 2020 income tax provision. In fiscal 2020 the Company recognized a stock compensation shortfall charge of approximately $322,000, and recognized a one-time benefit of approximately $93,000, related to a return to provision true up of the fiscal 2019 income tax provision.

 

 

(6)         Shareholders’ Equity

 

Preferred Stock

 

In April 1998, the Company issued 250,000 shares of its $.001 par value preferred stock at a price of $4.00 per share, less issuance costs of $112,187. Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder. The shares have a liquidation value of $4.00 per share and may pay dividends at the sole discretion of the Company. The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company. At March 31, 2022 and 2021, 2,500 shares of the convertible preferred stock remained unconverted and outstanding.

 

Share Repurchase Plan

 

On November 8, 2006, the Company's Board of Directors approved a share repurchase plan of up to $20.0 million. On October 31, 2008, November 1, 2010, and August 1, 2011, the Company’s Board of Directors approved an increase under the repurchase plan each for an additional $20.0 million. On January 25, 2019, the Company’s Board of Directors authorized an additional $30.0 million under the repurchase plan. The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company's discretion, subject to market conditions and other factors, in accordance with Securities and Exchange Commission requirements. There can be no assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company may discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements. Shares purchased pursuant to the share repurchase plan will either be retired or held in the Company's treasury. During fiscal 2020 the Company purchased and retired approximately 613,000 shares of its common stock for approximately $11.5 million. During fiscal 2022 and 2021 the Company had no share repurchases. At March 31, 2022 the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

 

39
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(6)         Shareholders’ Equity (Continued)

 

Dividends

 

On May 3, 2021, the Company’s Board of Directors increased the quarterly dividend to $0.30 per share, on its common stock. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance. During fiscal 2022, our Board of Directors declared the following dividends:

 

Declaration Date

 

Per Share

Dividend

 

Record Date

 

Total Amount

(In thousands)

 

Payment Date

           

May 3, 2021

  $0.30 

May 14, 2021

  $6,081 

May 21, 2021

July 26, 2021

  $0.30 

August 6, 2021

  $6,102 

August 13, 2021

October 25, 2021

  $0.30 

November 8, 2021

  $6,283 

November 19, 2021

January 24, 2022

  $0.30 

February 7, 2022

  $6,294 

February 18, 2022

 

 

(7)         Restricted Stock

 

In July 2015, the Company’s 2015 Outside Director Equity Compensation Restricted Stock Plan (“2015 Director Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The 2015 Director Plan authorizes 400,000 shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of 10% of the shares authorized under the plan. In July 2016, the Company’s 2016 Employee Equity Compensation Restricted Stock Plan (“2016 Employee Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The 2016 Employee Plan authorizes 1,000,000 shares of the Company's Common stock available for issuance under the plan. The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company’s Board and is to be no less than 1 year and no more than ten years unless otherwise specified by the Board of Directors.

 

At March 31, 2022, the Company had 893,258 restricted common shares issued under the 2016 Employee Plan and 208,880 restricted common shares issued under the 2015 Director Plan. The majority of shares were issued subject to a restriction and forfeiture period which lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over a one to three-year restriction period. For the fiscal years ended March 31, 2022, 2021, and 2020, the Company recognized compensation expense related to the Employee and Director Plans of $4.5 million, $3.3 million, and $2.8 million, respectively.

 

A summary of the Company’s non-vested restricted stock at March 31, 2022 is as follows (in thousands):

 

  

Employee

Plan

Number of

Shares

  

Director

Plan

Number of

Shares

  

Both Plans

Number of

Shares

 
             

Non-vested restricted stock outstanding at March 31, 2021

  98   62   160 
             

Restricted stock granted

  676   44   720 
             

Restricted stock vested

  (69)  (30)  (99)
             

Restricted stock forfeited or expired

  (3)  (7)  (10)
             

Non-vested restricted stock outstanding at March 31, 2022

  702   69   771 

 

At March 31, 2022 and 2021, there were 770,652 and 160,117, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended March 31, 2022 and 2021, the Company issued, net of forfeitures, 709,599 and 102,931 restricted shares, respectively. At March 31, 2022 and 2021, there were $13.4 million and $2.5 million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 and 1.8 years for fiscal 2022 and 2021, respectively.

 

40
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(8)         Fair Value Measurements

 

The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurements”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s cash equivalents are classified within Level 1. At March 31, 2022 and 2021 the Company had invested the majority of its cash and cash equivalents balance in money market funds (level 1).

 

 

(9)         Net Income Per Share

 

In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding. The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 

Net income (numerator):

            
             

Net income

 $21,100  $30,603  $25,851 
             

Shares (denominator)

            
             

Weighted average number of common shares outstanding used in basic computation

  20,176   20,060   20,041 

Common shares issuable upon the vesting of restricted stock

  172   49   4 

Common shares issuable upon conversion of preferred shares

  10   10   10 

Shares used in diluted computation

  20,358   20,119   20,055 
             

Net income per common share:

            
             

Basic

 $1.05  $1.53  $1.29 

Diluted

 $1.04  $1.52  $1.29 

 

At March 31, 2022, 2021, and 2020, 220,727, 20,952, and 72,120 shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share.

 

41
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(10)         Commitments and Contingencies

 

Legal Matters and Routine Proceedings

 

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

 

Operating Leases

 

Upon acquisition of the Delray Beach property in January 2016, 48% of the property, approximately 88,000 square feet of the property was leased to two tenants. At March 31, 2022, the leases with these two tenants had a remaining weighted average lease term of 3.0 years. The Company recorded approximately $689,000 and $670,000 in rental revenue in fiscal 2022 and 2021, respectively, which was included in other income. The Company expects to receive the following future lease payments, under the current lease agreements, over the next five years: $710,000 in fiscal 2023; $731,000 in fiscal 2024, $566,000 in fiscal 2025, and $110,000 in fiscal 2026.

 

Employment Agreements

 

On July 12, 2019, the Company entered into Amendment No. 7 , with Menderes Akdag (“Mr. Akdag”), former CEO & President and Director, providing that in the event that a Change in Control (as was thereinafter defined) of the Company was to occur at any time, Mr. Akdag would have the right to terminate his employment for “Good Reason,” (as was thereinafter defined) upon thirty (30) days written notice given at any time within one (1) year after the occurrence of such event, and upon such termination Mr. Akdag would be entitled to a one-time payment of two times his salary as of the date of such termination. On July 31, 2020, the Company entered into Amendment No. 8 which extended Mr. Akdag’s contract for an additional year at an annual rate of $626,860 and granted Mr. Akdag 37,800 restricted shares, which were subject to restriction and forfeiture until July 31, 2021, in accordance with the parameters of his executive compensation plan.

 

On May 28, 2021, the Board of Directors notified Mr. Akdag that the Company would not extend Mr. Akdag’s employment agreement with the Company, and the employment agreement would therefore end on July 30, 2021, in accordance with the scheduled end date of the agreement. Effective July 31, 2021, the Board of Directors appointed Bruce S. Rosenbloom (“Mr. Rosenbloom”), the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President of the Company, until a permanent successor chief executive officer was appointed. Mr. Rosenbloom received an additional cash stipend of $10,000 for the additional responsibilities while serving as Interim Chief Executive Officer and President, which ended on August 30, 2021.

 

On June 11, 2021, the Company and Mr. Akdag, entered into a CEO Separation Agreement and General Release setting forth certain matters relating to the expiration of Mr. Akdag’s employment with the Company (the “Separation Agreement”). The Separation Agreement provided that Mr. Akdag’s employment with the Company, and service as an officer and director of the Company, would terminate as of July 30, 2021. The Separation Agreement also documented Mr. Akdag’s agreement that, during his remaining period of employment through July 30, 2021, he would continue to provide his fulltime and attention to the business affairs of the Company and cooperate with the Company’s Board of Directors on the transition to a new chief executive officer. The Separation Agreement provided that Mr. Akdag would be paid two lump-sum severance payments of $325,000 each, with the first such payment to be paid, and was paid, on August 10, 2021, and the second to be paid, and was paid, on December 31, 2021, subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company’s agreement to make the severance payments, Mr. Akdag granted the Company a full release of any and all claims that he may have against the Company and its affiliates and related parties.

 
42
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(10)         Commitments and Contingencies (Continued)

 

In addition, as a part of the Separation Agreement, the Company confirmed that the 37,800 restricted shares held by Mr. Akdag will be, and were, released from restriction and forfeiture on July 31, 2021, and that the Company would, and did, cover the tax withholding obligations in connection with such release of shares from restriction and forfeiture. Under the Separation Agreement, Mr. Akdag agreed that he would continue to comply with his existing confidentiality, non-solicitation, and non-compete obligations, and he further agreed that until July 31, 2022, he would comply with certain “standstill” covenants relating to the Company.

 

On August 25, 2021, the Board of Directors appointed Mathew N. Hulett (Mr. Hulett”) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments were effective as of August 30, 2021. On August 25, 2021, the Company entered into an employment agreement with Mr. Hulett to serve as the Company’s Chief Executive Officer and President. The employment agreement is for an initial term of three (3) years commencing on August 30, 2021 and will automatically renew for successive one (1) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement is expressly cancelled by either Mr. Hulett or the Company sixty (60) days prior to the end of the then current term, or is otherwise terminated as provided in the agreement. The employment agreement provides that Mr. Hulett will receive an annual base salary of $500,000, subject to periodic review for increases with the approval of the Board of Directors, and will be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company’s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement also provides that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contains certain rights of Mr. Hulett and the Company to terminate Mr. Hulett’s employment, including termination by the Company for “Cause” as defined in the employment agreement, and termination by Mr. Hulett for “Good Reason” as defined in the employment agreement within twelve (12) months of a Change in Control as defined in the employment agreement. Mr. Hulett is also entitled to severance pay equal to twelve (12) months of Mr. Hulett’s current base salary and eighteen (18) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett’s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (1) year non-compete following the termination of the agreement.

 

On August 30, 2021, Mr. Hulett also received an award of 90,000 shares of restricted stock under the Company’s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of August 30, 2022, August 30, 2023, and August 30, 2024, which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the three-year period from the date of grant, and (ii) continued employment through the performance period of three years from the date of grant, in accordance with the following schedule: 85,000 shares at the stock hurdle price of $40 per share, 107,000 shares at the stock hurdle price of $45 per share, 106,000 shares at the stock hurdle price of $50, 106,000 shares at the stock hurdle price of $55, and 106,000 shares at the stock hurdle price of $60.

 

Should none of the absolute stock price hurdles be met during the three-year period from the date of grant no shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (90) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett’s continued employment through the performance period of three years from the date of grant (except as provided in the performance restricted stock agreement). As of March 31, 2022, none of the performance restricted stock vested, as no performance stock price hurdles were met.

 

43
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(11)         Employee Benefit Plan

 

The Company maintains a 401(k) Savings Plan for eligible employees.  The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing one year of service and having attained the age of 21.  The plan provides for growth in savings through contributions and income from investments.  It is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended. Plan participants are allowed to contribute a specified percentage of their base salary. In 2006, the Company approved a matching contribution which is funded subsequent to the calendar year. During the fiscal years ended March 31, 2022, 2021, and 2020, the Company charged $238,000, $245,000, and $211,000, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.

 

 

(12)         COVID-19

 

On March 11, 2020, the World Health Organization declared that the novel coronavirus (COVID-19) had become a pandemic, and on March 13, 2020, the U.S. President declared a National Emergency concerning the disease. Additionally, in March 2020, state governments in the Company’s geographic operating area began instituting preventative shut down measures in order to combat the novel coronavirus pandemic. The coronavirus and actions taken to mitigate the spread of it have had and are expected to continue to have an adverse impact on the economies and financial markets of the geographical area in which the Company operates. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted to amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the novel coronavirus pandemic. The Company’s business being deemed essential resulted in incremental financial performance that may not be indicative of future financial results and there remains uncertainty and increased risks concerning its employees, customers, supply chain and government regulation.

 

During fiscal 2022, the Company has been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain; however, we have experienced some delays in the delivery of some inventory items. We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our workplace.

 

 

(13)         Subsequent Events

 

Subsequent to March 31, 2022 the Company issued 7,450 restricted shares to certain employees of the Company under the 2016 Employee Plan, with a fair value of $23.50 per share. In April 2022, the Company issued 1,875 restricted shares to Diana Garvis Purcell, a newly appointed director on our Board of Directors, with a fair value of $25.53 per share. In connection with Ms. Purcel’s appointment on the Board, the Board voted to increase the size of the Board by one director to seven persons effective April 4, 2022.

 

On April 19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (“Vetster”), a veterinary telehealth Canadian company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million The Company also received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company becomes the exclusive e-commerce provider for Vetster, and Vetster becomes the exclusive provider of telehealth and telemedicine services to the Company.

 

On May 9, 2022, the Company’s Board of Directors declared a quarterly dividend of $0.30 per share on its common stock. The $6.3 million dividend will be payable on May 27, 2022, to shareholders of record at the close of business on May 20, 2022.

 

44
 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

(14)         Related Party Transaction

 

The Company’s Board of Directors Chairman, Gian Fulgoni, serves on the board of directors of Prophet, a brand and marketing consulting company, which PetMed Express, Inc. engaged with in March 2021 for $292,000. The Company expensed $32,000 in fiscal 2021, with the remaining $260,000 expensed in fiscal 2022. This transaction was approved by the Company’s Board of Directors with terms that are comparable to those with an unrelated third party.

 

 

(15)         Quarterly Financial Data (Unaudited)

 

Summarized unaudited quarterly financial data for fiscal 2022 and 2021 is as follows (in thousands, except for per share amounts):

 

Quarter Ended:

 

June 30, 2021

  

September 30, 2021

  

December 31, 2021

  

March 31, 2022

 
                 

Sales

 $79,312  $67,386  $60,717  $66,002 

Gross Profit

 $21,780  $19,174  $17,725  $19,397 

Income from operations

 $5,419  $8,087  $5,147  $7,057 

Net income

 $4,428  $6,349  $4,257  $6,066 

Diluted net income per common share

 $0.22  $0.31  $0.21  $0.30 
                 

Quarter Ended:

 

June 30, 2020

  

September 30, 2020

  

December 31, 2020

  

March 31, 2021

 
                 

Sales

 $96,204  $75,436  $65,896  $71,679 

Gross Profit

 $26,785  $23,018  $19,623  $20,522 

Income from operations

 $9,436  $10,471  $9,293  $8,387 

Net income

 $7,768  $8,412  $7,611  $6,812 

Diluted net income per common share

 $0.39  $0.42  $0.38  $0.34 

 

45
 
  
 

REPORT OF MANAGEMENT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

 

Management of the Company is responsible for the preparation and integrity of the Consolidated Financial Statements appearing in our Annual Report on Form 10-K. The financial statements were prepared in conformity with generally accepted accounting principles appropriate in the circumstances and, accordingly, include certain amounts based on our best judgments and estimates. Financial information in the Annual Report on Form 10-K is consistent with that in the financial statements.

 

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) under the Securities Exchange Act of 1934 (“Exchange Act”). The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Consolidated Financial Statements. Our internal control over financial reporting is supported by a team of consultants and appropriate reviews by management, written policies and guidelines, careful selection and training of qualified personnel, and a written Corporate Code of Business Conduct and Ethics adopted by our Company’s Board of Directors, applicable to all Company Directors and all officers and employees of our Company and subsidiaries.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements and even when determined to be effective, can only provide reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

The Audit Committee (“Committee”) of our Company’s Board of Directors, comprised solely of Directors who are independent in accordance with the requirements of The NASDAQ Stock Market LLC listing standards, the Exchange Act and the Company’s Corporate Governance Guidelines, meets with the independent auditors and management periodically to discuss internal control over financial reporting, and auditing and financial reporting matters. The Committee reviews with the independent auditors the scope and results of the audit effort. The Committee also meets periodically with the independent auditors without management present to ensure that the independent auditors have free access to the Committee.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework - 2013. Based on our assessment, management believes that the Company maintained effective internal control over financial reporting as of March 31, 2022.

 

The Company’s independent auditors, RSM US LLP, a registered public accounting firm, are appointed by the Audit Committee of the Company’s Board of Directors, subject to ratification by our Company’s shareholders. RSM US LLP have audited and reported on the Consolidated Financial Statements of PetMed Express, Inc. and subsidiaries, and issued a report on the Company’s internal control over financial reporting. The reports of the independent auditors are contained in our Annual Report on Form 10-K.

 

 

/s/ Mathew N. Hulett

Mathew N. Hulett

President, Chief Executive Officer, Director

 

May 24, 2022

 

/s/ Bruce S. Rosenbloom

Bruce S. Rosenbloom

Chief Financial Officer

 

May 24, 2022

 

46
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and the Board of Directors of PetMed Express, Inc. and subsidiaries

 

Opinion on the Internal Control Over Financial Reporting

We have audited PetMed Express, Inc. and subsidiaries’ (the Company) internal control over financial reporting as of March 31, 2022, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.  In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of March 31, 2022, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

 

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements of the Company and our report dated May 24, 2022 expressed an unqualified opinion.

 

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

 

/s/ RSM US LLP

 

 

Fort Lauderdale, Florida
May 24, 2022

 

47
 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE                  

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures                  

 

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15(e) and 15d-15(e) promulgated under the Exchange Act) as of March 31, 2022, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date, that our disclosure controls and procedures were effective such that the information relating to PetMed Express, Inc., including our consolidated subsidiaries, required to be disclosed in our SEC reports (i) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2022 based on the framework in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control — Integrated Framework, management concluded that our internal control over financial reporting was effective, as of March 31, 2022, as stated in our report which is included herein. Our internal control over financial reporting as of March 31, 2022 has been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report which is contained in “Item 8. Financial Statements and Supplementary Data” of this Annual Report on Form 10-K.

 

Changes in Internal Controls over Financial Reporting

 

There have been no changes in our internal controls over financial reporting during the fourth quarter ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

Not applicable.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

None.

 

48
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE          

 

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2022, relating to our 2022 Annual Meeting of Stockholders to be held on July 28, 2022, and is incorporated herein by reference.

 

We adopted a Corporate Code of Business Conduct and Ethics applicable to all officers, directors, and employees. The Company’s Corporate Code of Business Conduct and Ethics is available on our website at www.petmeds.com under “About Us - Corporate Governance”. You may also obtain a copy of our Corporate Code of Business Conduct and Ethics free of charge by contacting Investor Relations at 1-800-738-6337.

 

ITEM 11. EXECUTIVE COMPENSATION                  

 

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2022, relating to our 2022 Annual Meeting of Stockholders to be held on July 28, 2022, and is incorporated herein by reference.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS                  

 

The information required by this item (other than information required by Item 201(d) of Regulation S-K with respect to equity compensation plans, which is set forth under Item 5. in this Annual Report on Form 10-K) will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2022, relating to our 2022 Annual Meeting of Stockholders to be held on July 28, 2022, and is incorporated herein by reference.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2021, relating to our 2021 Annual Meeting of Stockholders to be held on July 28, 2022, and is incorporated herein by reference.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this item will be set forth in our Proxy Statement, to be filed with the SEC within 120 days after the end of the fiscal year ended March 31, 2022, relating to our 2022 Annual Meeting of Stockholders to be held on July 28, 2022, and is incorporated herein by reference.

 

49
 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES                   

 

(a)

The following documents are filed as part of this Annual Report on Form 10-K.

 

 

(1)

Consolidated Financial Statements – See the Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K.

 

The following exhibits are filed as part of this Annual Report on Form 10-K or hereby incorporated by reference to exhibits previously filed with the SEC.

 

 

(3)

 Articles of Incorporation and By-Laws

 

 

3.1

Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).
 

3.2

Articles of Amendment to the Amended and Restated Articles of Incorporation filed June 6, 2001 (incorporated by reference to Exhibit 3.2 of the Registrant’s Form 10-K for the year ended March 31, 2015, filed May 22, 2015).
 

3.4

Second Amended and Restated By-Laws of PetMed Express, Inc. (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K, filed March 26, 2020).

 

 

(4)

 Instruments Defining the Rights of Security Holders

 

 

4.1

Specimen common stock certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10-SB, File No. 000-28827, filed January 10, 2000).
 

4.2

Description of Securities.*

 

 

(10)

 Material Contracts

 

 

10.1+

Employment Letter with Bruce Rosenbloom dated May 30, 2001 (incorporated by reference to Exhibit 10.9 of the Registrant’s Form 8-K filed April 7, 2009).
 

10.2+

2015 Outside Director Equity Compensation Restricted Stock Plan (incorporated by reference to Exhibit B of our definitive Proxy Statement for our 2015 Annual Meeting of Stockholders filed June 8, 2015).
 

10.2.1

Form of Restricted Stock Agreement used for grants of restricted stock under the 2015 Outside Director Equity Compensation Restricted Stock Plan (incorporated by reference to Exhibit 10.10.1 of the Registrant’s Form 10-K for the year ended March 31, 2017 filed May 23, 2017).
 

10.3

Agreement of Purchase and Sale [420 South Congress Avenue] (incorporated by reference to Exhibit 10.11 of the Registrant’s Form 10-Q for the quarter ended December 31, 2015, filed February 2, 2016).
 

10.4+

2016 Employee Equity Compensation Restricted Stock Plan, including form of Restricted Stock Agreement used for grants of restricted stock (incorporated by reference to Exhibit A of our definitive Proxy Statement for our 2016 Annual Meeting of Stockholders filed June 13, 2016).
 

10.5+

Amendment No. 1 to Offer Letter with Bruce Rosenbloom (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 10-Q for the quarter ended September 30, 2017, filed October 31, 2017).
 

10.6+

Form of Indemnification Agreement entered into with the Directors and Executive Officers of the Company (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 10-Q for the quarter ended June 30, 2019, filed July 30, 2019).
 

10.7+

CEO Separation Agreement and General Release with Menderes Akdag (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed June 15, 2021).
 

10.8+

Letter Agreement with Bruce Rosenbloom (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed July 6, 2021).
 

10.9+

Executive Employment Agreement with Mathew N. Hulett (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed August 30, 2021).
 

10.10+

Restricted Stock Agreement with Mathew N. Hulett (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed August 30, 2021).
 

10.11+

Restricted Performance Stock Agreement with Mathew N. Hulett (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K filed August 30, 2021).

 

50
 

 

 

(21)

 Subsidiaries of Registrant

 

 

21.1

Subsidiaries of Registrant*

 

 

(23)

 Consents of Experts and Counsel

 

 

23.1

Consent of RSM US LLP*

 

 

(31)

 Certifications

 

 

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)*
 

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*

 

 

(32)

 Certifications

 

 

32.1

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 1350**

 

 

*Filed herewith

**Furnished herewith

+ Indicates a management contract or compensatory plan or arrangement

 

101.INS*** Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
   
101.SCH*** Inline XBRL Taxonomy Extension Schema Document
   
101.CAL*** Inline XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF*** Inline XBRL Taxonomy Extension Definition LInkbase Document
   
101.LAB*** Inline XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE*** Inline XBRL Taxonomy Extension Presentation Linkbase Document
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

***    XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act, as amended, is deemed not filed for purposes of section 18 of the Exchange Act, and otherwise is not subject to liability under these sections.

 

ITEM 16. FORM 10–K SUMMARY

 

None.

 

51
 

 

SIGNATURES

 

    Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: May 24, 2022

 

 

PETMED EXPRESS, INC.

 
  (the “registrant”)  

 

 

 

 

 

  By:

/s/ Mathew N. Hulett

 

 

  Mathew N. Hulett

 

 

  Chief Executive Officer and President

 
    (principal executive officer)  

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on May 24, 2022.

 

      SIGNATURE

  

        TITLE
     

/s/ Mathew N. Hulett

  

Chief Executive Officer, President and Director

(principal executive officer)

Mathew N. Hulett

    
     

/s/ Gian M. Fulgoni

  

Chairman of the Board and Director

Gian M. Fulgoni

  

 
     

/s/ Bruce S. Rosenbloom

  

Chief Financial Officer and Treasurer

(principal financial and accounting officer)

Bruce S. Rosenbloom

    
     

/s/ Ronald J. Korn

  

Director

Ronald J. Korn

    
     

/s/ Leslie C.G. Campbell

  

Director

Leslie C.G. Campbell

  

 
     
/s/ Jodi Watson   Director

Jodi Watson

    
     

/s/ Peter S. Cobb

  

Director

Peter S. Cobb

  

 
     
/s/ Diana Garvis Purcel   Director

Diana Garvis Purcel

    

 

52
EX-4.2 2 ex_378979.htm EXHIBIT 4.2 ex_378979.htm

Exhibit 4.2

 

DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED

PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

The following is a brief description of the common stock, $0.001 par value per share (the “Common Stock”), of PetMed Express, Inc., a Florida corporation (the “Company”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.

 

Description of Common Stock

 

General

 

The following descriptions of our Common Stock and of certain provisions of Florida law do not purport to be complete and are subject to and qualified in their entirety by reference to our amended and restated articles of incorporation, our amended and restated bylaws and the Florida Business Corporation Act, as amended (the “Florida Act”). The Company has authorized 40,000,000 shares of Common Stock of which as of May 24, 2022, 20,988,237 shares of Common Stock are issued and outstanding. All of our outstanding shares of Common Stock are fully paid and non-assessable. Our Common Stock is listed on the NASDAQ Global Select Market under the symbol “PETS.”

 

Common Stock

 

Holders of the Common Stock have no pre-emptive, redemption, subscription or conversion rights. Each outstanding share of Common Stock is entitled to one vote on all matters submitted to a vote of the Company's shareholders. Subject to the dividend rights of the holders of any outstanding preferred stock, each share of Common Stock is entitled to participate equally with respect to dividends as may be declared by the board of directors out of funds legally available therefor. In the case of voluntary or involuntary liquidation, distribution or sale of assets, dissolution, or winding up of the Company, holders of our Common Stock are entitled to receive a pro rata share of the amount distributed after provisions for payment of all debts, other liabilities and any liquidation preferences of outstanding preferred stock. The Florida Act also may affect the terms of these securities.

 

Limitations on Rights of Holders of Common Stock – Preferred Stock

 

The rights of holders of Common Stock may be materially limited or qualified by the rights of holders of preferred stock that we may issue in the future. Set forth below is a description of the Company’s authority to issue preferred stock and the possible terms of that stock.

 

Our amended and restated articles of incorporation authorizes our board of directors, without further shareholder action, to provide for the issuance of up to 5,000,000 shares of preferred stock, with a par value of $.001 per share, in one or more series, and to fix the designations, preferences, conversion rights, cumulative, relative, participating, optional or other rights, including voting rights, qualifications, limitations or restrictions, redemption and liquidation preferences of each of these series. Of the preferred stock, 250,000 shares have been designated Convertible Preferred Stock of which as of May 24, 2022, 2,500 shares of Convertible Preferred Stock are issued and outstanding. We may amend from time to time our amended and restated articles of incorporation to increase the number of authorized shares of preferred stock. Any such amendment would require the approval of the holders of a majority of our shares of Common Stock entitled to vote.

 

Shareholder Action by Written Consent and Special Meeting

 

Our amended and restated bylaws provide for action by our shareholders without a meeting with the written consent of shareholders holding the number of shares necessary to approve such action if it were taken at a meeting at which all shares entitled to vote thereon were present. Our amended and restated bylaws also provide that shareholder action can be taken at an annual meeting of the shareholders or at a special meeting which may be called, for any purpose or purposes, by the board of directors or the person or persons authorized to do so by the board of directors and must be called by the Secretary if the holders of not less than ten percent of all votes entitled to be cast on any issue proposed to be considered at such special meeting sign, date and deliver to the Secretary one or more written demands for a special meeting, describing the purpose or purposes for which it is to be held.

 

 
 

 

Authorized but Unissued Shares 

 

Our authorized but unissued shares of Common Stock and preferred stock are available for future issuance without shareholder approval, subject to the requirements of applicable law or regulation, including any listing requirement of the principal stock exchange on which our Common Stock is then listed. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of Common Stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our Common Stock by means of a proxy contest, tender offer, merger or otherwise.

 

Board Authority to Amend Bylaws

 

Under our amended and restated bylaws, our board of directors has the authority to adopt, amend or repeal the bylaws without the approval of our shareholders unless the Florida Act reserves the power to amend a particular bylaw provision exclusively to the shareholders.

 

Certain Anti-Takeover provisions of Florida Law and our Bylaws

 

Florida Business Corporation Act

 

We are subject to certain anti-takeover provisions that apply to public corporations under Florida law. Pursuant to Section 607.0901 of the Florida Act, a publicly held Florida corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an “interested shareholder” without the approval of the holders of two-thirds of the voting shares of such corporation (excluding shares held by the interested shareholder), unless:

 

 

●

the transaction is approved by a majority of disinterested directors before the shareholder becomes an interested shareholder;

 

 

●

the interested shareholder has owned at least 80% of the corporation’s outstanding voting shares for at least five years preceding the announcement date of any such business combination;

 

 

●

the interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or

 

 

●

the consideration paid to the holders of the corporation’s voting stock is at least equal to certain fair price criteria.

 

An “interested shareholder” is defined as a person who together with affiliates and associates beneficially owns more than 10% of a corporation’s outstanding voting shares. We have not made an election in our amended and restated articles of incorporation to opt out of Section 607.0901.

 

In addition, we are subject to Section 607.0902 of the Florida Act which prohibits the voting of shares in a publicly held Florida corporation that are acquired in a “control share acquisition” unless (i) our board of directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by our board of directors, the holders of a majority of the corporation’s voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A “control share acquisition” is defined as an acquisition that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.

 

These statutory provisions may prevent takeover attempts that might result in a premium over the market price for shares of our common stock.

 

 
 

 

Advance Notice of Shareholder Proposals or Nominations

 

Our amended and restated bylaws provide that shareholders at an annual meeting may only consider proposals or nominations (i) specified in the notice of meeting given by or at the direction of the Board, (ii) properly brought before the meeting by or at the direction of the Board or (iii) otherwise properly brought before the meeting by a shareholder of the Company who was a shareholder of record on (a) the date of the giving of timely notice to our Corporate Secretary and (b) the record date for the meeting, who is entitled to vote at the meeting and who has given our Corporate Secretary timely written notice, in proper form. In addition to certain other applicable requirements, for business to be properly brought before an annual meeting by a shareholder, such shareholder generally must have given notice thereof in proper written form to our Corporate Secretary not less than 90 days nor more than 120 days prior to the anniversary date of the immediately preceding annual meeting of shareholders. Our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or defer a potential acquiror from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.

 

Proxy Access

 

Our By-Laws permit a shareholder (or a group of up to 20 shareholders) owning three percent (3%) or more of our common stock continuously for at least three years to nominate and include in our proxy statement candidates for up to the greater of 2 of 20% of our Board. To be timely, a notice of a nomination under our proxy access bylaw provisions must be delivered to or mailed and received at the principal executive offices of the Company not less than one-hundred twenty (120) days nor more than one-hundred fifty (150) days prior to the anniversary of the date that the Company first distributed its proxy statement to shareholders for the immediately preceding annual meeting of shareholders. The notice must contain certain information specified in our amended and restated bylaws.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for the Company's common stock is Continental Stock Transfer & Trust Company.

 

 
 EX-21.1 3 ex_378684.htm EXHIBIT 21.1 ex_378684.htm

Exhibit 21.1

 

SUBSIDIARIES OF PETMED EXPRESS, INC.

 

PetMed Express, Inc. directly owns all of the outstanding interests in the following subsidiaries:

 

Southeastern Veterinary Exports, Inc., a Florida Corporation

 

First Image Marketing, Inc., a Florida Corporation

 

Global Veterinary Supply, Inc., a Florida Corporation

 

420 South Congress Avenue LLC, a Florida Limited Liability Company

 

 

 

 

 
 EX-23.1 4 ex_378685.htm EXHIBIT 23.1 ex_378685.htm

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in these Registration Statements (No. 333-218917, No. 333-145179, No. 333-145180) on Form S-8 and related Reoffer Prospectus of PetMed Express, Inc. of our reports dated May 24, 2022, relating to the consolidated financial statements of PetMed Express, Inc., and the effectiveness of internal control over financial reporting appearing in the Annual Report on Form 10-K of PetMed Express, Inc. for the year ended March 31, 2022.

 

We also consent to the reference to our firm under the heading “Experts” in such Reoffer Prospectus.

 

/s/ RSM US LLP

West Palm Beach, Florida

May 24, 2022

 

 

 

 
 EX-31.1 5 ex_378686.htm EXHIBIT 31.1 ex_378686.htm

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Mathew N. Hulett, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of PetMed Express, Inc. for the fiscal year ended March 31, 2022;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

May 24, 2022

 

 

 

 

 

 

By:

/s/ Mathew N. Hulett

 

 

Mathew N. Hulett

 

 

Chief Executive Officer and President

 

 

 
 EX-31.2 6 ex_378687.htm EXHIBIT 31.2 ex_378687.htm

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Bruce S. Rosenbloom, certify that:

 

1.

I have reviewed this Annual Report on Form 10-K of PetMed Express, Inc. for the fiscal year ended March 31, 2022;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

May 24, 2022

 

 

 

 

 

 

By:

/s/ Bruce S. Rosenbloom

 

 

Bruce S. Rosenbloom

 

 

Chief Financial Officer

 

 

 
 EX-32.1 7 ex_378688.htm EXHIBIT 32.1 ex_378688.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Mathew N. Hulett, and I, Bruce S. Rosenbloom, each certify to the best of our knowledge, based upon a review of the Annual Report on Form 10-K for the year ended March 31, 2022 (the “Report”) of PetMed Express, Inc. (the “Registrant”), that:

 

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

 

(2)

the information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

 

 

Date: May 24, 2022

 

 

 

 

 

 

By:

  /s/  Mathew N. Hulett

 

 

Mathew N. Hulett

 

 

Chief Executive Officer and President

 
       
  By:   /s/  Bruce S. Rosenbloom  
  Bruce S. Rosenbloom  
  Chief Financial Officer  

  

 
 EX-101.SCH 8 pets-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Income link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Valuation and Qualifying Accounts link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Restricted Stock link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Net Income Per Share link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Employee Benefit Plan link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - COVID-19 link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Related Party Transaction link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 2 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 3 - Valuation and Qualifying Accounts (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Shareholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Restricted Stock (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Net Income Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 5 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 5 - Income Taxes - Deferred Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 5 - Income Taxes - Components of Income Tax Provision (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 6 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Shareholder's Equity - Declared Dividends (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 7 - Restricted Stock (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Restricted Stock - Non-vested Restricted Stock (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 9 - Net Income Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 11 - Employee Benefit Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 13 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 14 - Related Party Transaction (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 9 pets-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 pets-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 pets-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies us-gaap_OfficersCompensation Salary and Wage, Officer, Excluding Cost of Good and Service Sold Note 1 - Summary of Significant Accounting Policies Income taxes at U.S. statutory rates Note 2 - Property and Equipment Note 3 - Valuation and Qualifying Accounts Note 4 - Accrued Expenses and Other Current Liabilities Note 5 - Income Taxes us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1 Deferred Compensation Arrangement with Individual, Requisite Service Period (Year) Note 6 - Shareholders' Equity Note 7 - Restricted Stock Share-Based Payment Arrangement, Employee [Member] Note 9 - Net Income Per Share Income Tax Disclosure [Text Block] Note 15 - Quarterly Financial Data (Unaudited) us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details) Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details) Share based compensation Share-Based Payment Arrangement, Noncash Expense, Total Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details) Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details) us-gaap_LiabilitiesCurrent Total current liabilities us-gaap_DueToRelatedPartiesCurrent Due to Related Parties, Current, Total Note 5 - Income Taxes - Deferred Income Taxes (Details) Note 5 - Income Taxes - Components of Income Tax Provision (Details) Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details) Note 6 - Shareholder's Equity - Declared Dividends (Details) Note 7 - Restricted Stock - Non-vested Restricted Stock (Details) Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] pets_RevenueFromContractWithCustomerVariancePercentage Revenues, variance, percentage The percentage of changes in revenue in current period comparing to the same period in the previous year. Operating expenses: pets_RevenueFromContractWithCustomerVariance Revenues, variance The amount of changes in revenue in current period comparing to the same period in the previous year. Comprehensive Income, Policy [Policy Text Block] pets_RevenueFromContractWithCustomerPercentage Revenues, percentage Percentage of revenue from the specified category to the total revenue during the period. Income Tax, Policy [Policy Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Restricted stock forfeited or expired (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) Non-vested restricted stock outstanding at March 31, 2021 (in shares) Non-vested restricted stock outstanding at March 31, 2022 (in shares) Schedule of Nonvested Share Activity [Table Text Block] Depreciation Restricted stock granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Restricted stock vested (in shares) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Noncurrent assets: Stockholders' Equity Note Disclosure [Text Block] Compensation Related Costs, Policy [Policy Text Block] Advertising Cost [Policy Text Block] Common stock, $.001 par value, 40,000 shares authorized; 20,979 and 20,269 shares issued and outstanding, respectively Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Accrued sales tax Revenue from Contract with Customer [Policy Text Block] us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Accrued dividends payable Accounts payable us-gaap_DeferredTaxAssetsNet Total deferred tax assets Statistical Measurement [Axis] Preferred stock, liquidation preference (in dollars per share) Preferred Stock, Liquidation Preference Per Share (in dollars per share) Accrued salaries and benefits Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share Other accrued liabilities Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued, Total (in shares) Prepaid income taxes us-gaap_PolicyTextBlockAbstract Accounting Policies Cash paid for income taxes Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Accrued professional expenses Preferred stock, par value (in dollars per share) Dividends payable in accrued expenses us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion (in shares) Sales Revenues us-gaap_InventoryValuationReserves Inventory Valuation Reserves us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Common shares issuable upon the vesting of restricted stock (in shares) Inventories - finished goods Common shares issuable upon conversion of preferred shares (in shares) Dividend Declared May 4, 2020 [Member] Represents the dividend declared May 4, 2020. Dividend Declared July 20, 2020 [Member] Represents the dividend declared July 20, 2020. Customer [Axis] Dividend Declared October 26, 2020 [Member] Represents the dividend declared October 26, 2020. Customer [Domain] Dividend Declared January 19, 2021 [Member] Represents the dividend declared January 19, 2021. Grantee Status [Domain] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Grantee Status [Axis] Weighted average number of common shares outstanding: Prophet [Member] Represents Prophet. Bad debt and inventory reserves Current liabilities: Supplemental disclosure of cash flow information: Accrued expenses us-gaap_Assets Total assets Software and Software Development Costs [Member] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Plan Name [Axis] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Statement [Line Items] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Furniture and Fixtures [Member] Accounts receivable, less allowance for doubtful accounts of $39 and $39, respectively Accrued expenses and other current liabilities Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Additional paid-in capital Deferred stock compensation Building [Member] Share-Based Payment Arrangement [Text Block] Building Improvements [Member] Shareholders' equity: Land [Member] Property, Plant and Equipment, Policy [Policy Text Block] Other, net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other income Long-Lived Tangible Asset [Domain] Award Type [Domain] Chief Executive Officer [Member] 2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan") [Member] Refers to information regarding 2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan"). Current assets: Fair Value Disclosures [Text Block] us-gaap_RentalIncomeNonoperating Rental Income, Nonoperating Award Type [Axis] Net income Net income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, at beginning of year Cash and cash equivalents, at end of year Intangible assets Inventory, Policy [Policy Text Block] Furniture, Fixtures, Equipment and Computer Software [Member] Refers to information regarding furniture, fixtures, equipment and computer software. Interest income, net Deferred tax assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net (decrease) increase in cash and cash equivalents Restricted Stock [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies Director [Member] Income from operations Income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other income (expense): us-gaap_DeferredTaxLiabilities Total net deferred tax liabilities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets Gross Profit Gross profit Cost of sales Counterparty Name [Axis] Counterparty Name [Domain] Deferred tax liabilities Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: accumulated depreciation Property and equipment, net Property and equipment, net Property and equipment, gross Accrued real estate taxes us-gaap_PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Property and equipment Deferred tax liabilities: us-gaap_PaymentsOfDividendsCommonStock Dividends paid us-gaap_Investments Investments, Total Property and equipment in current assets The amount of property and equipment transferred to current assets during the period. Cash flows from investing activities: us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase and retirement of common stock us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions Tax Adjustments, Settlements, and Unusual Provisions Net income per common share: Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party Title of Individual [Domain] State Title of Individual [Axis] State us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Federal Common Stock [Member] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Related Party Transactions Disclosure [Text Block] Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Preferred Stock [Member] Provision for income taxes Total provision for income taxes Deferred taxes Equity Components [Axis] Equity Component [Domain] Current taxes us-gaap_CurrentIncomeTaxExpenseBenefit Total current taxes us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before provision for income taxes us-gaap_OperatingExpenses Total operating expenses pets_PaymentsForStipend Payments for Stipend Represents payments for stipend. pets_LumpsumSeverancePayments Lump-sum Severance Payments Represents lump-sum severance payments. Five Suppliers [Member] Represents information related to five suppliers. ICFR Auditor Attestation Flag General and administrative us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Partnership Agreement with Vetster [Member] Represents partnership agreement with Vestster. Cash and cash equivalents pets_NoncontrollingInterestOwnershipPercentagePurchased Noncontrolling Interest, Ownership Percentage Purchased Represents minority interest purchased. Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Document Annual Report Cash and Cash Equivalents, Policy [Policy Text Block] Amendment Flag Entity Incorporation, State or Country Code Accounting Policies [Abstract] Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current Cash dividends declared per common share (in dollars per share) us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Accrued expenses and other current liabilities us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Title of 12(b) Security Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] us-gaap_ValuationAllowancesAndReservesBalance Balance at beginning of period Balance at end of year Document Period End Date us-gaap_ValuationAllowancesAndReservesDeductions Write-off of uncollectible accounts receivable Entity File Number us-gaap_IncreaseDecreaseInPrepaidTaxes Prepaid income taxes Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Performance Restricted Stock [Member] Represents performance restricted stock. Performance Restricted Stock Price Hurdle 3 [Member] Represents Performance Restricted Stock Price Hurdle 3. Accrued merchandise credits / reward program The amount of accrued merchandise credits and rewards classified as current. Document Information [Line Items] Document Information [Table] Performance Restricted Stock Price Hurdle 4 [Member] Represents Performance Restricted Stock Price Hurdle 4. us-gaap_AreaOfRealEstateProperty Area of Real Estate Property (Square Foot) Entity Public Float Entity Filer Category Performance Restricted Stock Price Hurdle1 [Member] Represents Performance Restricted Stock Price Hurdle 1. Entity Current Reporting Status Performance Restricted Stock Price Hurdle 2 [Member] Represents Performance Restricted Stock Price Hurdle 2. Entity Voluntary Filers us-gaap_DividendsCommonStock Dividends declared Entity Well-known Seasoned Issuer Name of Property [Axis] Name of Property [Domain] Performance Restricted Stock Price Hurdle 5 [Member] Represents Performance Restricted Stock Price Hurdle 5. pets_NumberOfSuppliers Number of Suppliers Represents the number of major suppliers of the Company. us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Shares used in diluted computation (in shares) us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears Lessor, Operating Lease, Payment to be Received, Year Five us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Share based compensation us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Quarterly Financial Information [Text Block] Entity Tax Identification Number Entity Central Index Key us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Entity Registrant Name us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears Lessor, Operating Lease, Payment to be Received, Year Two us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears Lessor, Operating Lease, Payment to be Received, Year Three us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears Lessor, Operating Lease, Payment to be Received, Year Four Entity [Domain] Legal Entity [Axis] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Statement [Table] Effect of Covid-19 Pandemic [Text Block] The entire disclosure for effects of COVID-19 pandemic. Entity Address, Address Line One Statement of Financial Position [Abstract] Supplier Concentration Risk [Member] Valuation and Qualifying Accounts [Table Text Block] The tabular disclosure of valuation and qualifying accounts and reserves. Diluted net income per common share (in dollars per share) Diluted (in dollars per share) Basic (in shares) Accrued sales return allowance Represents accrued sales returns and allowances. Used to reflect the current portion (due within one year or within the normal operating cycle if longer). Accrued credit card fees Carrying value as of the balance sheet date of obligations incurred and payable for credit card fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Entity Address, City or Town Entity Address, Postal Zip Code Basic (in dollars per share) Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] Statement of Cash Flows [Abstract] Entity Common Stock, Shares Outstanding us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value Repurchased and retired shares Statement of Stockholders' Equity [Abstract] us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Stock Repurchased and Retired During Period, Shares (in shares) Repurchased and retired shares (in shares) Cost of Goods and Service Benchmark [Member] Income Statement [Abstract] Advertising Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Trading Symbol Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] pets_RestrictionPeriod Restriction Period (Year) Period of restriction of forfeiture. Quarterly Financial Information [Table Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] pets_TermOfAgreement Term of Agreement (Year) Represents term of agreement. pets_DefinedContributionPlanWithIndividualAge Defined Contribution Plan With Individual Age (Year) The minimum age that the individual is required in order to participate in the defined contribution plan. pets_NumberOfTenants Number of Tenants Represents number of tenants. Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Local Phone Number pets_PercentageOfPropertyLeasedToTenants Percentage of Property Leased to Tenants The percentage amount of property that was leased to tenants of the property. The 2016 Employee Equity Compensation Restricted Stock Plan [Member] represents the 2016 Employee Equity Compensation Restricted Stock Plan. Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Delray Beach Property [Member] Related to the Delray Beach Property. Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Director Plan [Member] Represents information relating to the 2006 and 2015 Director Plans. us-gaap_TableTextBlock Notes Tables 2015 Outside Director Equity Compensation Restricted Stock Plan [Member] Related to the 2015 Outside Director Equity Compensation Restricted Stock Plan. Employee Plan [Member] Information relating to the 2006 and 2016 Employee Plans. pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance Percentage of Automatic Increase in Shares Available for Issuance Represents percentage of automatic increase in the amount of shares available for issuance. us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) Employee and Director Equity Compensation Plan [Member] Related to both the employee and director equity compensation plans. Non-vested Restricted Stock [Member] Related to non-vested restricted stock awards. Issuance of restricted stock, net (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares) 2016 Employee Equity Compensation Restricted Stock Plan [Member] Related to the 2016 Employee Equity Compensation Restricted Stock Plan. pets_StockRepurchaseProgramAdditionalAuthorizedAmount Stock Repurchase Program, Additional Authorized Amount Amount of additional stock repurchase plan authorized. Issuance of restricted stock, net Related Party [Axis] Related Party [Domain] pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm Lessor, Operating Lease, Remaining Weighted Average Lease Term (Year) Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Provision for doubtful accounts Bad debt expense Dividends Declared [Table Text Block] Cash flows from financing activities: Other Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Record Date Restricted stock (windfall) shortfall adjustment Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Total Amount Dividends Payable Per Share Dividend (in dollars per share) Dividends Payable, Amount Per Share (in dollars per share) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and shareholders' equity us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories Inventories - finished goods Dividends [Axis] Dividends [Domain] Retained earnings us-gaap_AssetsNoncurrent Total noncurrent assets Convertible Preferred Stock [Member] New Order Customer [Member] The disaggregate of revenue in new order sales. (Increase) decrease in operating assets and increase (decrease) in liabilities: Reorder Customer [Member] The disaggregate of revenue in reorder sales. us-gaap_StockholdersEquity Total shareholders' equity Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Contact Center [Member] The disaggregate of revenue in contact center sales. Internet [Member] The disaggregate of revenue in internet sales. Subsequent Event [Member] Class of Stock [Axis] Class of Stock [Domain] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_DeferredIncomeTaxesAndTaxCredits Total deferred taxes Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] Deferred income taxes State income taxes, net of federal tax benefit Auditor Name Auditor Location Auditor Firm ID EX-101.PRE 12 pets-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 13 graph01.jpg begin 644 graph01.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information - USD ($)
 12 Months Ended
Mar. 31, 2022
May 24, 2022
Sep. 30, 2021
Document Information [Line Items]      
Entity Central Index Key 0001040130    
Entity Registrant Name PETMED EXPRESS INC    
Amendment Flag false    
Current Fiscal Year End Date --03-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Mar. 31, 2022    
Document Transition Report false    
Entity File Number 000-28827    
Entity Incorporation, State or Country Code FL    
Entity Tax Identification Number 65-0680967    
Entity Address, Address Line One 420 South Congress Avenue    
Entity Address, City or Town Delray Beach    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33445    
City Area Code 561    
Local Phone Number 526-4444    
Title of 12(b) Security Common Stock, PETS $.001 Par value per share    
Trading Symbol PETS    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 540,100,000
Entity Common Stock, Shares Outstanding   20,988,237  
Auditor Name RSM US LLP    
Auditor Location Fort Lauderdale, Florida    
Auditor Firm ID 49    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2022
Mar. 31, 2021
Current assets:    
Cash and cash equivalents $ 111,080 $ 118,718
Accounts receivable, less allowance for doubtful accounts of $39 and $39, respectively 1,913 2,587
Inventories - finished goods 32,455 34,420
Prepaid expenses and other current assets 4,866 4,503
Prepaid income taxes 681 959
Total current assets 150,995 161,187
Noncurrent assets:    
Property and equipment, net 24,464 25,450
Intangible assets 860 860
Total noncurrent assets 25,324 26,310
Total assets 176,319 187,497
Current liabilities:    
Accounts payable 27,500 39,548
Accrued expenses and other current liabilities 5,697 5,387
Total current liabilities 33,197 44,935
Deferred tax liabilities 936 1,281
Total liabilities 34,133 46,216
Commitments and contingencies
Shareholders' equity:    
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share 9 9
Common stock, $.001 par value, 40,000 shares authorized; 20,979 and 20,269 shares issued and outstanding, respectively 21 20
Additional paid-in capital 11,660 7,111
Retained earnings 130,496 134,141
Total shareholders' equity 142,186 141,281
Total liabilities and shareholders' equity $ 176,319 $ 187,497
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
Mar. 31, 2022
Mar. 31, 2021
Allowance for doubtful accounts $ 39,000 $ 39,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, liquidation preference (in dollars per share) $ 4 $ 4
Preferred stock, shares issued (in shares) 3,000 3,000
Preferred stock, shares outstanding (in shares) 3,000 3,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 40,000,000 40,000,000
Common stock, shares issued (in shares) 20,979,000 20,269,000
Common stock, shares outstanding (in shares) 20,979,000 20,269,000
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Sales $ 273,417 $ 309,215 $ 284,125
Cost of sales 195,341 219,267 202,879
Gross profit 78,076 89,948 81,246
Operating expenses:      
General and administrative 30,829 28,293 25,264
Advertising 18,799 21,641 22,748
Depreciation 2,738 2,427 2,257
Total operating expenses 52,366 52,361 50,269
Income from operations 25,710 37,587 30,977
Other income (expense):      
Interest income, net 335 314 1,747
Other, net 1,026 1,315 1,169
Total other income 1,361 1,629 2,916
Income before provision for income taxes 27,071 39,216 33,893
Provision for income taxes 5,971 8,613 8,042
Net income $ 21,100 $ 30,603 $ 25,851
Net income per common share:      
Basic (in dollars per share) $ 1.05 $ 1.53 $ 1.29
Diluted (in dollars per share) $ 1.04 $ 1.52 $ 1.29
Weighted average number of common shares outstanding:      
Basic (in shares) 20,176 20,060 20,041
Diluted (in shares) 20,358 20,119 20,055
Cash dividends declared per common share (in dollars per share) $ 1.20 $ 1.12 $ 1.08
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Mar. 31, 2019 3,000 20,674,000      
Balance at Mar. 31, 2019 $ 9 $ 21 $ 12,478 $ 122,172 $ 134,680
Issuance of restricted stock, net (in shares) 0 105,000      
Issuance of restricted stock, net $ 0 $ 0 0 0 0
Share based compensation $ 0 $ 0 2,822 0 $ 2,822
Repurchased and retired shares (in shares) 0 (613,000)     (613,000)
Repurchased and retired shares $ 0 $ (1) (11,496) 0 $ (11,497)
Dividends declared 0 0 0 (21,846) (21,846)
Net income $ 0 $ 0 0 25,851 25,851
Balance (in shares) at Mar. 31, 2020 3,000 20,166,000      
Balance at Mar. 31, 2020 $ 9 $ 20 3,804 126,177 130,010
Issuance of restricted stock, net (in shares) 0 103,000      
Issuance of restricted stock, net $ 0 $ 0 0 0 0
Share based compensation 0 0 3,307 0 $ 3,307
Repurchased and retired shares (in shares)         0
Dividends declared 0 0 0 (22,639) $ (22,639)
Net income $ 0 $ 0 0 30,603 30,603
Balance (in shares) at Mar. 31, 2021 3,000 20,269,000      
Balance at Mar. 31, 2021 $ 9 $ 20 7,111 134,141 141,281
Issuance of restricted stock, net (in shares) 0 710,000      
Issuance of restricted stock, net $ 0 $ 1 0 0 1
Share based compensation 0 0 4,549 0 $ 4,549
Repurchased and retired shares (in shares)         0
Dividends declared 0 0 0 (24,745) $ (24,745)
Net income $ 0 $ 0 0 21,100 21,100
Balance (in shares) at Mar. 31, 2022 3,000 20,979,000      
Balance at Mar. 31, 2022 $ 9 $ 21 $ 11,660 $ 130,496 $ 142,186
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:      
Net income $ 21,100 $ 30,603 $ 25,851
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation 2,738 2,427 2,257
Share based compensation 4,549 3,307 2,822
Deferred income taxes (345) 311 (151)
Bad debt expense 165 130 191
(Increase) decrease in operating assets and increase (decrease) in liabilities:      
Accounts receivable 509 1,126 (1,492)
Inventories - finished goods 1,965 (16,536) 3,486
Prepaid income taxes 278 (959) 582
Prepaid expenses and other current assets (363) (974) (376)
Accounts payable (12,048) 19,890 3,383
Accrued expenses and other current liabilities (50) 1,221 1,820
Income taxes payable 0 (471) 471
Net cash provided by operating activities 18,498 40,075 38,844
Cash flows from investing activities:      
Purchases of property and equipment (1,752) (2,432) (2,311)
Net cash used in investing activities (1,752) (2,432) (2,311)
Cash flows from financing activities:      
Dividends paid (24,384) (22,687) (21,803)
Repurchase and retirement of common stock 0 0 (11,497)
Net cash used in financing activities (24,384) (22,687) (33,300)
Net (decrease) increase in cash and cash equivalents (7,638) 14,956 3,233
Cash and cash equivalents, at beginning of year 118,718 103,762 100,529
Cash and cash equivalents, at end of year 111,080 118,718 103,762
Supplemental disclosure of cash flow information:      
Cash paid for income taxes 6,085 10,018 7,140
Property and equipment in current assets 0 0 1,745
Dividends payable in accrued expenses $ 558 $ 198 $ 246
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Note 1 - Summary of Significant Accounting Policies
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

(1)         Summary of Significant Accounting Policies

 

Organization

 

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds® (the “Company”), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs, cats, and horses, direct to the consumer. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the “1-800-PetMeds” brand name and “PetMeds” family of trademarks, increase traffic on its website atwww.petmeds.com, acquire new customers, and maximize repeat purchases. Virtually all of the Company's sales are to residents in the United States. The Company’s corporate headquarters and distribution facility are located in Delray Beach, Florida. The Company's fiscal year end is March 31, and references herein to fiscal 2022, 2021, or 2020 refer to the Company's fiscal years ended March 31, 2022, 2021, and 2020, respectively.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.

 

Revenue Recognition

 

The Company generates revenue by selling pet medication products and pet supplies. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

 

The Company disaggregates revenue in the following two categories: (1) reorder sales vs new order sales, and (2) internet sales vs contact center sales. The following table illustrates s by various classifications:

 

Year Ended March 31,

 

Sales (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $250,401   91.6% $272,648   88.2% $(22,247)  -8.2%

New Order Sales

 $23,016   8.4% $36,567   11.8% $(13,551)  -37.1%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%
                         

Internet Sales

 $230,263   84.2% $259,404   83.9% $(29,141)  -11.2%

Contact Center Sales

 $43,154   15.8% $49,811   16.1% $(6,657)  -13.4%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%

 

Year Ended March 31,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $272,648   88.2% $248,560   87.5% $24,088   9.7%

New Order Sales

 $36,567   11.8% $35,565   12.5% $1,002   2.8%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%
                         

Internet Sales

 $259,404   83.9% $238,054   83.8% $21,350   9.0%

Contact Center Sales

 $49,811   16.1% $46,071   16.2% $3,740   8.1%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%

 

Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had no material contract asset or liability balances as of March 31, 2022 and 2021.

 

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at March 31, 2022 and March 31, 2021.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2022 and 2021 consisted of the Company’s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Inventories

 

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at March 31, 2022 and 2021, respectively.

 

Property and Equipment

 

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from three to ten years.

 

Long-lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.

 

Intangible Assets

 

The intangible assets consist of a toll-free telephone number and an internet domain name. In accordance with the Accounting Standards Codification (“ASC”) Topic 350 (“Goodwill and Other Intangible Assets”) the intangible assets are not being amortized and are subject to an annual review for impairment.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

 

Advertising

 

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.

 

Comprehensive Income

 

The Company applies ASC Topic 220 (“Reporting Comprehensive Income”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended March 31, 2022, 2021 and 2020 the Company had no unrealized gains or losses.

 

Income Taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

The Company applies “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remains open. The Company files tax returns in the U.S. federal jurisdiction and Florida and Arizona.  With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March 31, 2019, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).

 

Business Concentrations

 

The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our products to obtain the lowest cost. There were five suppliers from which we purchased approximately 80% of all products in fiscal 2022 and 2021.

 

Accounting for Share Based Compensation

 

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.

 

Recent Accounting Pronouncements         

 

In March 2020, the Financial Accounting Standards Board issued ASU 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU 2020-03 on April 1, 2022. The Company does not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

 

The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Property and Equipment
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

(2)         Property and Equipment

 

Major classifications of property and equipment consist of the following (in thousands):

 

  

March 31,

 
  

2022

  

2021

 
         

Building

 $14,997  $14,997 

Land

  3,700   3,700 

Building Improvements

  2,834   2,834 

Computer Software

  5,512   5,621 

Furniture, fixtures and equipment

  9,106   8,626 
   36,149   35,778 

Less: accumulated depreciation

  (11,685)  (10,328)
         

Property and equipment, net

 $24,464  $25,450 

 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Note 3 - Valuation and Qualifying Accounts
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

(3)         Valuation and Qualifying Accounts

 

Activity in the Company's valuation and qualifying accounts consists of the following (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Allowance for doubtful accounts:

            

Balance at beginning of period

 $39  $59  $39 

Provision for doubtful accounts

  165   130   191 

Write-off of uncollectible accounts receivable

  (165)  (150)  (171)
             

Balance at end of year

 $39  $39  $59 

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Accrued Expenses and Other Current Liabilities
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(4)         Accrued Expenses and Other Current Liabilities

 

Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):

 

  

March 31,

 
  

2022

  

2021

 
         

Accrued sales tax

 $1,106  $1,063 

Accrued credit card fees

  428   456 

Accrued salaries and benefits

  1,134   1,525 

Accrued merchandise credits / reward program

  1,623   1,413 

Accrued professional expenses

  459   290 

Accrued sales return allowance

  190   220 

Accrued dividends payable

  558   198 

Accrued real estate taxes

  111   114 

Other accrued liabilities

  88   108 
         

Accrued expenses and other current liabilities

 $5,697  $5,387 

 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

(5)         Income Taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):

 

  

March 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Accrued expenses

 $364  $406 

Deferred stock compensation

  662   321 

Bad debt and inventory reserves

  27   29 
         

Total deferred tax assets

  1,053   756 
         

Deferred tax liabilities:

        

Property and equipment

  (1,989)  (2,037)
         

Total net deferred tax liabilities

 $(936) $(1,281)

 

At March 31, 2022, the Company had no federal net operating loss carryforwards.

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Current taxes

            

Federal

 $5,801  $7,446  $7,352 

State

  515   856   841 

Total current taxes

  6,316   8,302   8,193 
             

Deferred taxes

            

Federal

  (317)  279   (135)

State

  (28)  32   (16)

Total deferred taxes

  (345)  311   (151)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 

 

The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Income taxes at U.S. statutory rates

 $5,685  $8,235  $7,118 

State income taxes, net of federal tax benefit

  379   708   649 

Restricted stock (windfall) shortfall adjustment

  33   (135)  322 

Other

  (126)  (195)  (47)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 

 

In fiscal 2022 the Company recognized a stock compensation shortfall charge of approximately $33,000 and recognized a one-time charge of approximately $29,000 related to a return to provision true up of the fiscal 2021 income tax provision. In fiscal 2021 the Company recognized a stock compensation windfall benefit of approximately $135,000, and recognized a one-time benefit of approximately $194,000, related to a return to provision true up of the fiscal 2020 income tax provision. In fiscal 2020 the Company recognized a stock compensation shortfall charge of approximately $322,000, and recognized a one-time benefit of approximately $93,000, related to a return to provision true up of the fiscal 2019 income tax provision.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Shareholders' Equity
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

(6)         Shareholders’ Equity

 

Preferred Stock

 

In April 1998, the Company issued 250,000 shares of its $.001 par value preferred stock at a price of $4.00 per share, less issuance costs of $112,187. Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder. The shares have a liquidation value of $4.00 per share and may pay dividends at the sole discretion of the Company. The Company does not anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to one vote on all matters submitted to a vote of shareholders of the Company. At March 31, 2022 and 2021, 2,500 shares of the convertible preferred stock remained unconverted and outstanding.

 

Share Repurchase Plan

 

On November 8, 2006, the Company's Board of Directors approved a share repurchase plan of up to $20.0 million. On October 31, 2008, November 1, 2010, and August 1, 2011, the Company’s Board of Directors approved an increase under the repurchase plan each for an additional $20.0 million. On January 25, 2019, the Company’s Board of Directors authorized an additional $30.0 million under the repurchase plan. The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company's discretion, subject to market conditions and other factors, in accordance with Securities and Exchange Commission requirements. There can be no assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company may discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements. Shares purchased pursuant to the share repurchase plan will either be retired or held in the Company's treasury. During fiscal 2020 the Company purchased and retired approximately 613,000 shares of its common stock for approximately $11.5 million. During fiscal 2022 and 2021 the Company had no share repurchases. At March 31, 2022 the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

 

Dividends

 

On May 3, 2021, the Company’s Board of Directors increased the quarterly dividend to $0.30 per share, on its common stock. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance. During fiscal 2022, our Board of Directors declared the following dividends:

 

Declaration Date

 

Per Share

Dividend

 

Record Date

 

Total Amount

(In thousands)

 

Payment Date

           

May 3, 2021

  $0.30 

May 14, 2021

  $6,081 

May 21, 2021

July 26, 2021

  $0.30 

August 6, 2021

  $6,102 

August 13, 2021

October 25, 2021

  $0.30 

November 8, 2021

  $6,283 

November 19, 2021

January 24, 2022

  $0.30 

February 7, 2022

  $6,294 

February 18, 2022
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Note 7 - Restricted Stock
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

(7)         Restricted Stock

 

In July 2015, the Company’s 2015 Outside Director Equity Compensation Restricted Stock Plan (“2015 Director Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The 2015 Director Plan authorizes 400,000 shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of 10% of the shares authorized under the plan. In July 2016, the Company’s 2016 Employee Equity Compensation Restricted Stock Plan (“2016 Employee Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The 2016 Employee Plan authorizes 1,000,000 shares of the Company's Common stock available for issuance under the plan. The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company’s Board and is to be no less than 1 year and no more than ten years unless otherwise specified by the Board of Directors.

 

At March 31, 2022, the Company had 893,258 restricted common shares issued under the 2016 Employee Plan and 208,880 restricted common shares issued under the 2015 Director Plan. The majority of shares were issued subject to a restriction and forfeiture period which lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over a one to three-year restriction period. For the fiscal years ended March 31, 2022, 2021, and 2020, the Company recognized compensation expense related to the Employee and Director Plans of $4.5 million, $3.3 million, and $2.8 million, respectively.

 

A summary of the Company’s non-vested restricted stock at March 31, 2022 is as follows (in thousands):

 

  

Employee

Plan

Number of

Shares

  

Director

Plan

Number of

Shares

  

Both Plans

Number of

Shares

 
             

Non-vested restricted stock outstanding at March 31, 2021

  98   62   160 
             

Restricted stock granted

  676   44   720 
             

Restricted stock vested

  (69)  (30)  (99)
             

Restricted stock forfeited or expired

  (3)  (7)  (10)
             

Non-vested restricted stock outstanding at March 31, 2022

  702   69   771 

 

At March 31, 2022 and 2021, there were 770,652 and 160,117, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended March 31, 2022 and 2021, the Company issued, net of forfeitures, 709,599 and 102,931 restricted shares, respectively. At March 31, 2022 and 2021, there were $13.4 million and $2.5 million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 and 1.8 years for fiscal 2022 and 2021, respectively.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Note 8 - Fair Value Measurements
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

(8)         Fair Value Measurements

 

The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurements”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s cash equivalents are classified within Level 1. At March 31, 2022 and 2021 the Company had invested the majority of its cash and cash equivalents balance in money market funds (level 1).
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Note 9 - Net Income Per Share
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

(9)         Net Income Per Share

 

In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding. The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):

 

  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 

Net income (numerator):

            
             

Net income

 $21,100  $30,603  $25,851 
             

Shares (denominator)

            
             

Weighted average number of common shares outstanding used in basic computation

  20,176   20,060   20,041 

Common shares issuable upon the vesting of restricted stock

  172   49   4 

Common shares issuable upon conversion of preferred shares

  10   10   10 

Shares used in diluted computation

  20,358   20,119   20,055 
             

Net income per common share:

            
             

Basic

 $1.05  $1.53  $1.29 

Diluted

 $1.04  $1.52  $1.29 

 

At March 31, 2022, 2021, and 2020, 220,727, 20,952, and 72,120 shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Note 10 - Commitments and Contingencies
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

(10)         Commitments and Contingencies

 

Legal Matters and Routine Proceedings

 

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

 

Operating Leases

 

Upon acquisition of the Delray Beach property in January 2016, 48% of the property, approximately 88,000 square feet of the property was leased to two tenants. At March 31, 2022, the leases with these two tenants had a remaining weighted average lease term of 3.0 years. The Company recorded approximately $689,000 and $670,000 in rental revenue in fiscal 2022 and 2021, respectively, which was included in other income. The Company expects to receive the following future lease payments, under the current lease agreements, over the next five years: $710,000 in fiscal 2023; $731,000 in fiscal 2024, $566,000 in fiscal 2025, and $110,000 in fiscal 2026.

 

Employment Agreements

 

On July 12, 2019, the Company entered into Amendment No. 7 , with Menderes Akdag (“Mr. Akdag”), former CEO & President and Director, providing that in the event that a Change in Control (as was thereinafter defined) of the Company was to occur at any time, Mr. Akdag would have the right to terminate his employment for “Good Reason,” (as was thereinafter defined) upon thirty (30) days written notice given at any time within one (1) year after the occurrence of such event, and upon such termination Mr. Akdag would be entitled to a one-time payment of two times his salary as of the date of such termination. On July 31, 2020, the Company entered into Amendment No. 8 which extended Mr. Akdag’s contract for an additional year at an annual rate of $626,860 and granted Mr. Akdag 37,800 restricted shares, which were subject to restriction and forfeiture until July 31, 2021, in accordance with the parameters of his executive compensation plan.

 

On May 28, 2021, the Board of Directors notified Mr. Akdag that the Company would not extend Mr. Akdag’s employment agreement with the Company, and the employment agreement would therefore end on July 30, 2021, in accordance with the scheduled end date of the agreement. Effective July 31, 2021, the Board of Directors appointed Bruce S. Rosenbloom (“Mr. Rosenbloom”), the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President of the Company, until a permanent successor chief executive officer was appointed. Mr. Rosenbloom received an additional cash stipend of $10,000 for the additional responsibilities while serving as Interim Chief Executive Officer and President, which ended on August 30, 2021.

 

On June 11, 2021, the Company and Mr. Akdag, entered into a CEO Separation Agreement and General Release setting forth certain matters relating to the expiration of Mr. Akdag’s employment with the Company (the “Separation Agreement”). The Separation Agreement provided that Mr. Akdag’s employment with the Company, and service as an officer and director of the Company, would terminate as of July 30, 2021. The Separation Agreement also documented Mr. Akdag’s agreement that, during his remaining period of employment through July 30, 2021, he would continue to provide his fulltime and attention to the business affairs of the Company and cooperate with the Company’s Board of Directors on the transition to a new chief executive officer. The Separation Agreement provided that Mr. Akdag would be paid two lump-sum severance payments of $325,000 each, with the first such payment to be paid, and was paid, on August 10, 2021, and the second to be paid, and was paid, on December 31, 2021, subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company’s agreement to make the severance payments, Mr. Akdag granted the Company a full release of any and all claims that he may have against the Company and its affiliates and related parties.

 

In addition, as a part of the Separation Agreement, the Company confirmed that the 37,800 restricted shares held by Mr. Akdag will be, and were, released from restriction and forfeiture on July 31, 2021, and that the Company would, and did, cover the tax withholding obligations in connection with such release of shares from restriction and forfeiture. Under the Separation Agreement, Mr. Akdag agreed that he would continue to comply with his existing confidentiality, non-solicitation, and non-compete obligations, and he further agreed that until July 31, 2022, he would comply with certain “standstill” covenants relating to the Company.

 

On August 25, 2021, the Board of Directors appointed Mathew N. Hulett (Mr. Hulett”) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments were effective as of August 30, 2021. On August 25, 2021, the Company entered into an employment agreement with Mr. Hulett to serve as the Company’s Chief Executive Officer and President. The employment agreement is for an initial term of three (3) years commencing on August 30, 2021 and will automatically renew for successive one (1) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement is expressly cancelled by either Mr. Hulett or the Company sixty (60) days prior to the end of the then current term, or is otherwise terminated as provided in the agreement. The employment agreement provides that Mr. Hulett will receive an annual base salary of $500,000, subject to periodic review for increases with the approval of the Board of Directors, and will be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company’s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The employment agreement also provides that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contains certain rights of Mr. Hulett and the Company to terminate Mr. Hulett’s employment, including termination by the Company for “Cause” as defined in the employment agreement, and termination by Mr. Hulett for “Good Reason” as defined in the employment agreement within twelve (12) months of a Change in Control as defined in the employment agreement. Mr. Hulett is also entitled to severance pay equal to twelve (12) months of Mr. Hulett’s current base salary and eighteen (18) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett’s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (1) year non-compete following the termination of the agreement.

 

On August 30, 2021, Mr. Hulett also received an award of 90,000 shares of restricted stock under the Company’s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of August 30, 2022, August 30, 2023, and August 30, 2024, which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the three-year period from the date of grant, and (ii) continued employment through the performance period of three years from the date of grant, in accordance with the following schedule: 85,000 shares at the stock hurdle price of $40 per share, 107,000 shares at the stock hurdle price of $45 per share, 106,000 shares at the stock hurdle price of $50, 106,000 shares at the stock hurdle price of $55, and 106,000 shares at the stock hurdle price of $60.

 

Should none of the absolute stock price hurdles be met during the three-year period from the date of grant no shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (90) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett’s continued employment through the performance period of three years from the date of grant (except as provided in the performance restricted stock agreement). As of March 31, 2022, none of the performance restricted stock vested, as no performance stock price hurdles were met.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Note 11 - Employee Benefit Plan
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

(11)         Employee Benefit Plan

 

The Company maintains a 401(k) Savings Plan for eligible employees.  The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing one year of service and having attained the age of 21.  The plan provides for growth in savings through contributions and income from investments.  It is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended. Plan participants are allowed to contribute a specified percentage of their base salary. In 2006, the Company approved a matching contribution which is funded subsequent to the calendar year. During the fiscal years ended March 31, 2022, 2021, and 2020, the Company charged $238,000, $245,000, and $211,000, respectively, of 401(k) matching contribution and administration expense to general and administrative expenses.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Note 12 - COVID-19
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Effect of Covid-19 Pandemic [Text Block]

(12)         COVID-19

 

On March 11, 2020, the World Health Organization declared that the novel coronavirus (COVID-19) had become a pandemic, and on March 13, 2020, the U.S. President declared a National Emergency concerning the disease. Additionally, in March 2020, state governments in the Company’s geographic operating area began instituting preventative shut down measures in order to combat the novel coronavirus pandemic. The coronavirus and actions taken to mitigate the spread of it have had and are expected to continue to have an adverse impact on the economies and financial markets of the geographical area in which the Company operates. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted to amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the novel coronavirus pandemic. The Company’s business being deemed essential resulted in incremental financial performance that may not be indicative of future financial results and there remains uncertainty and increased risks concerning its employees, customers, supply chain and government regulation.

 

During fiscal 2022, the Company has been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain; however, we have experienced some delays in the delivery of some inventory items. We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our workplace.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Note 13 - Subsequent Events
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Subsequent Events [Text Block]

(13)         Subsequent Events

 

Subsequent to March 31, 2022 the Company issued 7,450 restricted shares to certain employees of the Company under the 2016 Employee Plan, with a fair value of $23.50 per share. In April 2022, the Company issued 1,875 restricted shares to Diana Garvis Purcell, a newly appointed director on our Board of Directors, with a fair value of $25.53 per share. In connection with Ms. Purcel’s appointment on the Board, the Board voted to increase the size of the Board by one director to seven persons effective April 4, 2022.

 

On April 19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (“Vetster”), a veterinary telehealth Canadian company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million The Company also received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company becomes the exclusive e-commerce provider for Vetster, and Vetster becomes the exclusive provider of telehealth and telemedicine services to the Company.

 

On May 9, 2022, the Company’s Board of Directors declared a quarterly dividend of $0.30 per share on its common stock. The $6.3 million dividend will be payable on May 27, 2022, to shareholders of record at the close of business on May 20, 2022.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Note 14 - Related Party Transaction
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

(14)         Related Party Transaction

 

The Company’s Board of Directors Chairman, Gian Fulgoni, serves on the board of directors of Prophet, a brand and marketing consulting company, which PetMed Express, Inc. engaged with in March 2021 for $292,000. The Company expensed $32,000 in fiscal 2021, with the remaining $260,000 expensed in fiscal 2022. This transaction was approved by the Company’s Board of Directors with terms that are comparable to those with an unrelated third party.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Note 15 - Quarterly Financial Data (Unaudited)
 12 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Quarterly Financial Information [Text Block]

(15)         Quarterly Financial Data (Unaudited)

 

Summarized unaudited quarterly financial data for fiscal 2022 and 2021 is as follows (in thousands, except for per share amounts):

 

Quarter Ended:

 

June 30, 2021

  

September 30, 2021

  

December 31, 2021

  

March 31, 2022

 
                 

Sales

 $79,312  $67,386  $60,717  $66,002 

Gross Profit

 $21,780  $19,174  $17,725  $19,397 

Income from operations

 $5,419  $8,087  $5,147  $7,057 

Net income

 $4,428  $6,349  $4,257  $6,066 

Diluted net income per common share

 $0.22  $0.31  $0.21  $0.30 
                 

Quarter Ended:

 

June 30, 2020

  

September 30, 2020

  

December 31, 2020

  

March 31, 2021

 
                 

Sales

 $96,204  $75,436  $65,896  $71,679 

Gross Profit

 $26,785  $23,018  $19,623  $20,522 

Income from operations

 $9,436  $10,471  $9,293  $8,387 

Net income

 $7,768  $8,412  $7,611  $6,812 

Diluted net income per common share

 $0.39  $0.42  $0.38  $0.34 

 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
 12 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.
Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

The Company generates revenue by selling pet medication products and pet supplies. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is not considered a key judgment. There are no amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

 

The Company disaggregates revenue in the following two categories: (1) reorder sales vs new order sales, and (2) internet sales vs contact center sales. The following table illustrates s by various classifications:

 

Year Ended March 31,

 

Sales (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $250,401   91.6% $272,648   88.2% $(22,247)  -8.2%

New Order Sales

 $23,016   8.4% $36,567   11.8% $(13,551)  -37.1%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%
                         

Internet Sales

 $230,263   84.2% $259,404   83.9% $(29,141)  -11.2%

Contact Center Sales

 $43,154   15.8% $49,811   16.1% $(6,657)  -13.4%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%

 

Year Ended March 31,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $272,648   88.2% $248,560   87.5% $24,088   9.7%

New Order Sales

 $36,567   11.8% $35,565   12.5% $1,002   2.8%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%
                         

Internet Sales

 $259,404   83.9% $238,054   83.8% $21,350   9.0%

Contact Center Sales

 $49,811   16.1% $46,071   16.2% $3,740   8.1%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%

 

Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had no material contract asset or liability balances as of March 31, 2022 and 2021.

 

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at March 31, 2022 and March 31, 2021.
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at March 31, 2022 and 2021 consisted of the Company’s cash accounts and money market accounts with a maturity of three months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Inventory, Policy [Policy Text Block]

Inventories

 

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at March 31, 2022 and 2021, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of thirty years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from three to ten years.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.
Goodwill and Intangible Assets, Policy [Policy Text Block]

Intangible Assets

 

The intangible assets consist of a toll-free telephone number and an internet domain name. In accordance with the Accounting Standards Codification (“ASC”) Topic 350 (“Goodwill and Other Intangible Assets”) the intangible assets are not being amortized and are subject to an annual review for impairment.
Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.
Advertising Cost [Policy Text Block]

Advertising

 

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.
Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income

 

The Company applies ASC Topic 220 (“Reporting Comprehensive Income”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended March 31, 2022, 2021 and 2020 the Company had no unrealized gains or losses.
Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic 740, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

The Company applies “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remains open. The Company files tax returns in the U.S. federal jurisdiction and Florida and Arizona.  With few exceptions, the Company is no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending March 31, 2019, or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Business Concentrations

 

The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our products to obtain the lowest cost. There were five suppliers from which we purchased approximately 80% of all products in fiscal 2022 and 2021.
Compensation Related Costs, Policy [Policy Text Block]

Accounting for Share Based Compensation

 

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements         

 

In March 2020, the Financial Accounting Standards Board issued ASU 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU 2020-03 on April 1, 2022. The Company does not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

 

The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Note 1 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]

Year Ended March 31,

 

Sales (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $250,401   91.6% $272,648   88.2% $(22,247)  -8.2%

New Order Sales

 $23,016   8.4% $36,567   11.8% $(13,551)  -37.1%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%
                         

Internet Sales

 $230,263   84.2% $259,404   83.9% $(29,141)  -11.2%

Contact Center Sales

 $43,154   15.8% $49,811   16.1% $(6,657)  -13.4%
                         

Total Net Sales

 $273,417   100.0% $309,215   100.0% $(35,798)  -11.6%

Year Ended March 31,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $272,648   88.2% $248,560   87.5% $24,088   9.7%

New Order Sales

 $36,567   11.8% $35,565   12.5% $1,002   2.8%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%
                         

Internet Sales

 $259,404   83.9% $238,054   83.8% $21,350   9.0%

Contact Center Sales

 $49,811   16.1% $46,071   16.2% $3,740   8.1%
                         

Total Net Sales

 $309,215   100.0% $284,125   100.0% $25,090   8.8%
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Property and Equipment (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]
  

March 31,

 
  

2022

  

2021

 
         

Building

 $14,997  $14,997 

Land

  3,700   3,700 

Building Improvements

  2,834   2,834 

Computer Software

  5,512   5,621 

Furniture, fixtures and equipment

  9,106   8,626 
   36,149   35,778 

Less: accumulated depreciation

  (11,685)  (10,328)
         

Property and equipment, net

 $24,464  $25,450 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Note 3 - Valuation and Qualifying Accounts (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Valuation and Qualifying Accounts [Table Text Block]
  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Allowance for doubtful accounts:

            

Balance at beginning of period

 $39  $59  $39 

Provision for doubtful accounts

  165   130   191 

Write-off of uncollectible accounts receivable

  (165)  (150)  (171)
             

Balance at end of year

 $39  $39  $59 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
  

March 31,

 
  

2022

  

2021

 
         

Accrued sales tax

 $1,106  $1,063 

Accrued credit card fees

  428   456 

Accrued salaries and benefits

  1,134   1,525 

Accrued merchandise credits / reward program

  1,623   1,413 

Accrued professional expenses

  459   290 

Accrued sales return allowance

  190   220 

Accrued dividends payable

  558   198 

Accrued real estate taxes

  111   114 

Other accrued liabilities

  88   108 
         

Accrued expenses and other current liabilities

 $5,697  $5,387 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

March 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Accrued expenses

 $364  $406 

Deferred stock compensation

  662   321 

Bad debt and inventory reserves

  27   29 
         

Total deferred tax assets

  1,053   756 
         

Deferred tax liabilities:

        

Property and equipment

  (1,989)  (2,037)
         

Total net deferred tax liabilities

 $(936) $(1,281)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Current taxes

            

Federal

 $5,801  $7,446  $7,352 

State

  515   856   841 

Total current taxes

  6,316   8,302   8,193 
             

Deferred taxes

            

Federal

  (317)  279   (135)

State

  (28)  32   (16)

Total deferred taxes

  (345)  311   (151)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 
             

Income taxes at U.S. statutory rates

 $5,685  $8,235  $7,118 

State income taxes, net of federal tax benefit

  379   708   649 

Restricted stock (windfall) shortfall adjustment

  33   (135)  322 

Other

  (126)  (195)  (47)
             

Total provision for income taxes

 $5,971  $8,613  $8,042 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Shareholders' Equity (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Dividends Declared [Table Text Block]

Declaration Date

 

Per Share

Dividend

 

Record Date

 

Total Amount

(In thousands)

 

Payment Date

           

May 3, 2021

  $0.30 

May 14, 2021

  $6,081 

May 21, 2021

July 26, 2021

  $0.30 

August 6, 2021

  $6,102 

August 13, 2021

October 25, 2021

  $0.30 

November 8, 2021

  $6,283 

November 19, 2021

January 24, 2022

  $0.30 

February 7, 2022

  $6,294 

February 18, 2022
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Note 7 - Restricted Stock (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Nonvested Share Activity [Table Text Block]
  

Employee

Plan

Number of

Shares

  

Director

Plan

Number of

Shares

  

Both Plans

Number of

Shares

 
             

Non-vested restricted stock outstanding at March 31, 2021

  98   62   160 
             

Restricted stock granted

  676   44   720 
             

Restricted stock vested

  (69)  (30)  (99)
             

Restricted stock forfeited or expired

  (3)  (7)  (10)
             

Non-vested restricted stock outstanding at March 31, 2022

  702   69   771 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Note 9 - Net Income Per Share (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended March 31,

 
  

2022

  

2021

  

2020

 

Net income (numerator):

            
             

Net income

 $21,100  $30,603  $25,851 
             

Shares (denominator)

            
             

Weighted average number of common shares outstanding used in basic computation

  20,176   20,060   20,041 

Common shares issuable upon the vesting of restricted stock

  172   49   4 

Common shares issuable upon conversion of preferred shares

  10   10   10 

Shares used in diluted computation

  20,358   20,119   20,055 
             

Net income per common share:

            
             

Basic

 $1.05  $1.53  $1.29 

Diluted

 $1.04  $1.52  $1.29 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Note 15 - Quarterly Financial Data (Unaudited) (Tables)
 12 Months Ended
Mar. 31, 2022
Notes Tables  
Quarterly Financial Information [Table Text Block]

Quarter Ended:

 

June 30, 2021

  

September 30, 2021

  

December 31, 2021

  

March 31, 2022

 
                 

Sales

 $79,312  $67,386  $60,717  $66,002 

Gross Profit

 $21,780  $19,174  $17,725  $19,397 

Income from operations

 $5,419  $8,087  $5,147  $7,057 

Net income

 $4,428  $6,349  $4,257  $6,066 

Diluted net income per common share

 $0.22  $0.31  $0.21  $0.30 
                 

Quarter Ended:

 

June 30, 2020

  

September 30, 2020

  

December 31, 2020

  

March 31, 2021

 
                 

Sales

 $96,204  $75,436  $65,896  $71,679 

Gross Profit

 $26,785  $23,018  $19,623  $20,522 

Income from operations

 $9,436  $10,471  $9,293  $8,387 

Net income

 $7,768  $8,412  $7,611  $6,812 

Diluted net income per common share

 $0.39  $0.42  $0.38  $0.34 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Note 1 - Summary of Significant Accounting Policies (Details Textual)
 12 Months Ended
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Accounts Receivable, Allowance for Credit Loss, Current $ 39,000 $ 39,000  
Inventory Valuation Reserves 81,000 86,000  
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax $ 0 $ 0 $ 0
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member]      
Number of Suppliers 5 5  
Supplier Concentration Risk [Member] | Cost of Goods and Service Benchmark [Member] | Five Suppliers [Member]      
Concentration Risk, Percentage 80.00% 80.00%  
Building [Member]      
Property, Plant and Equipment, Useful Life (Year)   30 years  
Furniture, Fixtures, Equipment and Computer Software [Member] | Minimum [Member]      
Property, Plant and Equipment, Useful Life (Year)   3 years  
Furniture, Fixtures, Equipment and Computer Software [Member] | Maximum [Member]      
Property, Plant and Equipment, Useful Life (Year)   10 years  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Revenues $ 66,002 $ 60,717 $ 67,386 $ 79,312 $ 71,679 $ 65,896 $ 75,436 $ 96,204 $ 273,417 $ 309,215 $ 284,125
Revenues, percentage                 100.00% 100.00% 100.00%
Revenues, variance                 $ (35,798) $ 25,090  
Revenues, variance, percentage                 (11.60%) 8.80%  
Internet [Member]                      
Revenues                 $ 230,263 $ 259,404 $ 238,054
Revenues, percentage                 84.20% 83.90% 83.80%
Revenues, variance                 $ (29,141) $ 21,350  
Revenues, variance, percentage                 (11.20%) 9.00%  
Contact Center [Member]                      
Revenues                 $ 43,154 $ 49,811 $ 46,071
Revenues, percentage                 15.80% 16.10% 16.20%
Revenues, variance                 $ (6,657) $ 3,740  
Revenues, variance, percentage                 (13.40%) 8.10%  
Reorder Customer [Member]                      
Revenues                 $ 250,401 $ 272,648 $ 248,560
Revenues, percentage                 91.60% 88.20% 87.50%
Revenues, variance                 $ (22,247) $ 24,088  
Revenues, variance, percentage                 (8.20%) 9.70%  
New Order Customer [Member]                      
Revenues                 $ 23,016 $ 36,567 $ 35,565
Revenues, percentage                 8.40% 11.80% 12.50%
Revenues, variance                 $ (13,551) $ 1,002  
Revenues, variance, percentage                 (37.10%) 2.80%  
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Mar. 31, 2021
Property and equipment, gross $ 36,149 $ 35,778
Less: accumulated depreciation (11,685) (10,328)
Property and equipment, net 24,464 25,450
Building [Member]    
Property and equipment, gross 14,997 14,997
Land [Member]    
Property and equipment, gross 3,700 3,700
Building Improvements [Member]    
Property and equipment, gross 2,834 2,834
Software and Software Development Costs [Member]    
Property and equipment, gross 5,512 5,621
Furniture and Fixtures [Member]    
Property and equipment, gross $ 9,106 $ 8,626
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Balance at beginning of period $ 39 $ 59 $ 39
Provision for doubtful accounts 165 130 191
Write-off of uncollectible accounts receivable (165) (150) (171)
Balance at end of year $ 39 $ 39 $ 59
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Mar. 31, 2021
Accrued sales tax $ 1,106 $ 1,063
Accrued credit card fees 428 456
Accrued salaries and benefits 1,134 1,525
Accrued merchandise credits / reward program 1,623 1,413
Accrued professional expenses 459 290
Accrued sales return allowance 190 220
Accrued dividends payable 558 198
Accrued real estate taxes 111 114
Other accrued liabilities 88 108
Accrued expenses and other current liabilities $ 5,697 $ 5,387
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes (Details Textual) - USD ($)
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount $ 33,000 $ (135,000) $ 322,000
Tax Adjustments, Settlements, and Unusual Provisions $ (29,000) (194,000) $ (93,000)
Domestic Tax Authority [Member]      
Operating Loss Carryforwards, Total   $ 0  
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Mar. 31, 2021
Deferred tax assets:    
Accrued expenses $ 364 $ 406
Deferred stock compensation 662 321
Bad debt and inventory reserves 27 29
Total deferred tax assets 1,053 756
Deferred tax liabilities:    
Property and equipment (1,989) (2,037)
Total net deferred tax liabilities $ (936) $ (1,281)
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes - Components of Income Tax Provision (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Current taxes      
Federal $ 5,801 $ 7,446 $ 7,352
State 515 856 841
Total current taxes 6,316 8,302 8,193
Deferred taxes      
Federal (317) 279 (135)
State (28) 32 (16)
Total deferred taxes (345) 311 (151)
Total provision for income taxes $ 5,971 $ 8,613 $ 8,042
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details) - USD ($)
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Income taxes at U.S. statutory rates $ 5,685,000 $ 8,235,000 $ 7,118,000
State income taxes, net of federal tax benefit 379,000 708,000 649,000
Restricted stock (windfall) shortfall adjustment 33,000 (135,000) 322,000
Other (126,000) (195,000) (47,000)
Total provision for income taxes $ 5,971,000 $ 8,613,000 $ 8,042,000
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Shareholders' Equity (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Jan. 25, 2019
Oct. 31, 2008
Apr. 30, 1998
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
May 03, 2021
Nov. 08, 2006
Preferred Stock, Shares Issued, Total (in shares)     250,000 3,000 3,000      
Shares Issued, Price Per Share (in dollars per share)     $ 4.00          
Payments of Stock Issuance Costs     $ 112,187          
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)     4.05          
Preferred Stock, Liquidation Preference Per Share (in dollars per share)     $ 4.00 $ 4 $ 4      
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       3,000 3,000      
Stock Repurchase Program, Authorized Amount               $ 20,000,000.0
Stock Repurchase Program, Additional Authorized Amount $ 30,000,000.0 $ 20,000,000.0            
Stock Repurchased and Retired During Period, Shares (in shares)       0 0 613,000    
Stock Repurchased and Retired During Period, Value           $ 11,497,000    
Stock Repurchase Program, Remaining Authorized Repurchase Amount       $ 28,700,000        
Dividends Payable, Amount Per Share (in dollars per share)             $ 0.30  
Convertible Preferred Stock [Member]                
Preferred Stock, Shares Outstanding, Ending Balance (in shares)       2,500 2,500      
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Note 6 - Shareholder's Equity - Declared Dividends (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
May 03, 2021
Per Share Dividend (in dollars per share)   $ 0.30
Dividend Declared May 4, 2020 [Member]    
Per Share Dividend (in dollars per share) $ 0.30  
Total Amount $ 6,081  
Record Date May 21, 2021  
Dividend Declared July 20, 2020 [Member]    
Per Share Dividend (in dollars per share) $ 0.30  
Total Amount $ 6,102  
Record Date Aug. 13, 2021  
Dividend Declared October 26, 2020 [Member]    
Per Share Dividend (in dollars per share) $ 0.30  
Total Amount $ 6,283  
Record Date Nov. 19, 2021  
Dividend Declared January 19, 2021 [Member]    
Per Share Dividend (in dollars per share) $ 0.30  
Total Amount $ 6,294  
Record Date Feb. 18, 2022  
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Note 7 - Restricted Stock (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jul. 31, 2016
Jul. 31, 2015
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Share-Based Payment Arrangement, Noncash Expense, Total     $ 4,549 $ 3,307 $ 2,822
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)     771,000 160,000  
2015 Outside Director Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares)   400,000      
Percentage of Automatic Increase in Shares Available for Issuance   10.00%      
2016 Employee Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 1,000,000   893,258    
2016 Employee Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member] | Minimum [Member]          
Restriction Period (Year) 1 year        
2016 Employee Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member] | Maximum [Member]          
Restriction Period (Year) 10 years        
2015 Outside Director Equity Compensation Restricted Stock Plan ("2015 Director Plan") [Member] | Restricted Stock [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares)     208,880    
Employee and Director Equity Compensation Plan [Member] | Non-vested Restricted Stock [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)     770,652 160,117  
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)     709,599 102,931  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total     $ 13,400 $ 2,500  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     2 years 3 months 18 days 1 year 9 months 18 days  
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Note 7 - Restricted Stock - Non-vested Restricted Stock (Details)
shares in Thousands
 12 Months Ended
Mar. 31, 2022
shares
Non-vested restricted stock outstanding at March 31, 2021 (in shares) 160
Restricted stock granted (in shares) 720
Restricted stock vested (in shares) (99)
Restricted stock forfeited or expired (in shares) (10)
Non-vested restricted stock outstanding at March 31, 2022 (in shares) 771
Employee Plan [Member]  
Non-vested restricted stock outstanding at March 31, 2021 (in shares) 98
Restricted stock granted (in shares) 676
Restricted stock vested (in shares) (69)
Restricted stock forfeited or expired (in shares) (3)
Non-vested restricted stock outstanding at March 31, 2022 (in shares) 702
Director Plan [Member]  
Non-vested restricted stock outstanding at March 31, 2021 (in shares) 62
Restricted stock granted (in shares) 44
Restricted stock vested (in shares) (30)
Restricted stock forfeited or expired (in shares) (7)
Non-vested restricted stock outstanding at March 31, 2022 (in shares) 69
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Note 9 - Net Income Per Share (Details Textual) - shares
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 220,727 20,952 72,120
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Net income $ 6,066 $ 4,257 $ 6,349 $ 4,428 $ 6,812 $ 7,611 $ 8,412 $ 7,768 $ 21,100 $ 30,603 $ 25,851
Basic (in shares)                 20,176 20,060 20,041
Common shares issuable upon the vesting of restricted stock (in shares)                 172 49 4
Common shares issuable upon conversion of preferred shares (in shares)                 10 10 10
Shares used in diluted computation (in shares)                 20,358 20,119 20,055
Basic (in dollars per share)                 $ 1.05 $ 1.53 $ 1.29
Diluted (in dollars per share) $ 0.30 $ 0.21 $ 0.31 $ 0.22 $ 0.34 $ 0.38 $ 0.42 $ 0.39 $ 1.04 $ 1.52 $ 1.29
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Note 10 - Commitments and Contingencies (Details Textual)
 1 Months Ended 12 Months Ended
Aug. 30, 2021
$ / shares
shares
Aug. 25, 2021
USD ($)
Aug. 10, 2021
USD ($)
Jul. 31, 2020
USD ($)
shares
Aug. 30, 2021
USD ($)
$ / shares
Jan. 31, 2016
ft²
Mar. 31, 2022
USD ($)
shares
Mar. 31, 2021
USD ($)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)             720,000  
Chief Executive Officer [Member]                
Salary and Wage, Officer, Excluding Cost of Good and Service Sold | $   $ 500,000   $ 626,860        
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)       37,800        
Payments for Stipend | $         $ 10,000      
Lump-sum Severance Payments | $     $ 325,000          
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 90,000              
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 510,000              
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock Price Hurdle1 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 85,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares $ 40       $ 40      
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock Price Hurdle 2 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 107,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares $ 45       45      
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock Price Hurdle 3 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 106,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares $ 50       50      
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock Price Hurdle 4 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 106,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares $ 55       55      
Chief Executive Officer [Member] | The 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Performance Restricted Stock Price Hurdle 5 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 106,000              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share) | $ / shares $ 60       $ 60      
Delray Beach Property [Member]                
Percentage of Property Leased to Tenants           48.00%    
Area of Real Estate Property (Square Foot) | ft²           88,000    
Number of Tenants           2 2  
Lessor, Operating Lease, Remaining Weighted Average Lease Term (Year)             3 years  
Rental Income, Nonoperating | $             $ 689,000 $ 670,000
Lessor, Operating Lease, Payment to be Received, Year Two | $             710,000  
Lessor, Operating Lease, Payment to be Received, Year Three | $             731,000  
Lessor, Operating Lease, Payment to be Received, Year Four | $             566,000  
Lessor, Operating Lease, Payment to be Received, Year Five | $             $ 110,000  
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Note 11 - Employee Benefit Plan (Details Textual) - USD ($)
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Deferred Compensation Arrangement with Individual, Requisite Service Period (Year) 1 year    
Defined Contribution Plan With Individual Age (Year) 21 years    
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount $ 238,000 $ 245,000 $ 211,000
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Note 13 - Subsequent Events (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 2 Months Ended 12 Months Ended
Apr. 22, 2022
Apr. 19, 2022
May 24, 2022
Mar. 31, 2022
May 27, 2022
May 09, 2022
May 03, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)       720,000      
Dividends Payable, Amount Per Share (in dollars per share)             $ 0.30
Subsequent Event [Member]              
Dividends Payable, Amount Per Share (in dollars per share)           $ 0.30  
Dividends Payable         $ 6.3    
Subsequent Event [Member] | Partnership Agreement with Vetster [Member]              
Term of Agreement (Year)   3 years          
Noncontrolling Interest, Ownership Percentage Purchased   5.00%          
Investments, Total   $ 5.0          
Restricted Stock [Member] | 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Subsequent Event [Member] | Director [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 1,875            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) $ 25.53   $ 23.50        
Restricted Stock [Member] | 2016 Employee Equity Compensation Restricted Stock Plan [Member] | Share-Based Payment Arrangement, Employee [Member] | Subsequent Event [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     7,450        
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Note 14 - Related Party Transaction (Details Textual) - Prophet [Member] - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2021
Mar. 31, 2022
Related Party Transaction, Amounts of Transaction $ 292,000    
Related Party Transaction, Expenses from Transactions with Related Party   $ 32,000  
Due to Related Parties, Current, Total     $ 260,000
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Sales $ 66,002 $ 60,717 $ 67,386 $ 79,312 $ 71,679 $ 65,896 $ 75,436 $ 96,204 $ 273,417 $ 309,215 $ 284,125
Gross Profit 19,397 17,725 19,174 21,780 20,522 19,623 23,018 26,785 78,076 89,948 81,246
Income from operations 7,057 5,147 8,087 5,419 8,387 9,293 10,471 9,436 25,710 37,587 30,977
Net income $ 6,066 $ 4,257 $ 6,349 $ 4,428 $ 6,812 $ 7,611 $ 8,412 $ 7,768 $ 21,100 $ 30,603 $ 25,851
Diluted net income per common share (in dollars per share) $ 0.30 $ 0.21 $ 0.31 $ 0.22 $ 0.34 $ 0.38 $ 0.42 $ 0.39 $ 1.04 $ 1.52 $ 1.29
XML 65 pets20220331_10k_htm.xml IDEA: XBRL DOCUMENT 0001040130 2021-04-01 2022-03-31 0001040130 2021-09-30 0001040130 2022-05-24 0001040130 2022-03-31 0001040130 2021-03-31 0001040130 2020-04-01 2021-03-31 0001040130 2019-04-01 2020-03-31 0001040130 us-gaap:PreferredStockMember 2019-03-31 0001040130 us-gaap:CommonStockMember 2019-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001040130 us-gaap:RetainedEarningsMember 2019-03-31 0001040130 2019-03-31 0001040130 us-gaap:PreferredStockMember 2019-04-01 2020-03-31 0001040130 us-gaap:CommonStockMember 2019-04-01 2020-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2020-03-31 0001040130 us-gaap:RetainedEarningsMember 2019-04-01 2020-03-31 0001040130 us-gaap:PreferredStockMember 2020-03-31 0001040130 us-gaap:CommonStockMember 2020-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001040130 us-gaap:RetainedEarningsMember 2020-03-31 0001040130 2020-03-31 0001040130 us-gaap:PreferredStockMember 2020-04-01 2021-03-31 0001040130 us-gaap:CommonStockMember 2020-04-01 2021-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2021-03-31 0001040130 us-gaap:RetainedEarningsMember 2020-04-01 2021-03-31 0001040130 us-gaap:PreferredStockMember 2021-03-31 0001040130 us-gaap:CommonStockMember 2021-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001040130 us-gaap:RetainedEarningsMember 2021-03-31 0001040130 us-gaap:PreferredStockMember 2021-04-01 2022-03-31 0001040130 us-gaap:CommonStockMember 2021-04-01 2022-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2022-03-31 0001040130 us-gaap:RetainedEarningsMember 2021-04-01 2022-03-31 0001040130 us-gaap:PreferredStockMember 2022-03-31 0001040130 us-gaap:CommonStockMember 2022-03-31 0001040130 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001040130 us-gaap:RetainedEarningsMember 2022-03-31 0001040130 pets:ReorderMember 2021-04-01 2022-03-31 0001040130 pets:ReorderMember 2020-04-01 2021-03-31 0001040130 pets:NewOrderMember 2021-04-01 2022-03-31 0001040130 pets:NewOrderMember 2020-04-01 2021-03-31 0001040130 pets:InternetMember 2021-04-01 2022-03-31 0001040130 pets:InternetMember 2020-04-01 2021-03-31 0001040130 pets:ContactCenterMember 2021-04-01 2022-03-31 0001040130 pets:ContactCenterMember 2020-04-01 2021-03-31 0001040130 pets:ReorderMember 2019-04-01 2020-03-31 0001040130 pets:NewOrderMember 2019-04-01 2020-03-31 0001040130 pets:InternetMember 2019-04-01 2020-03-31 0001040130 pets:ContactCenterMember 2019-04-01 2020-03-31 0001040130 us-gaap:BuildingMember 2020-04-01 2021-03-31 0001040130 srt:MinimumMember pets:FurnitureFixturesEquipmentAndComputerSoftwareMember 2020-04-01 2021-03-31 0001040130 srt:MaximumMember pets:FurnitureFixturesEquipmentAndComputerSoftwareMember 2020-04-01 2021-03-31 0001040130 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-03-31 0001040130 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-03-31 0001040130 pets:FiveSuppliersMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-04-01 2022-03-31 0001040130 pets:FiveSuppliersMember us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-04-01 2021-03-31 0001040130 us-gaap:BuildingMember 2022-03-31 0001040130 us-gaap:BuildingMember 2021-03-31 0001040130 us-gaap:LandMember 2022-03-31 0001040130 us-gaap:LandMember 2021-03-31 0001040130 us-gaap:BuildingImprovementsMember 2022-03-31 0001040130 us-gaap:BuildingImprovementsMember 2021-03-31 0001040130 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-03-31 0001040130 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-03-31 0001040130 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001040130 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001040130 us-gaap:DomesticCountryMember 2021-03-31 0001040130 1998-04-30 0001040130 1998-04-01 1998-04-30 0001040130 us-gaap:ConvertiblePreferredStockMember 2022-03-31 0001040130 us-gaap:ConvertiblePreferredStockMember 2021-03-31 0001040130 2006-11-08 0001040130 2008-10-31 2008-10-31 0001040130 2019-01-25 2019-01-25 0001040130 2021-05-03 0001040130 pets:DividendDeclaredMay42020Member 2022-03-31 0001040130 pets:DividendDeclaredMay42020Member 2022-01-01 2022-03-31 0001040130 pets:DividendDeclaredJuly202020Member 2022-03-31 0001040130 pets:DividendDeclaredJuly202020Member 2022-01-01 2022-03-31 0001040130 pets:DividendDeclaredOctober262020Member 2022-03-31 0001040130 pets:DividendDeclaredOctober262020Member 2022-01-01 2022-03-31 0001040130 pets:DividendDeclaredJanuary192021Member 2022-03-31 0001040130 pets:DividendDeclaredJanuary192021Member 2022-01-01 2022-03-31 0001040130 us-gaap:RestrictedStockMember pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember 2015-07-31 0001040130 us-gaap:RestrictedStockMember pets:TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember 2015-07-01 2015-07-31 0001040130 us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember 2016-07-31 0001040130 srt:MinimumMember us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember 2016-07-01 2016-07-31 0001040130 srt:MaximumMember us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember 2016-07-01 2016-07-31 0001040130 us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember 2022-03-31 0001040130 us-gaap:RestrictedStockMember pets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember 2022-03-31 0001040130 pets:EmployeePlanMember 2021-03-31 0001040130 pets:DirectorPlanMember 2021-03-31 0001040130 pets:EmployeePlanMember 2021-04-01 2022-03-31 0001040130 pets:DirectorPlanMember 2021-04-01 2022-03-31 0001040130 pets:EmployeePlanMember 2022-03-31 0001040130 pets:DirectorPlanMember 2022-03-31 0001040130 pets:NonvestedRestrictedStockMember pets:EmployeeAndDirectorEquityCompensationPlanMember 2022-03-31 0001040130 pets:NonvestedRestrictedStockMember pets:EmployeeAndDirectorEquityCompensationPlanMember 2021-03-31 0001040130 pets:NonvestedRestrictedStockMember pets:EmployeeAndDirectorEquityCompensationPlanMember 2021-04-01 2022-03-31 0001040130 pets:NonvestedRestrictedStockMember pets:EmployeeAndDirectorEquityCompensationPlanMember 2020-04-01 2021-03-31 0001040130 pets:DelrayBeachPropertyMember 2016-01-01 2016-01-31 0001040130 pets:DelrayBeachPropertyMember 2016-01-31 0001040130 pets:DelrayBeachPropertyMember 2021-04-01 2022-03-31 0001040130 pets:DelrayBeachPropertyMember 2020-04-01 2021-03-31 0001040130 pets:DelrayBeachPropertyMember 2022-03-31 0001040130 srt:ChiefExecutiveOfficerMember 2020-07-31 2020-07-31 0001040130 srt:ChiefExecutiveOfficerMember 2021-07-31 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember 2021-08-10 2021-08-10 0001040130 srt:ChiefExecutiveOfficerMember 2021-08-25 2021-08-25 0001040130 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockMember pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle1Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle1Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle2Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle2Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle3Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle3Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle4Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle4Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle5Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 2021-08-30 0001040130 srt:ChiefExecutiveOfficerMember pets:PerformanceRestrictedStockPriceHurdle5Member pets:The2016EmployeeEquityCompensationRestrictedStockPlanMember 2021-08-30 0001040130 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementEmployeeMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember us-gaap:SubsequentEventMember 2022-04-01 2022-05-24 0001040130 srt:DirectorMember us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember us-gaap:SubsequentEventMember 2022-04-01 2022-05-24 0001040130 srt:DirectorMember us-gaap:RestrictedStockMember pets:TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember us-gaap:SubsequentEventMember 2022-04-22 2022-04-22 0001040130 us-gaap:SubsequentEventMember pets:PartnershipAgreementWithVetsterMember 2022-04-19 2022-04-19 0001040130 us-gaap:SubsequentEventMember pets:PartnershipAgreementWithVetsterMember 2022-04-19 0001040130 us-gaap:SubsequentEventMember 2022-05-09 0001040130 us-gaap:SubsequentEventMember 2022-05-27 0001040130 pets:ProphetMember 2021-03-01 2021-03-31 0001040130 pets:ProphetMember 2020-04-01 2021-03-31 0001040130 pets:ProphetMember 2022-03-31 0001040130 2021-04-01 2021-06-30 0001040130 2021-07-01 2021-09-30 0001040130 2021-10-01 2021-12-31 0001040130 2022-01-01 2022-03-31 0001040130 2020-04-01 2020-06-30 0001040130 2020-07-01 2020-09-30 0001040130 2020-10-01 2020-12-31 0001040130 2021-01-01 2021-03-31 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y utr:sqft 0001040130 PETMED EXPRESS INC false --03-31 FY 2022 39000 39000 0.001 0.001 5000000 5000000 3000 3000 3000 3000 4 4 0.001 0.001 40000000 40000000 20979000 20979000 20269000 20269000 -0.082 -0.371 -0.116 -0.112 -0.134 -0.116 39000 P30Y P3Y P10Y 0 0 5 0.80 2500 0 0.30 6081 2021-05-21 0.30 6102 2021-08-13 0.30 6283 2021-11-19 0.30 6294 2022-02-18 P10Y 2 2 P1Y P3Y 10-K true 2022-03-31 false 000-28827 FL 65-0680967 420 South Congress Avenue Delray Beach FL 33445 561 526-4444 Common Stock, PETS $.001 Par value per share PETS NASDAQ No No Yes Yes Accelerated Filer false false true false 540100000 20988237 49 RSM US LLP Fort Lauderdale, Florida 111080000 118718000 1913000 2587000 32455000 34420000 4866000 4503000 681000 959000 150995000 161187000 24464000 25450000 860000 860000 25324000 26310000 176319000 187497000 27500000 39548000 5697000 5387000 33197000 44935000 936000 1281000 34133000 46216000 9000 9000 21000 20000 11660000 7111000 130496000 134141000 142186000 141281000 176319000 187497000 273417000 309215000 284125000 195341000 219267000 202879000 78076000 89948000 81246000 30829000 28293000 25264000 18799000 21641000 22748000 2738000 2427000 2257000 52366000 52361000 50269000 25710000 37587000 30977000 335000 314000 1747000 1026000 1315000 1169000 1361000 1629000 2916000 27071000 39216000 33893000 5971000 8613000 8042000 21100000 30603000 25851000 1.05 1.53 1.29 1.04 1.52 1.29 20176000 20060000 20041000 20358000 20119000 20055000 1.20 1.12 1.08 3000 9000 20674000 21000 12478000 122172000 134680000 0 0 105000 0 0 0 0 0 0 2822000 0 2822000 -0 -0 613000 1000 11496000 -0 11497000 -0 -0 -0 21846000 21846000 0 0 0 25851000 25851000 3000 9000 20166000 20000 3804000 126177000 130010000 0 0 103000 0 0 0 0 0 0 3307000 0 3307000 -0 -0 -0 22639000 22639000 0 0 0 30603000 30603000 3000 9000 20269000 20000 7111000 134141000 141281000 0 0 710000 1000 0 0 1000 0 0 4549000 0 4549000 -0 -0 -0 24745000 24745000 0 0 0 21100000 21100000 3000 9000 20979000 21000 11660000 130496000 142186000 21100000 30603000 25851000 2738000 2427000 2257000 4549000 3307000 2822000 -345000 311000 -151000 165000 130000 191000 -509000 -1126000 1492000 -1965000 16536000 -3486000 -278000 959000 -582000 363000 974000 376000 -12048000 19890000 3383000 -50000 1221000 1820000 0 -471000 471000 18498000 40075000 38844000 1752000 2432000 2311000 -1752000 -2432000 -2311000 24384000 22687000 21803000 -0 -0 11497000 -24384000 -22687000 -33300000 -7638000 14956000 3233000 118718000 103762000 100529000 111080000 118718000 103762000 6085000 10018000 7140000 0 0 1745000 558000 198000 246000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">1</em>)</b>         <b>Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Organization</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">PetMed Express, Inc. and subsidiaries, d/b/a PetMeds® (the “Company”), is a leading nationwide pet pharmacy. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs, cats, and horses, direct to the consumer. The Company markets its products through national advertising campaigns, which aim to increase the recognition of the <em style="font: inherit;">“1</em>-<em style="font: inherit;">800</em>-PetMeds” brand name and “PetMeds” family of trademarks, increase traffic on its website at<i>www.petmeds.com</i>, acquire new customers, and maximize repeat purchases. Virtually all of the Company's sales are to residents in the United States. The Company’s corporate headquarters and distribution facility are located in Delray Beach, Florida. The Company's fiscal year end is <em style="font: inherit;"> March 31, </em>and references herein to fiscal <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021,</em> or <em style="font: inherit;">2020</em> refer to the Company's fiscal years ended <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Principles of Consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company generates revenue by selling pet medication products and pet supplies. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain <em style="font: inherit;">one</em> performance obligation, which is delivery of the product; customer care and support is deemed <em style="font: inherit;">not</em> to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is <em style="font: inherit;">not</em> considered a key judgment. There are <em style="font: inherit;">no</em> amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company disaggregates revenue in the following <em style="font: inherit;">two</em> categories: (<em style="font: inherit;">1</em>) reorder sales vs new order sales, and (<em style="font: inherit;">2</em>) internet sales vs contact center sales. The following table illustrates s by various classifications:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td colspan="24" style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">250,401</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">91.6</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(22,247</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559963">-8.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">23,016</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.4</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(13,551</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559969">-37.1</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559975">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">230,263</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">84.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(29,141</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559981">-11.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">43,154</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(6,657</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559987">-13.4</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559993">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="24" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">248,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">24,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">238,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">21,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">46,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">3,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in <em style="font: inherit;">two</em> to <em style="font: inherit;">three</em> banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had <em style="font: inherit;">no</em> material contract asset or liability balances as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><em style="font: inherit;"/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><em style="font: inherit;"/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company considers all highly liquid investments with maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Cash and cash equivalents at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> consisted of the Company’s cash accounts and money market accounts with a maturity of <em style="font: inherit;">three</em> months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times, <em style="font: inherit;"> may </em>exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of <span style="-sec-ix-hidden:c84559915">thirty</span> years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from <span style="-sec-ix-hidden:c84559916">three</span> to <span style="-sec-ix-hidden:c84559917">ten</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Long-lived Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The intangible assets consist of a toll-free telephone number and an internet domain name. In accordance with the Accounting Standards Codification (“ASC”) Topic <em style="font: inherit;">350</em> (“<i>Goodwill and Other Intangible Assets</i>”) the intangible assets are <em style="font: inherit;">not</em> being amortized and are subject to an annual review for impairment.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Fair Value of Financial Instruments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Advertising</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Comprehensive Income</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company applies ASC Topic <em style="font: inherit;">220</em> (“<i>Reporting Comprehensive Income</i>”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> the Company had no unrealized gains or losses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company accounts for income taxes under the provisions of ASC Topic <em style="font: inherit;">740</em> (“<i>Accounting for Income Taxes</i>”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic <em style="font: inherit;">740,</em> the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than <em style="font: inherit;">not</em> sustain the position following an audit. For tax positions meeting the more-likely-than-<em style="font: inherit;">not</em> threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than <em style="font: inherit;">50</em> percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company applies “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remains open. The Company files tax returns in the U.S. federal jurisdiction and Florida and Arizona.  With few exceptions, the Company is <em style="font: inherit;">no</em> longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending <em style="font: inherit;"> March 31, 2019, </em>or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Business Concentrations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our products to obtain the lowest cost. There were five suppliers from which we purchased approximately 80% of all products in fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><em style="font: inherit;"/></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Accounting for Share Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company records compensation expense associated with restricted stock in accordance with ASC Topic <em style="font: inherit;">718</em> (“<i>Share Based Payment</i>”). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Recent Accounting Pronouncements</b>         </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In <em style="font: inherit;"> March 2020, </em>the Financial Accounting Standards Board issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03,</em> “Codification Improvements to Financial Instruments” (“ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03”</em>). ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> improves and clarifies various financial instruments topics. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> includes <em style="font: inherit;">seven</em> different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> on <em style="font: inherit;"> April 1, 2022. </em>The Company does <em style="font: inherit;">not</em> expect the adoption of this new standard to have a material impact on our consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company does <em style="font: inherit;">not</em> believe that any other recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Principles of Consolidation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Revenue Recognition</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company generates revenue by selling pet medication products and pet supplies. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain <em style="font: inherit;">one</em> performance obligation, which is delivery of the product; customer care and support is deemed <em style="font: inherit;">not</em> to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns; however, this is <em style="font: inherit;">not</em> considered a key judgment. There are <em style="font: inherit;">no</em> amounts excluded from variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which shipment of the product occurs. This key judgment is determined as the shipping point represents the point in time in which the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company disaggregates revenue in the following <em style="font: inherit;">two</em> categories: (<em style="font: inherit;">1</em>) reorder sales vs new order sales, and (<em style="font: inherit;">2</em>) internet sales vs contact center sales. The following table illustrates s by various classifications:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td colspan="24" style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">250,401</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">91.6</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(22,247</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559963">-8.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">23,016</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.4</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(13,551</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559969">-37.1</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559975">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">230,263</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">84.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(29,141</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559981">-11.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">43,154</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(6,657</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559987">-13.4</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559993">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="24" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">248,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">24,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">238,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">21,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">46,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">3,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in <em style="font: inherit;">two</em> to <em style="font: inherit;">three</em> banking days. Credit card sales minimize accounts receivable balances relative to sales. The Company had <em style="font: inherit;">no</em> material contract asset or liability balances as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical bad debts and current economic trends. The allowance for doubtful accounts was approximately $39,000 at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021.</em></p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td colspan="24" style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>%</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">250,401</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">91.6</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(22,247</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559963">-8.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">23,016</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.4</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(13,551</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559969">-37.1</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559975">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">230,263</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">84.2</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(29,141</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c84559981">-11.2</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">43,154</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">15.8</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(6,657</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559987">-13.4</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">273,417</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(35,798</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c84559993">-11.6</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="24" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><b>Year Ended March 31,</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Sales (In thousands)</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>%</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Variance</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reorder Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">272,648</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">248,560</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">87.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">24,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">New Order Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">36,567</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">35,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Internet Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">259,404</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">238,054</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">21,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contact Center Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">49,811</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">46,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">3,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Net Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">309,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">284,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr> </tbody></table> 250401000 0.916 272648000 0.882 -22247000 23016000 0.084 36567000 0.118 -13551000 273417000 1.000 309215000 1.000 -35798000 230263000 0.842 259404000 0.839 -29141000 43154000 0.158 49811000 0.161 -6657000 273417000 1.000 309215000 1.000 -35798000 272648000 0.882 248560000 0.875 24088000 0.097 36567000 0.118 35565000 0.125 1002000 0.028 309215000 1.000 284125000 1.000 25090000 0.088 259404000 0.839 238054000 0.838 21350000 0.090 49811000 0.161 46071000 0.162 3740000 0.081 309215000 1.000 284125000 1.000 25090000 0.088 39000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Cash and Cash Equivalents</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company considers all highly liquid investments with maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Cash and cash equivalents at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> consisted of the Company’s cash accounts and money market accounts with a maturity of <em style="font: inherit;">three</em> months or less. The carrying amount of cash equivalents approximates fair value. The Company maintains its cash in bank deposit accounts which, at times, <em style="font: inherit;"> may </em>exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Use of Estimates</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or net realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $81,000 and $86,000 at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> 81000 86000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Our building is being depreciated over a period of <span style="-sec-ix-hidden:c84559915">thirty</span> years. The furniture, fixtures, equipment, and computer software are being depreciated over periods ranging from <span style="-sec-ix-hidden:c84559916">three</span> to <span style="-sec-ix-hidden:c84559917">ten</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Long-lived Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets is measured by a comparison of the carrying amount of the asset to the undiscounted cash flows expected to be generated from the asset.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Intangible Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The intangible assets consist of a toll-free telephone number and an internet domain name. In accordance with the Accounting Standards Codification (“ASC”) Topic <em style="font: inherit;">350</em> (“<i>Goodwill and Other Intangible Assets</i>”) the intangible assets are <em style="font: inherit;">not</em> being amortized and are subject to an annual review for impairment.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Fair Value of Financial Instruments</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Advertising</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related catalogs, brochures, and postcards are produced, distributed, or superseded. Television advertising costs are expensed as the advertisements are televised.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Comprehensive Income</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company applies ASC Topic <em style="font: inherit;">220</em> (“<i>Reporting Comprehensive Income</i>”) which requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. For the fiscal years ended <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> the Company had no unrealized gains or losses.</p> 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;"><b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company accounts for income taxes under the provisions of ASC Topic <em style="font: inherit;">740</em> (“<i>Accounting for Income Taxes</i>”) which generally requires the recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse. As required by “Accounting for Uncertainty in Income Taxes” guidance, which clarifies ASC Topic <em style="font: inherit;">740,</em> the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than <em style="font: inherit;">not</em> sustain the position following an audit. For tax positions meeting the more-likely-than-<em style="font: inherit;">not</em> threshold, the amount recognized in the Consolidated Financial Statements is the largest benefit that has a greater than <em style="font: inherit;">50</em> percent likelihood of being realized upon ultimate settlement with the relevant tax authority.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company applies “Accounting for Uncertainty in Income Taxes” guidance to all tax positions for which the statute of limitations remains open. The Company files tax returns in the U.S. federal jurisdiction and Florida and Arizona.  With few exceptions, the Company is <em style="font: inherit;">no</em> longer subject to U.S. federal, state or local income tax examinations by tax authorities for years ending <em style="font: inherit;"> March 31, 2019, </em>or earlier. Any interest and penalties related to income taxes will be recorded to other income (expenses).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Business Concentrations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company purchases its products from a variety of sources, including certain manufacturers, domestic distributors, and wholesalers. We have multiple suppliers for each of our products to obtain the lowest cost. There were five suppliers from which we purchased approximately 80% of all products in fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021.</em></p> 5 0.80 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><b>Accounting for Share Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company records compensation expense associated with restricted stock in accordance with ASC Topic <em style="font: inherit;">718</em> (“<i>Share Based Payment</i>”). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Recent Accounting Pronouncements</b>         </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In <em style="font: inherit;"> March 2020, </em>the Financial Accounting Standards Board issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03,</em> “Codification Improvements to Financial Instruments” (“ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03”</em>). ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> improves and clarifies various financial instruments topics. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> includes <em style="font: inherit;">seven</em> different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">03</em> on <em style="font: inherit;"> April 1, 2022. </em>The Company does <em style="font: inherit;">not</em> expect the adoption of this new standard to have a material impact on our consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company does <em style="font: inherit;">not</em> believe that any other recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards, if currently adopted, will have a material effect on the Company’s consolidated financial position, results of operations, or cash flows.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">2</em>)</b>         <b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Major classifications of property and equipment consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 54pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 70%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building Improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(11,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(10,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">24,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 54pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 70%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,700</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Building Improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer Software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,512</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,621</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36,149</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,778</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(11,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(10,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 70%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">24,464</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 14997000 14997000 3700000 3700000 2834000 2834000 5512000 5621000 9106000 8626000 36149000 35778000 11685000 10328000 24464000 25450000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">3</em>)</b>         <b>Valuation and Qualifying Accounts</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Activity in the Company's valuation and qualifying accounts consists of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Balance at beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Provision for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Write-off of uncollectible accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(171</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Balance at end of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b/></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for doubtful accounts:</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Balance at beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Provision for doubtful accounts</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Write-off of uncollectible accounts receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(150</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(171</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 55%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Balance at end of year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 39000 59000 39000 165000 130000 191000 165000 150000 171000 39000 39000 59000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">4</em>)</b>         <b>Accrued Expenses and Other Current Liabilities</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Major classifications of accrued expenses and other current liabilities consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued sales tax</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,063</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued credit card fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">456</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,134</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,525</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued merchandise credits / reward program</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued sales return allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">190</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">220</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued dividends payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued real estate taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued sales tax</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,106</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,063</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued credit card fees</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">456</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued salaries and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,134</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,525</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued merchandise credits / reward program</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued sales return allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">190</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">220</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued dividends payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued real estate taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">114</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">88</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">108</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1106000 1063000 428000 456000 1134000 1525000 1623000 1413000 459000 290000 190000 220000 558000 198000 111000 114000 88000 108000 5697000 5387000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">5</em>)</b>         <b>Income Taxes</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences that give rise to significant portions of deferred tax assets and deferred tax liabilities are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 54pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">321</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Bad debt and inventory reserves</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,989</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(2,037</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(1,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">At <em style="font: inherit;"> March 31, 2022, </em>the Company had no federal net operating loss carryforwards.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The components of the income tax provision consist of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,801</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,446</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(345</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The reconciliation of income tax provision computed at the U.S. federal statutory tax rates to income tax expense is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes at U.S. statutory rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">649</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock (windfall) shortfall adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In fiscal <em style="font: inherit;">2022</em> the Company recognized a stock compensation shortfall charge of approximately $33,000 and recognized a <em style="font: inherit;">one</em>-time charge of approximately $29,000 related to a return to provision true up of the fiscal <em style="font: inherit;">2021</em> income tax provision. In fiscal <em style="font: inherit;">2021</em> the Company recognized a stock compensation windfall benefit of approximately $135,000, and recognized a <em style="font: inherit;">one</em>-time benefit of approximately $194,000, related to a return to provision true up of the fiscal <em style="font: inherit;">2020</em> income tax provision. In fiscal <em style="font: inherit;">2020</em> the Company recognized a stock compensation shortfall charge of approximately $322,000, and recognized a <em style="font: inherit;">one</em>-time benefit of approximately $93,000, related to a return to provision true up of the fiscal <em style="font: inherit;">2019</em> income tax provision.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 54pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred stock compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">321</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Bad debt and inventory reserves</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">27</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(1,989</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(2,037</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(1,281</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 364000 406000 662000 321000 27000 29000 1053000 756000 1989000 2037000 936000 1281000 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; margin-left: 54pt; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,801</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,446</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,352</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">856</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,193</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">279</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(345</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(151</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5801000 7446000 7352000 515000 856000 841000 6316000 8302000 8193000 -317000 279000 -135000 -28000 32000 -16000 -345000 311000 -151000 5971000 8613000 8042000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes at U.S. statutory rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,685</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State income taxes, net of federal tax benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">708</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">649</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock (windfall) shortfall adjustment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(135</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(126</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(47</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total provision for income taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,042</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 5685000 8235000 7118000 379000 708000 649000 33000 -135000 322000 -126000 -195000 -47000 5971000 8613000 8042000 33000 -29000 -135000 -194000 322000 -93000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">6</em>)</b>         <b>Shareholders</b>’<b> Equity</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Preferred Stock</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In <em style="font: inherit;"> April 1998, </em>the Company issued 250,000 shares of its <em style="font: inherit;">$.001</em> par value preferred stock at a price of $4.00 per share, less issuance costs of $112,187. Each share of the preferred stock is convertible into approximately 4.05 shares of common stock at the election of the shareholder. The shares have a liquidation value of $4.00 per share and <em style="font: inherit;"> may </em>pay dividends at the sole discretion of the Company. The Company does <em style="font: inherit;">not</em> anticipate paying dividends to the preferred shareholders in the foreseeable future. Each share of preferred stock is entitled to <em style="font: inherit;">one</em> vote on all matters submitted to a vote of shareholders of the Company. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> 2,500 shares of the convertible preferred stock remained unconverted and outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Share Repurchase Plan</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> November 8, 2006, </em>the Company's Board of Directors approved a share repurchase plan of up to $20.0 million. On <em style="font: inherit;"> October 31, 2008, </em><em style="font: inherit;"> November 1, 2010, </em>and <em style="font: inherit;"> August 1, 2011, </em>the Company’s Board of Directors approved an increase under the repurchase plan each for an additional $20.0 million. On <em style="font: inherit;"> January 25, 2019, </em>the Company’s Board of Directors authorized an additional $30.0 million under the repurchase plan. The repurchase plan is intended to be implemented through purchases made from time to time in either the open market or through private transactions at the Company's discretion, subject to market conditions and other factors, in accordance with Securities and Exchange Commission requirements. There can be <em style="font: inherit;">no</em> assurances as to the precise number of shares that will be repurchased under the share repurchase plan, and the Company <em style="font: inherit;"> may </em>discontinue the share repurchase plan at any time subject to compliance with applicable regulatory requirements. Shares purchased pursuant to the share repurchase plan will either be retired or held in the Company's treasury. During fiscal <em style="font: inherit;">2020</em> the Company purchased and retired approximately 613,000 shares of its common stock for approximately $11.5 million. During fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> the Company had no share repurchases. At <em style="font: inherit;"> March 31, 2022 </em>the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Dividends</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> May 3, 2021, </em>the Company’s Board of Directors increased the quarterly dividend to $0.30 per share, on its common stock. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance. During fiscal <em style="font: inherit;">2022,</em> our Board of Directors declared the following dividends:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt; width: 22.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Declaration Date</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Per Share</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Dividend</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Record Date</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total Amount</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(In thousands)</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Payment Date</b></p> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">May 3, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560189">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">May 14, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560191">$6,081</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560192">May 21, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">July 26, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560193">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">August 6, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560195">$6,102</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560196">August 13, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">October 25, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560197">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">November 8, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560199">$6,283</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560200">November 19, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 24, 2022</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560201">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">February 7, 2022</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560203">$6,294</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560204">February 18, 2022</span></p> </td></tr> </tbody></table> 250000 4.00 112187 4.05 4.00 2500 20000000.0 20000000.0 30000000.0 613000 11500000 0 28700000 0.30 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt; width: 22.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Declaration Date</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Per Share</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Dividend</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Record Date</b></p> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total Amount</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(In thousands)</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Payment Date</b></p> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">May 3, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560189">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">May 14, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560191">$6,081</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560192">May 21, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">July 26, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560193">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">August 6, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560195">$6,102</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560196">August 13, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">October 25, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560197">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">November 8, 2021</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560199">$6,283</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560200">November 19, 2021</span></p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 24, 2022</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560201">$0.30</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">February 7, 2022</em></p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="-sec-ix-hidden:c84560203">$6,294</span></td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: undefined; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="-sec-ix-hidden:c84560204">February 18, 2022</span></p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">7</em>)</b>         <b>Restricted Stock</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In <em style="font: inherit;"> July 2015, </em>the Company’s <em style="font: inherit;">2015</em> Outside Director Equity Compensation Restricted Stock Plan (<em style="font: inherit;">“2015</em> Director Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The <em style="font: inherit;">2015</em> Director Plan authorizes 400,000 shares of the Company's common stock available for issuance under the plan and provides for an automatic increase every year in the amount of shares available for issuance under the plan of 10% of the shares authorized under the plan. In <em style="font: inherit;"> July 2016, </em>the Company’s <em style="font: inherit;">2016</em> Employee Equity Compensation Restricted Stock Plan (<em style="font: inherit;">“2016</em> Employee Plan”) became effective upon the approval of the plan by the Company’s Shareholders. The <em style="font: inherit;">2016</em> Employee Plan authorizes 1,000,000 shares of the Company's Common stock available for issuance under the plan. The value of the restricted stock is determined based on the market value of the stock at the issuance date. The restriction period or forfeiture period is determined by the Company’s Board and is to be <em style="font: inherit;">no</em> less than 1 year and <em style="font: inherit;">no</em> more than <span style="-sec-ix-hidden:c84560218">ten</span> years unless otherwise specified by the Board of Directors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">At <em style="font: inherit;"> March 31, 2022, </em>the Company had 893,258 restricted common shares issued under the <em style="font: inherit;">2016</em> Employee Plan and 208,880 restricted common shares issued under the <em style="font: inherit;">2015</em> Director Plan. The majority of shares were issued subject to a restriction and forfeiture period which lapses ratably on the first, second, and <em style="font: inherit;">third</em> anniversaries of the date of grant, and the fair value of which is being amortized over a <em style="font: inherit;">one</em> to <em style="font: inherit;">three</em>-year restriction period. For the fiscal years ended <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company recognized compensation expense related to the Employee and Director Plans of $4.5 million, $3.3 million, and $2.8 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">A summary of the Company’s non-vested restricted stock at <em style="font: inherit;"> March 31, 2022 </em>is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Employee</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Plan</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Director</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Plan</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Both Plans</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt; width: 55%;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-vested restricted stock outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">98</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">62</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">160</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock granted</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">676</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">44</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">720</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock vested</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(69</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(30</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(99</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock forfeited or expired</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(3</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(7</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(10</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-vested restricted stock outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">702</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">771</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> there were 770,652 and 160,117, restricted shares subject to restriction and forfeiture outstanding, respectively. During the fiscal years ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company issued, net of forfeitures, 709,599 and 102,931 restricted shares, respectively. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> there were $13.4 million and $2.5 million of unrecognized compensation costs related to the restricted stock subject to restriction and forfeiture awards, respectively, which is expected to be recognized over the remaining weighted average restriction and forfeiture period of 2.3 and 1.8 years for fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b/></p> 400000 0.10 1000000 P1Y 893258 208880 4500000 3300000 2800000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: undefined; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Employee</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Plan</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Director</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Plan</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Both Plans</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of</b></b></p> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td><td style="font-family: undefined; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt;"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt; width: 55%;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-vested restricted stock outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">98</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">62</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">160</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock granted</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">676</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">44</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">720</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock vested</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(69</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(30</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; text-align: right;">(99</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock forfeited or expired</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(3</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(7</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(10</td><td style="width: 1%; font-family: undefined; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td><td style="font-family: undefined; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: undefined; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: undefined; font-size: 10pt;"> <p style="font-family: undefined; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-vested restricted stock outstanding at March 31, 2022</p> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">702</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt;"> </td><td style="width: 1%; font-family: undefined; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: undefined; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">771</td><td style="width: 1%; font-family: undefined; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 98000 62000 160000 676000 44000 720000 69000 30000 99000 3000 7000 10000 702000 69000 771000 770652 160117 709599 102931 13400000 2500000 P2Y3M18D P1Y9M18D <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">8</em>)</b>         <b>Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company carries cash and cash equivalents and investments at fair value in the Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic <em style="font: inherit;">820</em> (“Fair Value Measurements”) establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Level <em style="font: inherit;">1</em> - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Level <em style="font: inherit;">2</em> - Include other inputs that are directly or indirectly observable in the marketplace.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Level <em style="font: inherit;">3</em> - Unobservable inputs which are supported by little or <em style="font: inherit;">no</em> market activity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s cash equivalents are classified within Level <em style="font: inherit;">1.</em> At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> the Company had invested the majority of its cash and cash equivalents balance in money market funds (level <em style="font: inherit;">1</em>).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">9</em>)</b>         <b>Net Income Per Share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In accordance with the provisions of ASC Topic <em style="font: inherit;">260</em> (“<i>Earnings Per Share</i>”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock, and convertible preferred shares issued by the Company represent the only dilutive effect reflected in diluted weighted average shares outstanding. The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (numerator):</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares (denominator)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average number of common shares outstanding used in basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Common shares issuable upon the vesting of restricted stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Common shares issuable upon conversion of preferred shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Shares used in diluted computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,119</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.05</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">At <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> 220,727, 20,952, and 72,120 shares of common restricted stock, respectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b/></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 54pt; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended March 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income (numerator):</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,603</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares (denominator)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Weighted average number of common shares outstanding used in basic computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Common shares issuable upon the vesting of restricted stock</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Common shares issuable upon conversion of preferred shares</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Shares used in diluted computation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,119</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income per common share:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Basic</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.05</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.04</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 21100000 30603000 25851000 20176000 20060000 20041000 172000 49000 4000 10000 10000 10000 20358000 20119000 20055000 1.05 1.53 1.29 1.04 1.52 1.29 220727 20952 72120 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">10</em>)</b>         <b>Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Legal Matters and Routine Proceedings</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be <em style="font: inherit;">no</em> assurances made that other states will <em style="font: inherit;">not</em> attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be <em style="font: inherit;">no</em> assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt;">Operating Leases</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Upon acquisition of the Delray Beach property in <em style="font: inherit;"> January 2016, </em>48% of the property, approximately 88,000 square feet of the property was leased to <span style="-sec-ix-hidden:c84560310">two</span> tenants. At <em style="font: inherit;"> March 31, 2022, </em>the leases with these <span style="-sec-ix-hidden:c84560311">two</span> tenants had a remaining weighted average lease term of 3.0 years. The Company recorded approximately $689,000 and $670,000 in rental revenue in fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively, which was included in other income. The Company expects to receive the following future lease payments, under the current lease agreements, over the next <em style="font: inherit;">five</em> years: $710,000 in fiscal <em style="font: inherit;">2023;</em> $731,000 in fiscal <em style="font: inherit;">2024,</em> $566,000 in fiscal <em style="font: inherit;">2025,</em> and $110,000 in fiscal <em style="font: inherit;">2026.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Employment Agreements</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> July 12, 2019, </em>the Company entered into Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">7</em> , with Menderes Akdag (“Mr. Akdag”), former CEO &amp; President and Director, providing that in the event that a Change in Control (as was thereinafter defined) of the Company was to occur at any time, Mr. Akdag would have the right to terminate his employment for “Good Reason,” (as was thereinafter defined) upon <em style="font: inherit;">thirty</em> (<em style="font: inherit;">30</em>) days written notice given at any time within <em style="font: inherit;">one</em> (<em style="font: inherit;">1</em>) year after the occurrence of such event, and upon such termination Mr. Akdag would be entitled to a <em style="font: inherit;">one</em>-time payment of <em style="font: inherit;">two</em> times his salary as of the date of such termination. On <em style="font: inherit;"> July 31, 2020, </em>the Company entered into Amendment <em style="font: inherit;">No.</em> <em style="font: inherit;">8</em> which extended Mr. Akdag’s contract for an additional year at an annual rate of $626,860 and granted Mr. Akdag 37,800 restricted shares, which were subject to restriction and forfeiture until <em style="font: inherit;"> July 31, 2021, </em>in accordance with the parameters of his executive compensation plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> May 28, 2021, </em>the Board of Directors notified Mr. Akdag that the Company would <em style="font: inherit;">not</em> extend Mr. Akdag’s employment agreement with the Company, and the employment agreement would therefore end on <em style="font: inherit;"> July 30, 2021, </em>in accordance with the scheduled end date of the agreement. Effective <em style="font: inherit;"> July 31, 2021, </em>the Board of Directors appointed Bruce S. Rosenbloom (“Mr. Rosenbloom”), the Company’s Chief Financial Officer, as Interim Chief Executive Officer and President of the Company, until a permanent successor chief executive officer was appointed. Mr. Rosenbloom received an additional cash stipend of $10,000 for the additional responsibilities while serving as Interim Chief Executive Officer and President, which ended on <em style="font: inherit;"> August 30, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> June 11, 2021, </em>the Company and Mr. Akdag, entered into a CEO Separation Agreement and General Release setting forth certain matters relating to the expiration of Mr. Akdag’s employment with the Company (the “Separation Agreement”). The Separation Agreement provided that Mr. Akdag’s employment with the Company, and service as an officer and director of the Company, would terminate as of <em style="font: inherit;"> July 30, 2021. </em>The Separation Agreement also documented Mr. Akdag’s agreement that, during his remaining period of employment through <em style="font: inherit;"> July 30, 2021, </em>he would continue to provide his fulltime and attention to the business affairs of the Company and cooperate with the Company’s Board of Directors on the transition to a new chief executive officer. The Separation Agreement provided that Mr. Akdag would be paid <em style="font: inherit;">two</em> lump-sum severance payments of $325,000 each, with the <em style="font: inherit;">first</em> such payment to be paid, and was paid, on <em style="font: inherit;"> August 10, 2021, </em>and the <em style="font: inherit;">second</em> to be paid, and was paid, on <em style="font: inherit;"> December 31, 2021, </em>subject to his compliance with the terms and conditions of his then existing employment agreement, and the Separation Agreement. In exchange for the Company’s agreement to make the severance payments, Mr. Akdag granted the Company a full release of any and all claims that he <em style="font: inherit;"> may </em>have against the Company and its affiliates and related parties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">In addition, as a part of the Separation Agreement, the Company confirmed that the 37,800 restricted shares held by Mr. Akdag will be, and were, released from restriction and forfeiture on <em style="font: inherit;"> July 31, 2021, </em>and that the Company would, and did, cover the tax withholding obligations in connection with such release of shares from restriction and forfeiture. Under the Separation Agreement, Mr. Akdag agreed that he would continue to comply with his existing confidentiality, non-solicitation, and non-compete obligations, and he further agreed that until <em style="font: inherit;"> July 31, 2022, </em>he would comply with certain “standstill” covenants relating to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> August 25, 2021, </em>the Board of Directors appointed Mathew N. Hulett (Mr. Hulett”) as Chief Executive Officer and President of the Company and as a member of the Board of Directors. These appointments were effective as of <em style="font: inherit;"> August 30, 2021. </em>On <em style="font: inherit;"> August 25, 2021, </em>the Company entered into an employment agreement with Mr. Hulett to serve as the Company’s Chief Executive Officer and President. The employment agreement is for an initial term of <em style="font: inherit;">three</em> (<em style="font: inherit;">3</em>) years commencing on <em style="font: inherit;"> August 30, 2021 </em>and will automatically renew for successive <em style="font: inherit;">one</em> (<em style="font: inherit;">1</em>) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement is expressly cancelled by either Mr. Hulett or the Company <em style="font: inherit;">sixty</em> (<em style="font: inherit;">60</em>) days prior to the end of the then current term, or is otherwise terminated as provided in the agreement. The employment agreement provides that Mr. Hulett will receive an annual base salary of $500,000, subject to periodic review for increases with the approval of the Board of Directors, and will be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stock under the Company’s equity compensation plan(s), <em style="font: inherit;">401</em>(k) plan, and paid time off and paid holidays. The employment agreement also provides that the Company will reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The employment agreement contains certain rights of Mr. Hulett and the Company to terminate Mr. Hulett’s employment, including termination by the Company for “Cause” as defined in the employment agreement, and termination by Mr. Hulett for “Good Reason” as defined in the employment agreement within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months of a Change in Control as defined in the employment agreement. Mr. Hulett is also entitled to severance pay equal to <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months of Mr. Hulett’s current base salary and <em style="font: inherit;">eighteen</em> (<em style="font: inherit;">18</em>) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett’s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a <em style="font: inherit;">one</em> (<em style="font: inherit;">1</em>) year non-compete following the termination of the agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> August 30, 2021, </em>Mr. Hulett also received an award of 90,000 shares of restricted stock under the Company’s <em style="font: inherit;">2016</em> Employee Plan, which stock restrictions will lapse pro rata on each of <em style="font: inherit;"> August 30, 2022, </em><em style="font: inherit;"> August 30, 2023, </em>and <em style="font: inherit;"> August 30, 2024, </em>which are subject to forfeiture in the event of termination of employment (except as provided in the restricted stock agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock under the <em style="font: inherit;">2016</em> Employee Plan, which stock restrictions will lapse on the <em style="font: inherit;">third</em> anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the <em style="font: inherit;">three</em>-year period from the date of grant, and (ii) continued employment through the performance period of <em style="font: inherit;">three</em> years from the date of grant, in accordance with the following schedule: 85,000 shares at the stock hurdle price of $40 per share, 107,000 shares at the stock hurdle price of $45 per share, 106,000 shares at the stock hurdle price of $50, 106,000 shares at the stock hurdle price of $55, and 106,000 shares at the stock hurdle price of $60.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Should <em style="font: inherit;">none</em> of the absolute stock price hurdles be met during the <em style="font: inherit;">three</em>-year period from the date of grant <em style="font: inherit;">no</em> shares would vest (as defined in the performance restricted stock agreement). Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the <em style="font: inherit;">third</em> anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of <em style="font: inherit;">ninety</em> (<em style="font: inherit;">90</em>) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the <em style="font: inherit;">third</em> anniversary of date of grant, subject to Mr. Hulett’s continued employment through the performance period of <em style="font: inherit;">three</em> years from the date of grant (except as provided in the performance restricted stock agreement). As of <em style="font: inherit;"> March 31, 2022, </em><em style="font: inherit;">none</em> of the performance restricted stock vested, as <em style="font: inherit;">no</em> performance stock price hurdles were met.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b/></p> 0.48 88000 P3Y 689000 670000 710000 731000 566000 110000 626860 37800 10000 325000 37800 500000 90000 510000 85000 40 107000 45 106000 50 106000 55 106000 60 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">11</em>)</b>         <b>Employee Benefit Plan</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company maintains a <em style="font: inherit;">401</em>(k) Savings Plan for eligible employees.  The plan is a defined contribution plan that is administered by the Company. All regular, full-time employees are eligible for voluntary participation upon completing <span style="-sec-ix-hidden:c84560395">one</span> year of service and having attained the age of 21.  The plan provides for growth in savings through contributions and income from investments.  It is subject to the provisions of the Employee Retirement Income Security Act of <em style="font: inherit;">1974,</em> as amended. Plan participants are allowed to contribute a specified percentage of their base salary. In <em style="font: inherit;">2006,</em> the Company approved a matching contribution which is funded subsequent to the calendar year. During the fiscal years ended <em style="font: inherit;"> March </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> the Company charged $238,000, $245,000, and $211,000, respectively, of <em style="font: inherit;">401</em>(k) matching contribution and administration expense to general and administrative expenses.</p> P21Y 238000 245000 211000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">12</em>)</b>         <b>COVID-<em style="font: inherit;">19</em></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> March 11, 2020, </em>the World Health Organization declared that the novel coronavirus (COVID-<em style="font: inherit;">19</em>) had become a pandemic, and on <em style="font: inherit;"> March 13, 2020, </em>the U.S. President declared a National Emergency concerning the disease. Additionally, in <em style="font: inherit;"> March 2020, </em>state governments in the Company’s geographic operating area began instituting preventative shut down measures in order to combat the novel coronavirus pandemic. The coronavirus and actions taken to mitigate the spread of it have had and are expected to continue to have an adverse impact on the economies and financial markets of the geographical area in which the Company operates. On <em style="font: inherit;"> March 27, 2020, </em>the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted to amongst other provisions, provide emergency assistance for individuals, families and businesses affected by the novel coronavirus pandemic. The Company’s business being deemed essential resulted in incremental financial performance that <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be indicative of future financial results and there remains uncertainty and increased risks concerning its employees, customers, supply chain and government regulation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">During fiscal <em style="font: inherit;">2022,</em> the Company has been open during our normal business hours without any material disruptions to our operations. We have <em style="font: inherit;">not</em> seen any major disruptions in our supply chain; however, we have experienced some delays in the delivery of some inventory items. We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our workplace.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">13</em>)</b>         <b>Subsequent Events</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Subsequent to <em style="font: inherit;"> March 31, 2022 </em>the Company issued 7,450 restricted shares to certain employees of the Company under the <em style="font: inherit;">2016</em> Employee Plan, with a fair value of $23.50 per share. In <em style="font: inherit;"> April 2022, </em>the Company issued 1,875 restricted shares to Diana Garvis Purcell, a newly appointed director on our Board of Directors, with a fair value of $25.53 per share. In connection with Ms. Purcel’s appointment on the Board, the Board voted to increase the size of the Board by <em style="font: inherit;">one</em> director to <em style="font: inherit;">seven</em> persons effective <em style="font: inherit;"> April 4, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> April 19, 2022, </em>the Company engaged in a <span style="-sec-ix-hidden:c84560421">three</span>-year partnership agreement with Vetster Inc. (“Vetster”), a veterinary telehealth Canadian company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million The Company also received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company becomes the exclusive e-commerce provider for Vetster, and Vetster becomes the exclusive provider of telehealth and telemedicine services to the Company.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">On <em style="font: inherit;"> May 9, 2022, </em>the Company’s Board of Directors declared a quarterly dividend of $0.30 per share on its common stock. The $6.3 million dividend will be payable on <em style="font: inherit;"> May 27, 2022, </em>to shareholders of record at the close of business on <em style="font: inherit;"> May 20, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b/></p> 7450 23.50 1875 25.53 0.05 5000000.0 0.30 6300000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(<em style="font: inherit;">14</em>)</b>         <b>Related Party Transaction</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Company’s Board of Directors Chairman, Gian Fulgoni, serves on the board of directors of Prophet, a brand and marketing consulting company, which PetMed Express, Inc. engaged with in <em style="font: inherit;"> March 2021 </em>for $292,000. The Company expensed $32,000 in fiscal <em style="font: inherit;">2021,</em> with the remaining $260,000 expensed in fiscal <em style="font: inherit;">2022.</em> This transaction was approved by the Company’s Board of Directors with terms that are comparable to those with an unrelated <em style="font: inherit;">third</em> party.</p> 292000 32000 260000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>(<em style="font: inherit;">15</em>)</b>         <b>Quarterly Financial Data (Unaudited)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Summarized unaudited quarterly financial data for fiscal <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> is as follows (in thousands, except for per share amounts):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Quarter Ended:</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>June 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">79,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">67,386</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">60,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">21,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">17,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,147</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Quarter Ended:</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">June 30, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">September 30, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">December 31, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">March 31, 2021</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">96,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">75,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">65,896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,679</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">26,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">23,018</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,522</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,412</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,611</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,812</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 36pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Quarter Ended:</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>June 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>September 30, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">79,312</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">67,386</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">60,717</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">66,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">21,780</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">17,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,087</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,147</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,428</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.22</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.31</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Quarter Ended:</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">June 30, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">September 30, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">December 31, 2020</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">March 31, 2021</em></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 36%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">96,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">75,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">65,896</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,679</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross Profit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">26,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">23,018</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">19,623</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,522</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income from operations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,436</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,387</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,768</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,412</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,611</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,812</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income per common share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.42</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 79312000 67386000 60717000 66002000 21780000 19174000 17725000 19397000 5419000 8087000 5147000 7057000 4428000 6349000 4257000 6066000 0.22 0.31 0.21 0.30 96204000 75436000 65896000 71679000 26785000 23018000 19623000 20522000 9436000 10471000 9293000 8387000 7768000 8412000 7611000 6812000 0.39 0.42 0.38 0.34 EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 139 240 1 false 47 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Income Sheet http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income- Consolidated Statements of Income Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity Consolidated Statements of Changes in Shareholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows- Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Summary of Significant Accounting Policies Sheet http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies Note 1 - Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Property and Equipment Sheet http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment Note 2 - Property and Equipment Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Valuation and Qualifying Accounts Sheet http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts Note 3 - Valuation and Qualifying Accounts Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities Sheet http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities Note 4 - Accrued Expenses and Other Current Liabilities Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Income Taxes Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes Note 5 - Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Shareholders' Equity Sheet http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity Note 6 - Shareholders' Equity Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Restricted Stock Sheet http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock Note 7 - Restricted Stock Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Fair Value Measurements Sheet http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements Note 8 - Fair Value Measurements Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Net Income Per Share Sheet http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share Note 9 - Net Income Per Share Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Commitments and Contingencies Sheet http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies Note 10 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Employee Benefit Plan Sheet http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan Note 11 - Employee Benefit Plan Notes 17 false false R18.htm 017 - Disclosure - Note 12 - COVID-19 Sheet http://www.1800petmeds.com/20220331/role/statement-note-12-covid19 Note 12 - COVID-19 Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Subsequent Events Sheet http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events Note 13 - Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Related Party Transaction Sheet http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction Note 14 - Related Party Transaction Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) Sheet http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited Note 15 - Quarterly Financial Data (Unaudited) Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables Note 1 - Summary of Significant Accounting Policies (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies 23 false false R24.htm 023 - Disclosure - Note 2 - Property and Equipment (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables Note 2 - Property and Equipment (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment 24 false false R25.htm 024 - Disclosure - Note 3 - Valuation and Qualifying Accounts (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables Note 3 - Valuation and Qualifying Accounts (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts 25 false false R26.htm 025 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables Note 4 - Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities 26 false false R27.htm 026 - Disclosure - Note 5 - Income Taxes (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables Note 5 - Income Taxes (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes 27 false false R28.htm 027 - Disclosure - Note 6 - Shareholders' Equity (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables Note 6 - Shareholders' Equity (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity 28 false false R29.htm 028 - Disclosure - Note 7 - Restricted Stock (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables Note 7 - Restricted Stock (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock 29 false false R30.htm 029 - Disclosure - Note 9 - Net Income Per Share (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables Note 9 - Net Income Per Share (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share 30 false false R31.htm 030 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) (Tables) Sheet http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables Note 15 - Quarterly Financial Data (Unaudited) (Tables) Tables http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited 31 false false R32.htm 031 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual Note 1 - Summary of Significant Accounting Policies (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables 32 false false R33.htm 032 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details) Details 33 false false R34.htm 033 - Disclosure - Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details) Details 34 false false R35.htm 034 - Disclosure - Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details) Details 35 false false R36.htm 035 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details) Details 36 false false R37.htm 036 - Disclosure - Note 5 - Income Taxes (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual Note 5 - Income Taxes (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables 37 false false R38.htm 037 - Disclosure - Note 5 - Income Taxes - Deferred Income Taxes (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details Note 5 - Income Taxes - Deferred Income Taxes (Details) Details 38 false false R39.htm 038 - Disclosure - Note 5 - Income Taxes - Components of Income Tax Provision (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details Note 5 - Income Taxes - Components of Income Tax Provision (Details) Details 39 false false R40.htm 039 - Disclosure - Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details) Details 40 false false R41.htm 040 - Disclosure - Note 6 - Shareholders' Equity (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual Note 6 - Shareholders' Equity (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables 41 false false R42.htm 041 - Disclosure - Note 6 - Shareholder's Equity - Declared Dividends (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details Note 6 - Shareholder's Equity - Declared Dividends (Details) Details 42 false false R43.htm 042 - Disclosure - Note 7 - Restricted Stock (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual Note 7 - Restricted Stock (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables 43 false false R44.htm 043 - Disclosure - Note 7 - Restricted Stock - Non-vested Restricted Stock (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details Note 7 - Restricted Stock - Non-vested Restricted Stock (Details) Details 44 false false R45.htm 044 - Disclosure - Note 9 - Net Income Per Share (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual Note 9 - Net Income Per Share (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables 45 false false R46.htm 045 - Disclosure - Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details) Details 46 false false R47.htm 046 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual Note 10 - Commitments and Contingencies (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies 47 false false R48.htm 047 - Disclosure - Note 11 - Employee Benefit Plan (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual Note 11 - Employee Benefit Plan (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan 48 false false R49.htm 048 - Disclosure - Note 13 - Subsequent Events (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual Note 13 - Subsequent Events (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events 49 false false R50.htm 049 - Disclosure - Note 14 - Related Party Transaction (Details Textual) Sheet http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual Note 14 - Related Party Transaction (Details Textual) Details http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction 50 false false R51.htm 050 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details) Sheet http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details) Details http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables 51 false false All Reports Book All Reports pets20220331_10k.htm ex_378684.htm ex_378685.htm ex_378686.htm ex_378687.htm ex_378688.htm ex_378979.htm pets-20220331.xsd pets-20220331_cal.xml pets-20220331_def.xml pets-20220331_lab.xml pets-20220331_pre.xml graph01.jpg http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "pets20220331_10k.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 139, "dts": { "calculationLink": { "local": [ "pets-20220331_cal.xml" ] }, "definitionLink": { "local": [ "pets-20220331_def.xml" ] }, "inline": { "local": [ "pets20220331_10k.htm" ] }, "labelLink": { "local": [ "pets-20220331_lab.xml" ] }, "presentationLink": { "local": [ "pets-20220331_pre.xml" ] }, "schema": { "local": [ "pets-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 380, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 44, "http://www.1800petmeds.com/20220331": 11, "http://xbrl.sec.gov/dei/2022": 6, "total": 61 }, "keyCustom": 22, "keyStandard": 218, "memberCustom": 27, "memberStandard": 20, "nsprefix": "pets", "nsuri": "http://www.1800petmeds.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities", "role": "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Income Taxes", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "shortName": "Note 5 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Shareholders' Equity", "role": "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "shortName": "Note 6 - Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Restricted Stock", "role": "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "shortName": "Note 7 - Restricted Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Fair Value Measurements", "role": "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "shortName": "Note 8 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Net Income Per Share", "role": "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share", "shortName": "Note 9 - Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Commitments and Contingencies", "role": "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "shortName": "Note 10 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Employee Benefit Plan", "role": "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "shortName": "Note 11 - Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:EffectOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - COVID-19", "role": "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "shortName": "Note 12 - COVID-19", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:EffectOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Subsequent Events", "role": "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "shortName": "Note 13 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Related Party Transaction", "role": "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "shortName": "Note 14 - Related Party Transaction", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "shortName": "Note 15 - Quarterly Financial Data (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 2 - Property and Equipment (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "shortName": "Note 2 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:ValuationAndQualifyingAccountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 3 - Valuation and Qualifying Accounts (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "shortName": "Note 3 - Valuation and Qualifying Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:ValuationAndQualifyingAccountsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 5 - Income Taxes (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "shortName": "Note 5 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 6 - Shareholders' Equity (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "shortName": "Note 6 - Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 7 - Restricted Stock (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "shortName": "Note 7 - Restricted Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 9 - Net Income Per Share (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables", "shortName": "Note 9 - Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) (Tables)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "shortName": "Note 15 - Quarterly Financial Data (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 1 - Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "shortName": "Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "0", "lang": null, "name": "pets:RevenueFromContractWithCustomerPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "shortName": "Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pets:ValuationAndQualifyingAccountsTableTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2021-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "shortName": "Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pets:ValuationAndQualifyingAccountsTableTextBlock", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2019-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesAndExciseTaxPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesAndExciseTaxPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 5 - Income Taxes (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "shortName": "Note 5 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 5 - Income Taxes - Deferred Income Taxes (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details", "shortName": "Note 5 - Income Taxes - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 5 - Income Taxes - Components of Income Tax Provision (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "shortName": "Note 5 - Income Taxes - Components of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Income", "role": "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "shortName": "Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_1998-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 6 - Shareholders' Equity (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual", "shortName": "Note 6 - Shareholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_1998-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2021-05-03", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 6 - Shareholder's Equity - Declared Dividends (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "shortName": "Note 6 - Shareholder's Equity - Declared Dividends (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 7 - Restricted Stock (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "shortName": "Note 7 - Restricted Stock (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2015-07-31_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2021-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 7 - Restricted Stock - Non-vested Restricted Stock (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details", "shortName": "Note 7 - Restricted Stock - Non-vested Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 9 - Net Income Per Share (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual", "shortName": "Note 9 - Net Income Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "shortName": "Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-08-25_2021-08-25_TitleOfIndividualAxis-ChiefExecutiveOfficerMember", "decimals": "INF", "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:DefinedContributionPlanWithIndividualAge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 11 - Employee Benefit Plan (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual", "shortName": "Note 11 - Employee Benefit Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pets:DefinedContributionPlanWithIndividualAge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 13 - Subsequent Events (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "shortName": "Note 13 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2022-05-09_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:DividendsPayableAmountPerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2019-03-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "role": "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "i_2019-03-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-03-01_2021-03-31_RelatedPartyTransactionsByRelatedPartyAxis-ProphetMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 14 - Related Party Transaction (Details Textual)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual", "shortName": "Note 14 - Related Party Transaction (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-03-01_2021-03-31_RelatedPartyTransactionsByRelatedPartyAxis-ProphetMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details)", "role": "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "shortName": "Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Summary of Significant Accounting Policies", "role": "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "shortName": "Note 1 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Property and Equipment", "role": "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "shortName": "Note 2 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Valuation and Qualifying Accounts", "role": "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "shortName": "Note 3 - Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pets20220331_10k.htm", "contextRef": "d_2021-04-01_2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables", "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r450", "r451", "r452" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables", "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "pets_AccruedCreditCardFeesCurrent": { "auth_ref": [], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 1.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for credit card fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued credit card fees" } } }, "localname": "AccruedCreditCardFeesCurrent", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pets_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pets_AccruedMerchandiseCreditsAndRewardsCurrent": { "auth_ref": [], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 3.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accrued merchandise credits and rewards classified as current.", "label": "Accrued merchandise credits / reward program" } } }, "localname": "AccruedMerchandiseCreditsAndRewardsCurrent", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pets_AccruedSalesReturnsAndAllowancesCurrent": { "auth_ref": [], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 5.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued sales returns and allowances. Used to reflect the current portion (due within one year or within the normal operating cycle if longer).", "label": "Accrued sales return allowance" } } }, "localname": "AccruedSalesReturnsAndAllowancesCurrent", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pets_ContactCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disaggregate of revenue in contact center sales.", "label": "Contact Center [Member]" } } }, "localname": "ContactCenterMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "pets_DefinedContributionPlanWithIndividualAge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum age that the individual is required in order to participate in the defined contribution plan.", "label": "pets_DefinedContributionPlanWithIndividualAge", "terseLabel": "Defined Contribution Plan With Individual Age (Year)" } } }, "localname": "DefinedContributionPlanWithIndividualAge", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual" ], "xbrltype": "durationItemType" }, "pets_DelrayBeachPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the Delray Beach Property.", "label": "Delray Beach Property [Member]" } } }, "localname": "DelrayBeachPropertyMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_DirectorPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the 2006 and 2015 Director Plans.", "label": "Director Plan [Member]" } } }, "localname": "DirectorPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "domainItemType" }, "pets_DividendDeclaredJanuary192021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the dividend declared January 19, 2021.", "label": "Dividend Declared January 19, 2021 [Member]" } } }, "localname": "DividendDeclaredJanuary192021Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "domainItemType" }, "pets_DividendDeclaredJuly202020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the dividend declared July 20, 2020.", "label": "Dividend Declared July 20, 2020 [Member]" } } }, "localname": "DividendDeclaredJuly202020Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "domainItemType" }, "pets_DividendDeclaredMay42020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the dividend declared May 4, 2020.", "label": "Dividend Declared May 4, 2020 [Member]" } } }, "localname": "DividendDeclaredMay42020Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "domainItemType" }, "pets_DividendDeclaredOctober262020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the dividend declared October 26, 2020.", "label": "Dividend Declared October 26, 2020 [Member]" } } }, "localname": "DividendDeclaredOctober262020Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "domainItemType" }, "pets_EffectOfCovid19PandemicTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for effects of COVID-19 pandemic.", "label": "Effect of Covid-19 Pandemic [Text Block]" } } }, "localname": "EffectOfCovid19PandemicTextBlock", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19" ], "xbrltype": "textBlockItemType" }, "pets_EmployeeAndDirectorEquityCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to both the employee and director equity compensation plans.", "label": "Employee and Director Equity Compensation Plan [Member]" } } }, "localname": "EmployeeAndDirectorEquityCompensationPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "pets_EmployeePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to the 2006 and 2016 Employee Plans.", "label": "Employee Plan [Member]" } } }, "localname": "EmployeePlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "domainItemType" }, "pets_FiveSuppliersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to five suppliers.", "label": "Five Suppliers [Member]" } } }, "localname": "FiveSuppliersMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pets_FurnitureFixturesEquipmentAndComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding furniture, fixtures, equipment and computer software.", "label": "Furniture, Fixtures, Equipment and Computer Software [Member]" } } }, "localname": "FurnitureFixturesEquipmentAndComputerSoftwareMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pets_InternetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disaggregate of revenue in internet sales.", "label": "Internet [Member]" } } }, "localname": "InternetMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "pets_LessorOperatingLeaseRemainingWeightedAverageLeaseTerm", "terseLabel": "Lessor, Operating Lease, Remaining Weighted Average Lease Term (Year)" } } }, "localname": "LessorOperatingLeaseRemainingWeightedAverageLeaseTerm", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "durationItemType" }, "pets_LumpsumSeverancePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents lump-sum severance payments.", "label": "pets_LumpsumSeverancePayments", "terseLabel": "Lump-sum Severance Payments" } } }, "localname": "LumpsumSeverancePayments", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pets_NewOrderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disaggregate of revenue in new order sales.", "label": "New Order Customer [Member]" } } }, "localname": "NewOrderMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "pets_NoncontrollingInterestOwnershipPercentagePurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents minority interest purchased.", "label": "pets_NoncontrollingInterestOwnershipPercentagePurchased", "terseLabel": "Noncontrolling Interest, Ownership Percentage Purchased" } } }, "localname": "NoncontrollingInterestOwnershipPercentagePurchased", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "percentItemType" }, "pets_NonvestedRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to non-vested restricted stock awards.", "label": "Non-vested Restricted Stock [Member]" } } }, "localname": "NonvestedRestrictedStockMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "pets_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_NumberOfSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major suppliers of the Company.", "label": "pets_NumberOfSuppliers", "terseLabel": "Number of Suppliers" } } }, "localname": "NumberOfSuppliers", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "pets_NumberOfTenants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of tenants.", "label": "pets_NumberOfTenants", "terseLabel": "Number of Tenants" } } }, "localname": "NumberOfTenants", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "integerItemType" }, "pets_OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to information regarding 2015 Outside Director Equity Compensation Restricted Stock Plan (\"2015 Director Plan\").", "label": "2015 Outside Director Equity Compensation Restricted Stock Plan (\"2015 Director Plan\") [Member]" } } }, "localname": "OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "pets_PartnershipAgreementWithVetsterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents partnership agreement with Vestster.", "label": "Partnership Agreement with Vetster [Member]" } } }, "localname": "PartnershipAgreementWithVetsterMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "pets_PaymentsForStipend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents payments for stipend.", "label": "pets_PaymentsForStipend", "terseLabel": "Payments for Stipend" } } }, "localname": "PaymentsForStipend", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of automatic increase in the amount of shares available for issuance.", "label": "pets_PercentageOfAutomaticIncreaseInSharesAvailableForIssuance", "terseLabel": "Percentage of Automatic Increase in Shares Available for Issuance" } } }, "localname": "PercentageOfAutomaticIncreaseInSharesAvailableForIssuance", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "percentItemType" }, "pets_PercentageOfPropertyLeasedToTenants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage amount of property that was leased to tenants of the property.", "label": "pets_PercentageOfPropertyLeasedToTenants", "terseLabel": "Percentage of Property Leased to Tenants" } } }, "localname": "PercentageOfPropertyLeasedToTenants", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "percentItemType" }, "pets_PerformanceRestrictedStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents performance restricted stock.", "label": "Performance Restricted Stock [Member]" } } }, "localname": "PerformanceRestrictedStockMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_PerformanceRestrictedStockPriceHurdle1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Performance Restricted Stock Price Hurdle 1.", "label": "Performance Restricted Stock Price Hurdle1 [Member]" } } }, "localname": "PerformanceRestrictedStockPriceHurdle1Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_PerformanceRestrictedStockPriceHurdle2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Performance Restricted Stock Price Hurdle 2.", "label": "Performance Restricted Stock Price Hurdle 2 [Member]" } } }, "localname": "PerformanceRestrictedStockPriceHurdle2Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_PerformanceRestrictedStockPriceHurdle3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Performance Restricted Stock Price Hurdle 3.", "label": "Performance Restricted Stock Price Hurdle 3 [Member]" } } }, "localname": "PerformanceRestrictedStockPriceHurdle3Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_PerformanceRestrictedStockPriceHurdle4Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Performance Restricted Stock Price Hurdle 4.", "label": "Performance Restricted Stock Price Hurdle 4 [Member]" } } }, "localname": "PerformanceRestrictedStockPriceHurdle4Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_PerformanceRestrictedStockPriceHurdle5Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Performance Restricted Stock Price Hurdle 5.", "label": "Performance Restricted Stock Price Hurdle 5 [Member]" } } }, "localname": "PerformanceRestrictedStockPriceHurdle5Member", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_ProphetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Prophet.", "label": "Prophet [Member]" } } }, "localname": "ProphetMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "domainItemType" }, "pets_ReorderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disaggregate of revenue in reorder sales.", "label": "Reorder Customer [Member]" } } }, "localname": "ReorderMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "pets_RestrictionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of restriction of forfeiture.", "label": "pets_RestrictionPeriod", "terseLabel": "Restriction Period (Year)" } } }, "localname": "RestrictionPeriod", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "durationItemType" }, "pets_RevenueFromContractWithCustomerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of revenue from the specified category to the total revenue during the period.", "label": "pets_RevenueFromContractWithCustomerPercentage", "terseLabel": "Revenues, percentage" } } }, "localname": "RevenueFromContractWithCustomerPercentage", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "percentItemType" }, "pets_RevenueFromContractWithCustomerVariance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of changes in revenue in current period comparing to the same period in the previous year.", "label": "pets_RevenueFromContractWithCustomerVariance", "terseLabel": "Revenues, variance" } } }, "localname": "RevenueFromContractWithCustomerVariance", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "monetaryItemType" }, "pets_RevenueFromContractWithCustomerVariancePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of changes in revenue in current period comparing to the same period in the previous year.", "label": "pets_RevenueFromContractWithCustomerVariancePercentage", "terseLabel": "Revenues, variance, percentage" } } }, "localname": "RevenueFromContractWithCustomerVariancePercentage", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "percentItemType" }, "pets_StockRepurchaseProgramAdditionalAuthorizedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional stock repurchase plan authorized.", "label": "pets_StockRepurchaseProgramAdditionalAuthorizedAmount", "terseLabel": "Stock Repurchase Program, Additional Authorized Amount" } } }, "localname": "StockRepurchaseProgramAdditionalAuthorizedAmount", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pets_TermOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents term of agreement.", "label": "pets_TermOfAgreement", "terseLabel": "Term of Agreement (Year)" } } }, "localname": "TermOfAgreement", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "durationItemType" }, "pets_The2016EmployeeEquityCompensationRestrictedStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "represents the 2016 Employee Equity Compensation Restricted Stock Plan.", "label": "The 2016 Employee Equity Compensation Restricted Stock Plan [Member]" } } }, "localname": "The2016EmployeeEquityCompensationRestrictedStockPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pets_TransferOfPropertyAndEquipmentToCurrentAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of property and equipment transferred to current assets during the period.", "label": "Property and equipment in current assets" } } }, "localname": "TransferOfPropertyAndEquipmentToCurrentAssets", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "pets_TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2015 Outside Director Equity Compensation Restricted Stock Plan.", "label": "2015 Outside Director Equity Compensation Restricted Stock Plan [Member]" } } }, "localname": "TwoThousandFifteenOutsideDirectorEquityCompensationRestrictedStockPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "pets_TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2016 Employee Equity Compensation Restricted Stock Plan.", "label": "2016 Employee Equity Compensation Restricted Stock Plan [Member]" } } }, "localname": "TwoThousandSixteenEmployeeEquityCompensationRestrictedStockPlanMember", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "pets_ValuationAndQualifyingAccountsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of valuation and qualifying accounts and reserves.", "label": "Valuation and Qualifying Accounts [Table Text Block]" } } }, "localname": "ValuationAndQualifyingAccountsTableTextBlock", "nsuri": "http://www.1800petmeds.com/20220331", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables" ], "xbrltype": "textBlockItemType" }, "pets_statement-statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue by Type (Details)" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-1-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Quarterly Financial Data (Unaudited) - Summarized Unaudited Quarterly Financial Data (Details)" } } }, "localname": "statement-statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-15-quarterly-financial-data-unaudited-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Quarterly Financial Data (Unaudited)" } } }, "localname": "statement-statement-note-15-quarterly-financial-data-unaudited-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Property and Equipment - Major Classifications of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-2-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Property and Equipment" } } }, "localname": "statement-statement-note-2-property-and-equipment-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Valuation and Qualifying Accounts - Activity in the Valuation and Qualifying Accounts (Details)" } } }, "localname": "statement-statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-3-valuation-and-qualifying-accounts-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Valuation and Qualifying Accounts" } } }, "localname": "statement-statement-note-3-valuation-and-qualifying-accounts-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Accrued Expenses and Other Current Liabilities - Major Classifications of Accrued Expenses and Other Current Liabilities (Details)" } } }, "localname": "statement-statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Accrued Expenses and Other Current Liabilities" } } }, "localname": "statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-5-income-taxes-components-of-income-tax-provision-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Components of Income Tax Provision (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-components-of-income-tax-provision-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-5-income-taxes-deferred-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Deferred Income Taxes (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-deferred-income-taxes-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes - Reconciliation of Income Tax Provision (Details)" } } }, "localname": "statement-statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-5-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Income Taxes" } } }, "localname": "statement-statement-note-5-income-taxes-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-6-shareholders-equity-declared-dividends-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Shareholder's Equity - Declared Dividends (Details)" } } }, "localname": "statement-statement-note-6-shareholders-equity-declared-dividends-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-6-shareholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Shareholders' Equity" } } }, "localname": "statement-statement-note-6-shareholders-equity-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-7-restricted-stock-nonvested-restricted-stock-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Restricted Stock - Non-vested Restricted Stock (Details)" } } }, "localname": "statement-statement-note-7-restricted-stock-nonvested-restricted-stock-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-7-restricted-stock-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Restricted Stock" } } }, "localname": "statement-statement-note-7-restricted-stock-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Net Income Per Share - Basic and Diluted Net Income Per Share (Details)" } } }, "localname": "statement-statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-note-9-net-income-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Net Income Per Share" } } }, "localname": "statement-statement-note-9-net-income-per-share-tables", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "pets_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.1800petmeds.com/20220331", "xbrltype": "stringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief executive officer.", "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r35", "r37", "r83", "r84", "r210", "r214", "r466" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r160", "r242", "r244", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r209", "r213", "r252", "r253", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r422", "r424", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r191", "r192", "r193", "r194", "r209", "r213", "r252", "r253", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r422", "r424", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r160", "r242", "r244", "r423" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r187", "r191", "r192", "r193", "r194", "r209", "r213", "r250", "r252", "r253", "r284", "r285", "r286", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r422", "r424", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r187", "r191", "r192", "r193", "r194", "r209", "r213", "r250", "r252", "r253", "r284", "r285", "r286", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r422", "r424", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by name of property.", "label": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.", "label": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r36", "r37", "r83", "r84", "r210", "r214" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r88", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r161", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r162", "r163" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, less allowance for doubtful accounts of $39 and $39, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r299", "r401", "r417" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 8.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrued real estate taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 0.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued salaries and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 2.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r10", "r183" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r90", "r91", "r92", "r292", "r293", "r294", "r343" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r256", "r295", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "verboseLabel": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r301" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r23", "r164", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Square Foot)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r78", "r147", "r150", "r156", "r166", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r336", "r339", "r351", "r370", "r372", "r398", "r410" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r27", "r78", "r166", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r336", "r339", "r351", "r370", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r78", "r166", "r196", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r336", "r339", "r351", "r370" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total noncurrent assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r8", "r66" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r60", "r66", "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, at end of year", "periodStartLabel": "Cash and cash equivalents, at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r60", "r352" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r14", "r16", "r17", "r76", "r78", "r105", "r109", "r112", "r114", "r116", "r128", "r129", "r130", "r166", "r196", "r201", "r202", "r203", "r207", "r208", "r211", "r212", "r216", "r220", "r227", "r351", "r454" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r402", "r415" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r195", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Cash dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r90", "r91", "r343" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.001 par value, 40,000 shares authorized; 20,979 and 20,269 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r248", "r249", "r254", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r160", "r349", "r350", "r431" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r160", "r349", "r350", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r160", "r349", "r350", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r133", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r160", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r160", "r349", "r350", "r431" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r73", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r242", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r242", "r245" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r211", "r212", "r216" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r15", "r16", "r223", "r228", "r230" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion", "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion (in shares)" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r52", "r384" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r79", "r320", "r327" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r320", "r327", "r329" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r79", "r320", "r327" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1": { "auth_ref": [ "r247", "r260" ], "lang": { "en-us": { "role": { "documentation": "Minimum period the individual is required to perform services to be fully vested under the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1", "terseLabel": "Deferred Compensation Arrangement with Individual, Requisite Service Period (Year)" } } }, "localname": "DeferredCompensationArrangementWithIndividualRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r321", "r327" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r64", "r79", "r321", "r327", "r328", "r329" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r306", "r307" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r65" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r79", "r321", "r327" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r314" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Bad debt and inventory reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r307", "r314" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Total net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum amount the employee may contribute to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r64", "r181" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r259", "r260", "r288", "r289", "r291", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r231", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "us-gaap_DividendsCommonStock", "negatedLabel": "Dividends declared" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Per Share Dividend (in dollars per share)", "terseLabel": "Dividends Payable, Amount Per Share (in dollars per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 4.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r12", "r13", "r399", "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Total Amount", "terseLabel": "Dividends Payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format.", "label": "Record Date" } } }, "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details" ], "xbrltype": "dateItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r28", "r82", "r199", "r201", "r202", "r206", "r207", "r208", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_DueToRelatedPartiesCurrent", "terseLabel": "Due to Related Parties, Current, Total" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r48", "r95", "r96", "r97", "r98", "r99", "r103", "r105", "r114", "r115", "r116", "r120", "r121", "r344", "r345", "r405", "r419" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r48", "r95", "r96", "r97", "r98", "r99", "r105", "r114", "r115", "r116", "r120", "r121", "r344", "r345", "r405", "r419" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r117", "r118", "r119", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r297", "r309" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Restricted stock (windfall) shortfall adjustment", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r90", "r91", "r92", "r94", "r100", "r102", "r127", "r167", "r227", "r231", "r292", "r293", "r294", "r323", "r324", "r343", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r176", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r255", "r257", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r255", "r257", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r51", "r78", "r147", "r149", "r152", "r155", "r157", "r166", "r196", "r197", "r198", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r351" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r180", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r46", "r147", "r149", "r152", "r155", "r157", "r397", "r403", "r406", "r420" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r80", "r310", "r312", "r316", "r325", "r330", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r81", "r101", "r102", "r146", "r308", "r326", "r331", "r421" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes", "totalLabel": "Total provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r42", "r304", "r305", "r312", "r313", "r315", "r322" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r309" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income taxes at U.S. statutory rates" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r309" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Other" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r309" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State income taxes, net of federal tax benefit" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r61", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.", "label": "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories", "negatedLabel": "Inventories - finished goods" } } }, "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "(Increase) decrease in operating assets and increase (decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidTaxes", "negatedLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r110", "r111", "r116" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Common shares issuable upon conversion of preferred shares (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r106", "r107", "r108", "r116", "r258" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Common shares issuable upon the vesting of restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r177", "r179" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r24" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventories - finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r7", "r25", "r74", "r123", "r170", "r171", "r173", "r383" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r26", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r54", "r145" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "us-gaap_Investments", "terseLabel": "Investments, Total" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears", "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Five" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears", "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Four" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears", "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Three" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears", "terseLabel": "Lessor, Operating Lease, Payment to be Received, Year Two" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r78", "r151", "r166", "r196", "r197", "r198", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r337", "r339", "r340", "r351", "r370", "r371" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r78", "r166", "r351", "r372", "r400", "r413" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAssumed1": { "auth_ref": [ "r69", "r70", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.", "label": "Dividends payable in accrued expenses" } } }, "localname": "LiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r6", "r31", "r78", "r166", "r196", "r197", "r198", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r337", "r339", "r340", "r351", "r370", "r371", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r62", "r65" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r41", "r45", "r47", "r65", "r78", "r93", "r95", "r96", "r97", "r98", "r101", "r102", "r113", "r147", "r149", "r152", "r155", "r157", "r166", "r196", "r197", "r198", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r345", "r351", "r404", "r418" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r55" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "stringItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "us-gaap_OfficersCompensation", "terseLabel": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r147", "r149", "r152", "r155", "r157" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Income from operations", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r2", "r89", "r142", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 7.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r38", "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "terseLabel": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase and retirement of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r58" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "us-gaap_PaymentsOfDividendsCommonStock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r57" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r16", "r76", "r216", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred stock, liquidation preference (in dollars per share)", "terseLabel": "Preferred Stock, Liquidation Preference Per Share (in dollars per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r211" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r211" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)", "terseLabel": "Preferred Stock, Shares Issued, Total (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r4", "r174", "r175" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r186", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r9", "r182" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r184", "r372", "r407", "r414" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r184", "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r50", "r169" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense", "verboseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r251", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r364", "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r251", "r364", "r367", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r362", "r363", "r365", "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction" ], "xbrltype": "textBlockItemType" }, "us-gaap_RentalIncomeNonoperating": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.", "label": "us-gaap_RentalIncomeNonoperating", "terseLabel": "Rental Income, Nonoperating" } } }, "localname": "RentalIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r231", "r372", "r412", "r428", "r429" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r90", "r91", "r92", "r94", "r100", "r102", "r167", "r292", "r293", "r294", "r323", "r324", "r343", "r425", "r427" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r143", "r144", "r148", "r153", "r154", "r158", "r159", "r160", "r241", "r242", "r384" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Sales", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r75", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details": { "order": 6.0, "parentTag": "pets_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued sales tax" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r63" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation", "terseLabel": "Share-Based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Restricted stock forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Restricted stock granted (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Non-vested restricted stock outstanding at March 31, 2022 (in shares)", "periodStartLabel": "Non-vested restricted stock outstanding at March 31, 2021 (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted stock vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r257", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r16", "r17", "r76", "r78", "r105", "r109", "r112", "r114", "r116", "r128", "r129", "r130", "r166", "r196", "r201", "r202", "r203", "r207", "r208", "r211", "r212", "r216", "r220", "r227", "r351", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r34", "r43", "r44", "r45", "r90", "r91", "r92", "r94", "r100", "r102", "r127", "r167", "r227", "r231", "r292", "r293", "r294", "r323", "r324", "r343", "r353", "r354", "r355", "r356", "r357", "r358", "r361", "r425", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables", "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r90", "r91", "r92", "r127", "r384" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets-parentheticals", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-cash-flows-", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-disaggregation-of-revenue-by-type-details", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies", "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan", "http://www.1800petmeds.com/20220331/role/statement-note-11-employee-benefit-plan-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-12-covid19", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction", "http://www.1800petmeds.com/20220331/role/statement-note-14-related-party-transaction-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-summarized-unaudited-quarterly-financial-data-details", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-major-classifications-of-property-and-equipment-details", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-major-classifications-of-accrued-expenses-and-other-current-liabilities-details", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-components-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-deferred-income-taxes-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-reconciliation-of-income-tax-provision-details", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-declared-dividends-details", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-nonvested-restricted-stock-details", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "http://www.1800petmeds.com/20220331/role/statement-note-8-fair-value-measurements", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-details-textual", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables", "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-10-commitments-and-contingencies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r16", "r17", "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Issuance of restricted stock, net (in shares)", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r227", "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Issuance of restricted stock, net" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r16", "r17", "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares", "negatedLabel": "Repurchased and retired shares (in shares)", "terseLabel": "Stock Repurchased and Retired During Period, Shares (in shares)" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r16", "r17", "r227", "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue", "negatedLabel": "Repurchased and retired shares", "terseLabel": "Stock Repurchased and Retired During Period, Value" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r20", "r21", "r78", "r165", "r166", "r351", "r372" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets", "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-changes-in-shareholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r231", "r232", "r342" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r359", "r374" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r359", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r359", "r374" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r373", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies", "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-1-summary-of-significant-accounting-policies-tables", "http://www.1800petmeds.com/20220331/role/statement-note-15-quarterly-financial-data-unaudited-tables", "http://www.1800petmeds.com/20220331/role/statement-note-2-property-and-equipment-tables", "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-tables", "http://www.1800petmeds.com/20220331/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables", "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-tables", "http://www.1800petmeds.com/20220331/role/statement-note-6-shareholders-equity-tables", "http://www.1800petmeds.com/20220331/role/statement-note-7-restricted-stock-tables", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r302", "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions", "terseLabel": "Tax Adjustments, Settlements, and Unusual Provisions" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events", "http://www.1800petmeds.com/20220331/role/statement-note-13-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r134", "r135", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r85", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "us-gaap_ValuationAllowancesAndReservesBalance", "periodEndLabel": "Balance at end of year", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "us-gaap_ValuationAllowancesAndReservesDeductions", "negatedLabel": "Write-off of uncollectible accounts receivable" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-note-3-valuation-and-qualifying-accounts-activity-in-the-valuation-and-qualifying-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r104", "r116" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Shares used in diluted computation (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r116" ], "calculation": { "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-", "http://www.1800petmeds.com/20220331/role/statement-note-9-net-income-per-share-basic-and-diluted-net-income-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.1800petmeds.com/20220331/role/statement-consolidated-statements-of-income-" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "https://asc.fasb.org/topic&trid=2126967" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28511-109314" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28446-109314" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r448": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r449": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r450": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r451": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r452": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r453": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r454": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r455": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r456": { "Footnote": "5", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r457": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r458": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r459": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r460": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r461": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r462": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r463": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r464": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r465": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r466": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r467": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule III", "Subsection": "04" }, "r468": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 73 0001437749-22-013417-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-013417-xbrl.zip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end